| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-001 | The Kids Research Institute Australia | Murray Valley Encephalitis Virus | The researchers are aiming to produce a more effective vaccine against Murray Valley encephalitis virus and to test potential vaccines in mice. | Expired | 8/03/2002 | 30/06/2007 |
| DNIR-002 | The University of Queensland | Investigate gene therapy for hypertension | The aim is to develop a new model for gene therapy by treating rats with hypertension (high blood pressure) with a gene which produces atrial natriuretic peptide. | Withdrawn | | |
| DNIR-003 | Institute of Medical and Veterinary Science | Construction of immortalized macrophage cell lines | This proposal aims to generate cell lines from macrophages isolated from patients who suffer from iron overload (haemochromatosis) to study the proteins involved in iron transport. | Surrendered | 21/01/2002 | 17/12/2002 |
| DNIR-004 | CSL Limited | Pilot Scale Fermentation and Processing of ESO-1 Antigen Expressed in Recombinant E.coli | The researchers will produce quantities of the protein coded for by the gene ESO-1, isolated from a human oesophageal carcinoma cell line, to be used to test the properties of the protein. | Expired | 4/02/2002 | 30/06/2009 |
| DNIR-005 | Murdoch University | Testing Protection of Cattle From Fluoroacetate | This proposal aims to test if cattle can be protected against fluoroacetate, a poison found in some native plants, by inoculating them with genetically modified bacteria. | Expired | 11/02/2002 | 30/06/2004 |
| DNIR-006 | RMIT University | Evaluation of chimeric influenza virus, incorporating the fusion glycoprotein of respiratory syncytial virus | The researchers aim to generate a virus strain with potential as a live vaccine by replacing a gene from an influenza A virus strain with a gene from the respiratory syncytial virus. | Expired | 15/02/2002 | 31/12/2004 |
| DNIR-007 | RMIT University | Cloning and inactivation of phospholipase gene from Clostridium perfringens to produce a non-toxic vaccine antigen - addional information received 13/02/02 | The researchers are aiming to produce a vaccine against the chicken disease, necrotic enteritis, which is caused by the bacterium Clostridium perfringens. | Surrendered | 5/03/2002 | 22/03/2012 |
| DNIR-008 | St Vincent's Hospital (Melbourne) | The role of Osteoclast Inhibitory Lectin in breast cancer mestases to bone | This research is to see if, in mice, an inhibitor of osteoclast formation can slow the spread of human breast cancer cells to bone. | Expired | 18/02/2002 | 30/04/2003 |
| DNIR-009 | Novozymes Biopharma AU Limited | Production of humanised monoclonal antibodies from NSO cells | This proposal is to produce quantities of antibodies to be used in clinical trials. | Expired | 11/03/2002 | 28/02/2003 |
| DNIR-010 | Australian Water Quality Centre | Rapid Methods for the Detection of Toxic Cyanobacteria | The aim of this project is to identify the genes associated with toxin synthesis in cyanobacteria and to construct cyanobacteria that don’t produce the toxin. | Expired | 2/04/2002 | 31/08/2006 |
| DNIR-011 | Westmead Institute for Medical Research | Cryptococcal phospholipases and secretion pathways: structure & potential targets for therapeutics | The structure and function of the phospholipase proteins in the fungus Cryptococcus neoformans will be studied and fungus without the proteins tested in mice and wax moth larvae, Galleria mellonella | Licence issued | 16/04/2002 | 31/03/2030 |
| DNIR-012 | Western Sydney Local Health District | Investigation of the roles of TNFa-related apoptosis-inducing ligand, TRAIL in the immune system | TRAIL is a molecule which is thought to specifically kill transformed and virus infected cells but not most normal human cells. The researchers are investigating the function of TRAIL within the immune system. | Surrendered | 11/04/2002 | 10/02/2005 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-013 | Western Sydney Local Health District | Studies of cell growth & survival | The aim of the proposed dealing is to investigate the biological processes that regulate cell growth and survival. | Expired | 16/04/2002 | 28/02/2008 |
| DNIR-014 | The Victor Chang Cardiac Research Institute | Transient overexpression of adrenergic receptors via the use of adenoviral vectors | The researchers will harvest and purify adrenergic receptors from rat livers to study the structure of the receptors. | Withdrawn | | |
| DNIR-015 | Novozymes Biopharma AU Limited | Production of NeoGARD antigens | The aim is to produce the antigens used in manufacturing a vaccine against neonatal scour in pigs. | Surrendered | 2/04/2002 | 28/04/2006 |
| DNIR-016 | Novozymes Biopharma AU Limited | Production of domain 1 of the human plasma protein Beta 2-glycoprotein 1 | The project will produce recombinant protein which will be chemically modified for use in preclinical studies | Expired | 18/02/2002 | 31/03/2003 |
| DNIR-017 | CSIRO | Reverse Genetics of Newcastle Disease Virus (NDV) | The researchers will determine the role of the matrix protein gene in NDV. | Expired | 20/05/2002 | 30/06/2005 |
| DNIR-018 | CSIRO | Bone Repair | The aim is to identify genes and their most effective routes of administration to enhance bone repair. | Withdrawn | | |
| DNIR-019 | Deakin University | B55 gene over expression in Psammomys obesus | The researchers will study the effects on obesity and diabetes of over-expression of the B55 gene. | Expired | 10/05/2002 | 31/08/2004 |
| DNIR-020 | Novozymes Biopharma AU Limited | Production of members of the inhibin hormone family in mammalian, insect, yeast and bacterial cells | The project will produce recombinant hormones for research reagents, clinical research and commercial biopharmaceuticals. | Surrendered | 16/04/2002 | 28/04/2006 |
| DNIR-021 | QIMR Berghofer | HIV replication and gene expression | This project aims to determine the role of virus regulatory proteins in HIV replication and gene expression. | Surrendered | 16/05/2002 | 12/03/2025 |
| DNIR-022 | Peter MacCallum Cancer Centre | Characterisation of the anti-apoptotic function of P-glycoprotein and transcriptional regulation of the MDR1 gene | The aim is to determine if the P-glycoprotein can protect tumour and normal cells against apoptosis (programmed cell death) produced by a variety of methods. | Surrendered | 3/06/2002 | 29/06/2007 |
| DNIR-023 | St Vincent's Hospital (Melbourne) | The role of the cytokines receptor gp130 in prostate cancer | This study aims to determine whether the activation of gp130 in prostate cells influences the progression of prostate cancer. | Withdrawn | | |
| DNIR-024 | Novozymes Biopharma AU Limited | Production of recombinant proteins in mammalian, insect, yeast and bacterial cells | The project will produce a large range of recombinant proteins for research reagents, clinical research and commercial biopharmaceuticals. | Surrendered | 25/06/2002 | 15/01/2008 |
| DNIR-025 | Royal Perth Hospital | Meningococcal virulence genes | The aim is to characterise the function and expression levels of virulence genes of the human bacterial pathogen Neisseria meningitidis. | Surrendered | 5/07/2002 | 1/05/2007 |
| DNIR-026 | La Trobe University | The mechanisms of establishing and maintaining immunological memory | The aim is to investigate the development and maintenance of cytotoxic T lymphocyte (CTL) immunological memory against influenza virus proteins. | Surrendered | 9/07/2002 | 18/07/2022 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-027 | University of Southern Queensland | Whooping Cough Vaccine IV | The aim is to create a safe non-invasive whooping cough vaccine which will neutralise consequences of the major toxin of Bordetella pertussis. | Surrendered | 14/06/2002 | 30/11/2009 |
| DNIR-028 | University of Southern Queensland | Whooping cough vaccine V | The aim is to study Bordetella pertussis genes which are important in developing immune responses and protection from infection in mice. | Surrendered | 5/07/2002 | 30/11/2009 |
| DNIR-029 | Australian National University | A drug screen for anti-viral compounds | The aim is to screen compounds for their ability to inhibit the human immunodeficiency virus (type 1) budding process. | Surrendered | 19/07/2002 | 17/01/2006 |
| DNIR-030 | Biotron Limited | A drug screen for anti-viral compounds | The aim is to screen compounds for their ability to inhibit the human immunodeficiency virus (type 1) budding process. | Surrendered | 19/07/2002 | 11/07/2007 |
| DNIR-031 | The University of Sydney | Porcine growth hormone production from recombinant E.coli | The aim is to model and optimise the production process of porcine growth hormone in 50 litre fermentations. | Withdrawn | | |
| DNIR-032 | CSIRO | In vivo analysis of modified myxoma virus for immunocontraception and vaccine development | The purpose of the proposed dealings is to produce recombinant myxoma viruses that could be used in the development of immunocontraceptives and/or vaccines. | Surrendered | 24/07/2002 | 26/08/2005 |
| DNIR-033 | Western Sydney Local Health District | Mechanisms by which CD44 variant exon 6 promotes disease progression in acute leukemia | The aim of the proposed dealings is to investigate the effect of the protein CD44v6 on the proliferation and survival of leukemic cells in culture and in mice. | Expired | 12/07/2002 | 30/06/2006 |
| DNIR-034 | Australian National University | Modification of myxoma virus for immunocontraception and vaccine development | The purpose of the proposed dealings is to produce recombinant myxoma viruses that could be used in the development of immunocontraceptives and/or vaccines. | Surrendered | 24/07/2002 | 27/02/2014 |
| DNIR-035 | Macfarlane Burnet Institute for Medical Research and Public Health | A replicon-based vaccine for Hepatitis C virus (HCV) | The purpose of the proposed dealings is to develop a vaccine for hepatitis C virus (HCV) using a novel RNA-based replicon system. | Surrendered | 23/08/2002 | 17/10/2007 |
| DNIR-036 | Macfarlane Burnet Institute for Medical Research and Public Health | A cell culture system for Hepatitis C virus | The aim of the proposed dealings is to develop a mammalian cell culture system to study Hepatitis C virus using recombinant baculoviruses. | Surrendered | 23/08/2002 | 17/10/2007 |
| DNIR-037 | Adelaide University | Replication of GB-Virus and related Chimeras | The aim of this study is to develop a mammalian cell culture system to study Hepatitis C virus (HCV) using chimerics of HCV and GB viruses. | Licence issued | 23/08/2002 | 31/03/2027 |
| DNIR-038 | Macfarlane Burnet Institute for Medical Research and Public Health | Molecular interactions between HIV-1 and host gene products | The aim of the proposed dealings is to test the impact of the expression of cellular proteins on HIV-1 and MLV replication in mammalian cell culture. | Licence issued | 2/09/2002 | 22/12/2028 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-039 | Macfarlane Burnet Institute for Medical Research and Public Health | Impact of host gene products on HIV-1 replication in mammalian cells | The aim of the proposed dealings is to test the impact of the expression of cellular proteins on HIV-1 and MLV replication in mammalian cell culture. | Integrated into DNIR-038 | | |
| DNIR-040 | Macfarlane Burnet Institute for Medical Research and Public Health | Effect of host gene products that interact with HIV-1 reverse transcriptase on MoMLV replication | The aim of the proposed dealings is to test the impact of the expression of cellular proteins on HIV-1 and MLV replication in mammalian cell culture. | Integrated into DNIR-038 | | |
| DNIR-041 | Peter MacCallum Cancer Centre | Characterisation of the signalling and cell biology of CD46 and the Dig family | The aim of the proposed dealing is to study the effects on immune cell function of the protein CD46 and its Dlg family in human and mouse cells. | Expired | 2/09/2002 | 30/03/2006 |
| DNIR-042 | James Cook University | Cross infection of bacteriophages in Vibrio cholerae, Vibrio mimicus and Vibrio harveyi | The effect of swapping bacteriophages from one species of Vibrio to another will be examined. The aim is to see if the cholera pandemic of 1989 could be related to an outbreak of Vibrio harveyi in prawns. | Withdrawn | | |
| DNIR-043 | CSIRO | In vivo testing of immuno-contraceptive effects and species specificity of a recombinant murine cytomegalovirus (MCMV) expressing mouse ZP3 | The aim of this dealing is to test the efficacy and specificity of a recombinant murine cytomegalovirus (MCMV) containing a mouse reproductive protein as an immunocontraceptive in house mice and a number of native and exotic rodent species. | Surrendered | 7/08/2002 | 26/08/2005 |
| DNIR-044 | Baker Medical Research Institute | A viral mediated approach to examine Sgk in cellular function | This dealing aims investigate the role of Sgk (serum and glucocorticoid induced kinase) in heart disease using replication deficient adenoviruses in cell culture. | Withdrawn | | |
| DNIR-045 | Hospira Adelaide Pty Ltd | Production of recombinant PST and amino acid analogues of that hormone | The proposed dealings are to produce the protein pig somatotropin. | Surrendered | 17/09/2002 | 13/02/2004 |
| DNIR-046 | Hospira Adelaide Pty Ltd | Production of recombinant MET - human growth hormone | The proposed dealings are to produce the therapeutic protein human growth hormone. | Surrendered | 17/09/2002 | 13/02/2004 |
| DNIR-047 | Hospira Adelaide Pty Ltd | Production of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and amino-acid analogues of this cytokine | The proposed dealings are to produce the therapeutic protein human granulocyte macrophage colony stimulating factor (GM-CSF) or analogue. | Surrendered | 17/09/2002 | 13/02/2004 |
| DNIR-048 | Hospira Adelaide Pty Ltd | Production of recombinant human interleukin 5 (IL-5) and amino acid analogues of this cytokine | The proposed dealings are to produce the protein human interleukin 5 (IL 5). | Surrendered | 17/09/2002 | 13/02/2004 |
| DNIR-049 | Western Sydney Local Health District | A preclinical model of pancreatic islet xenotransplatnation as treatment for Type 1 Diabetes | This dealing aims to produce pig and mouse pancreatic islet cells that can avoid the human immune system. | Expired | 26/09/2002 | 30/09/2007 |
| DNIR-050 | Western Sydney Local Health District | HIV immunopathogenesis and immune cell function | The aim of the proposed dealings is to study one possible mechanism whereby HIV depletes the immune cells in people. | Expired | 26/09/2002 | 30/11/2007 |
| DNIR-051 | Western Sydney Local Health District | Growth of tissue culture cells genetically modified to express cytokine receptor subunit | The aim is to study the function of lymphocytes (white blood cells) and the effect of cytokine receptors on the development or treatment of severe combined immunodeficiency. | Expired | 26/09/2002 | 30/11/2007 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-052 | Westmead Institute for Medical Research | Molecular pathogenesis of Bartonella henselae | The aim of the proposed dealings is to study Bartonella henselae, a bacterium which causes cat scratch disease. | Licence issued | 26/09/2002 | 30/09/2027 |
| DNIR-053 | Novozymes Biopharma AU Limited | Commercial production of LongR3IGF-1 and IGF-1 | The proposed dealings are to produce both native and variant forms of the protein IGF-1. | Withdrawn | | |
| DNIR-054 | Public and Environmental Health Reference Laboratories, Pathology Queensland | Cell complemented viruses as non-infectious diagnostic reagents and candidate vaccines. Australian Bat Lyssavirus | The dealings propose to produce diagnostic reagents and potential vaccines for the viral disease Australian Bat lyssavirus. | Surrendered | 20/09/2002 | 6/05/2010 |
| DNIR-055 | Public and Environmental Health Reference Laboratories, Pathology Queensland | Cell complemented Hendra virus as a non-infectious diagnostic reagent and as a model for studying genetic and phenotypic changes affecting pathogenicity and host range | The dealings propose to produce diagnostic reagents and potential vaccines for the disease caused by Hendra virus. | Surrendered | 20/09/2002 | 12/11/2007 |
| DNIR-056 | Public and Environmental Health Reference Laboratories, Pathology Queensland | Cell complemented viruses as non-infectious diagnostic reagents and candidate vaccines. Ross River Virus | The dealings propose to produce diagnostic reagents and potential vaccines for the disease caused by Ross River virus. | Expired | 20/09/2002 | 28/02/2014 |
| DNIR-057 | The Walter and Eliza Hall Institute of Medical Research | Transfection of Plasmodium falciparum | These dealings aim to study the parasite which causes malaria, Plasmodium falciparum. | Surrendered | 9/09/2002 | 7/11/2008 |
| DNIR-058 | The Walter and Eliza Hall Institute of Medical Research | Expression of genes in Leishmania | The aim of the proposed dealing is to study the parasite Leishmania and immune responses to the parasite in mice. | Expired | 13/09/2002 | 30/09/2010 |
| DNIR-059 | The Walter and Eliza Hall Institute of Medical Research | Transduction of cells and tissue by adenoviral vectors for transplantation | The proposed dealing aims to develop tissues which may be able to be transplanted in people from pigs, mice and human cell lines and test these tissues in mice. | Withdrawn | | |
| DNIR-060 | The Walter and Eliza Hall Institute of Medical Research | Transduction of cells and tissue by lentivirus vectors for transplantation | The proposed dealing aims to develop tissues which may be able to be transplanted in people from pigs, mice and human cell lines and test these tissues in mice. | Withdrawn | | |
| DNIR-061 | The Walter and Eliza Hall Institute of Medical Research | Generation and use of recombinant Adenovirus | This project aims to develop a recombinant adenovirus vector system to deliver mouse genes into mouse tissue cultures and organs. | Withdrawn | | |
| DNIR-062 | The Walter and Eliza Hall Institute of Medical Research | Adenovirus mediated gene transfer in murine models of rheumatoid arthritis | This project aims to use a mouse model of rheumatoid arthritis to test the effect of proteins thought to regulate inflammation of synovial tissue. | Withdrawn | | |
| DNIR-063 | The Walter and Eliza Hall Institute of Medical Research | Retroviral mediated gene transfer into murine haemopoietic cells | The researchers propose to transfer and study genes thought to be involved in cell growth, proliferation, apoptosis (programmed cell death) and differentiation in cell cultures. | Surrendered | 26/09/2002 | 28/09/2007 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-064 | Peter MacCallum Cancer Centre | Negative regulation of haematopoesis by P-selectin | The aim is to determine a signal transduction pathway and see how this results in suppression of blood cell production. | Expired | 26/09/2002 | 30/04/2004 |
| DNIR-065 | Peter MacCallum Cancer Centre | Immunotherapy of cancer using recombinant viruses | This project aims to assess the anti-tumour potential of a melanocyte protein vaccine. | Surrendered | 26/09/2002 | 24/08/2007 |
| DNIR-066 | CSIRO | Porcine adenovirus viral vectors | Adenovirus from pigs will be genetically modified for use as vaccines and therapeutics for a range of animal diseases. | Licence issued | 26/09/2002 | 31/08/2027 |
| DNIR-067 | CSIRO | Development of Vaccines to protect against members of the pasturellaceae | This project aims to develop vaccines against Pasteurellaceae associated diseases in production animal species. | Surrendered | 26/09/2002 | 27/09/2013 |
| DNIR-068 | CSIRO | Fowl adenovirus recombinants | The proponents intend to construct and test different genetically modified fowl adenoviruses as potential vaccines against diseases in chickens and dogs. | Expired | 26/09/2002 | 31/01/2024 |
| DNIR-069 | CSIRO | Identification of virulence factors for infectious bursal disease virus (IBDV) | The researchers are planning to identify what parts of the virus makes IBDV infectious to chickens. | Expired | 26/09/2002 | 31/12/2005 |
| DNIR-070 | CSL Limited | Expression of Helicobacter pylori proteins in E.coli | The dealing is to produce quantities of proteins from the "stomach -ulcer" bacterium Helicobacter pylori for potential use as vaccines. | Expired | 26/09/2002 | 31/12/2005 |
| DNIR-071 | Australian Defence Force Malaria and Infectious Disease Institute | JE CHIMERIVAX | The aim is to test the safety and efficacy of a yellow fever vaccine genetically modified to vaccinate against Japanese encephalitis in human volunteers. | Expired | 26/09/2002 | 31/12/2010 |
| DNIR-072 | CSIRO | Construction of recombinant ranaviruses | Ranaviruses are viruses of fish, frogs and reptiles and this project aims to develop technology to genetically modify these viruses. | Surrendered | 26/09/2002 | 28/09/2007 |
| DNIR-073 | Baker Medical Research Institute | Viral mediated approaches to examine the effects of dehydrogenase on cardiac function | The aim is to express four enzymes in cell culture and to test the effect of the enzymes on cultured heart cells. | Withdrawn | | |
| DNIR-074 | Baker Medical Research Institute | Signalling pathways in myocardial preparations | The aim is to study mechanisms which may be involved in sudden cardiac deaths. | Withdrawn | | |
| DNIR-075 | Baker Medical Research Institute | A viral mediated approach to examine SMAD in cellular functions | The researchers will study the role of specific proteins stimulated by Smad dependent mechanisms, by modulating Smad genes in wound healing, inflammation and cell development. | Withdrawn | | |
| DNIR-076 | Murdoch University | Generation of infectious cucumber mosaic virus clones | Cucumber mosaic virus is a disease of lupins and many other plants. The researchers intend to study the interactions between the virus and lupins. | Expired | 25/10/2002 | 30/04/2014 |
| DNIR-077 | Department of Primary Industries and Regional Development | Bioassay evaluation of bacteria expressing insecticidal genes | The aim is to identify proteins toxic to the rice bloodworm Chironomus tepperi from bacteria. | Surrendered | 25/10/2002 | 13/06/2007 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-078 | Department of Primary Industries and Regional Development | Toxicity of modified rice callus to Chironomus larvae | The aim is to insert and test proteins toxic to the rice bloodworm Chironomus tepperi in tissue cultures of rice. | Integrated into DNIR-077 | | |
| DNIR-079 | Centenary Institute of Cancer Medicine and Cell Biology | Development of new vaccines against tuberculosis | The aim is to develop and test vaccines to protect against the human bacterial disease tuberculosis. | Expired | 25/10/2002 | 31/12/2013 |
| DNIR-080 | Melbourne Health | Packaging of hepatitis delta virus (HDV) with modified envelope protein | The researchers propose to genetically modify hepatitis delta virus (HDV) so that it can infect cells other than liver cells, such as cancer cells, as a potential treatment. | Expired | 8/11/2002 | 30/09/2021 |
| DNIR-081 | University of Wollongong | Molecular analysis of Streptococcus pyogenes | The aim is to understand the role of specific gene products of the bacteria Streptococcus pyogenes in the onset of disease and to develop vaccines to protect against the disease. | Expired | 8/11/2002 | 31/10/2022 |
| DNIR-082 | University of Wollongong | Molecular analysis of Mycoplasma hyopneumoniae and vaccine development | The aim is to understand the role of specific gene products of the bacteria Mycoplasma hyopneumoniae in the onset of disease and to develop vaccines to protect against the disease. | Surrendered | 8/11/2002 | 9/12/2013 |
| DNIR-083 | St Vincent's Hospital (Melbourne) | Breast cancer invasion and metastasis | Tagged breast cancer cells will be inoculated into mice to assess how tumours develop. | Surrendered | 4/11/2002 | 11/07/2007 |
| DNIR-084 | Western Sydney Local Health District | The role of SDF-1 in normal leukemic pre-B cell interactions with bone marrow stroma | SDF-1 is thought to be a key regulator of the behaviour of cells involved in acute lymphoblastic leukemia and this project aims to study how it works. | Surrendered | 8/11/2002 | 12/09/2006 |
| DNIR-085 | Western Sydney Local Health District | Analysis of the effects of CD44 variant exon 6 expression on adhesion and migration of human leukemia cells | CD44 is thought to affect cells involved in myeloid leukemia and this project aims to study how variations of CD44 act. | Surrendered | 8/11/2002 | 7/01/2008 |
| DNIR-086 | Westmead Institute for Medical Research | HIV biology | The aim is to understand the biology of the human immune deficiency virus as the basis for better drug and vaccine development. | Licence issued | 15/11/2002 | 20/09/2031 |
| DNIR-087 | Australian National University | Molecular genetic studies of Shigella virulence | Shigella can cause dysentery. They hope to find the genes which are involved in disease development. | Licence issued | 15/11/2002 | 30/11/2027 |
| DNIR-088 | Monash University | Cloning of genes from Mycobacterium ulcerans in other mycobacteria | Mycobacterium ulcerans can cause skin ulcers in people. The ulcers are thought to be due to the production of mycolactone by the bacteria and the researchers are aiming to identify the genes responsible for mycolactone production. | Surrendered | 29/11/2002 | 6/05/2010 |
| DNIR-089 | Monash University | Cloning of genes from Mycobacterium ulcerans | Mycobacterium ulcerans can cause skin ulcers in people. The ulcers are thought to be due to the production of mycolactone by the bacteria and the researchers are aiming to identify the genes responsible for mycolactone production. | Surrendered | 29/11/2002 | 6/05/2010 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-090 | The University of Western Australia | Immunocontraception and antigen delivery by recombinant Cytomegaloviruses | The aim of this dealing is to genetically modify various cytomegaloviruses (CMVs) to contain reproductive proteins and other proteins and to test these GMOs as immunocontraceptives and vaccines in a number of animal species. | Surrendered | 23/12/2002 | 16/11/2020 |
| DNIR-091 | Harry Perkins Institute of Medical Research | Recombinant vaccinia virus encoding CMV or HCV genes | The aim is to examine the host response to cytomegalovirus and hepatitis C virus proteins to test for protective immune responses. | Expired | 25/11/2002 | 30/06/2026 |
| DNIR-092 | Central Adelaide Local Health Network | Molecular Models of Bone and Tissue Remodeling | The aim is to introduce genes of interest into primary human and rodent cell lines of bone origin to study the effects of their forced expression on the formation of bone and other connective tissue. | Surrendered | 21/11/2002 | 30/10/2008 |
| DNIR-093 | Institute of Medical and Veterinary Science | Novel Retroviral Expression Cloning Stratigies to Isolate Genes with Roles in Haemopoiesis and Stromal Biology | The aim is to isolate novel cDNAs which encode for proteins which regulate haemopoietic and stromal cell differentiation. This will be achieved using retroviral expression cloning techniques. | Surrendered | 25/11/2002 | 30/06/2008 |
| DNIR-094 | St Vincent's Hospital Sydney Limited | Clinical Protocol HVDDT - NO1-AI-05395 - Fowlpox vaccine | The aim of this dealing is to determine the safety and immunogenicity of an HIV vaccine regimen. | Expired | 27/11/2002 | 30/04/2006 |
| DNIR-095 | St Vincent's Hospital Sydney Limited | Clinical Protocol HVDDT - NO1-AI-05395 - DNA vaccine | The aim of this dealing is to determine the safety and immunogenicity of an HIV vaccine regimen. | Expired | 18/11/2002 | 30/04/2006 |
| DNIR-096 | The University of Sydney | Investigation into the genes responsible for ochratoxin A production in Aspergillus carbonarius and Aspergillus niger | The aim of this dealing is to clone and sequence the biosynthetic pathway genes involved in ochratoxin A synthesis in Aspergillus carbonarius. | Surrendered | 29/11/2002 | 25/05/2009 |
| DNIR-097 | Australian National University | Molecular biology of Phytophthora pathogenicity | The aim of this dealing is to identify Phytophthora genes that are involved in the infection of host plants. | Expired | 29/11/2002 | 30/04/2013 |
| DNIR-098 | Royal Perth Hospital | Construction of vaccinia virus recombinants carrying HCV antigens and their use in detecting cytokine reponses in human peripheral blood leucocytes | The aim of this dealing is to make recombinant vaccinia viruses that contain HCV genes and to use these viruses to observe the immunological responses of peripheral blood mononuclear cells (PBMCs) in vitro to endogenously synthesised HCV proteins. | Expired | 27/11/2002 | 31/01/2007 |
| DNIR-099 | Royal Perth Hospital | Development and characterisation of viral hybrids containing various segments of flaviviridae genomes | The aim of this dealing is to make recombinant attenuated hepatitis C viruses and to use these viruses to elucidate the replicative mechanisms of hepatitis C virus. | Expired | 29/11/2002 | 31/01/2005 |
| DNIR-100 | South Eastern Sydney Local Health District | Human and Ovine Adenovirus Vectors for Cancer gene therapy | The aim of this dealing is to examine the efficacy of a treatment for prostate cancer that uses adenoviral vectors, in the mouse model. | Surrendered | 4/03/2003 | 20/08/2012 |
| DNIR-101 | Western Sydney Local Health District | The identification & investigation of virulence factors in legionella longbeachae | The aim of this dealing is to create a mutant strain of Legionella longbeachae (LL) lacking the pilD virulence gene and to study the role of this gene in the virulence of LL. | Surrendered | 3/01/2003 | 31/07/2008 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-102 | Western Sydney Local Health District | Genetics and biochemical characterisation of cryptococcal phospholipases in relation to fungal virulence | The aim of this dealing is to first isolate the phospholipase gene from a particular cryptococcal strain and then study the role of this gene in the virulence of Cryptococcus neoformans by creating a mutant C. neoformans lacking the gene. | Surrendered | 9/01/2003 | 31/07/2008 |
| DNIR-103 | Department of Primary Industries | Cloning the Complete Genomes of Alphaherpiesviruses | The aim of this dealing is to produce recombinant herpesvirus vaccines through the utilisation of infectious clone technology. | Surrendered | 15/01/2003 | 22/06/2007 |
| DNIR-104 | The University of Melbourne | The Antigenicity and Replication of Hepatitis B Virus Vaccine and Lamivudine Resistant Mutants and Humoral Plus Cellular Immune Responses to Hepatic C Virus | The aim of this dealing is to study the antigenicity (ability of a substance to cause an immune response) and replication of hepatitis B virus mutants and to analyse the humoral (antibody) and cellular (T-cell) immune responses to hepatitis C virus. | Expired | 16/01/2003 | 30/04/2020 |
| DNIR-105 | Melbourne Health | Studies of Replication of Hepatitis C Virus and Hepatitis C Virus in Mammalian Cells | The aim of this dealing is to infect liver cells using baculovirus containing hepatitis B and C viral DNA and to study the replication of hepatitis B and C virus in these cells. | Surrendered | 16/01/2003 | 27/09/2013 |
| DNIR-106 | Monash University | Genetics and pathogenesis of the clostridia | The aim of this dealing is to study genes identified as potentially having a role in the pathogenesis, antibiotic resistance or gene transfer of C. perfringens, C. septicum and C. difficile. | Licence issued | 22/01/2003 | 31/01/2028 |
| DNIR-107 | Central Adelaide Local Health Network | Virus Replication and Viral Pathogenesis | The aim of this dealing is to investigate the function of different viral genes and their role in regulating viral replication and viral pathogenesis. | Expired | 24/01/2003 | 31/01/2013 |
| DNIR-108 | Central Adelaide Local Health Network | Targeted gene delivery for vascular and neoplastic disease | The aim of this dealing is to use targeted gene delivery to investigate pulmonary vascular disease, tumour vasculature and cancer. | Expired | 24/01/2003 | 31/03/2025 |
| DNIR-109 | Peter MacCallum Cancer Centre | Signal transduction pathways in human cancers | The aim of this dealing is to understand the genetic and biochemical changes involved in the development of cancer using human and mouse cells as model systems for human disease. | Surrendered | 29/01/2003 | 26/10/2007 |
| DNIR-110 | Peter MacCallum Cancer Centre | Novel approaches for activation and expansion of genetically engineered T cells in vivo | The aim of this dealing is to study the anti-tumour activity, expansion and survival of mouse and human primary lymphocytes (T cells) in vivo, that have been genetically modified to express single chain antibody receptors. | Expired | 17/01/2003 | 31/01/2018 |
| DNIR-111 | Peter MacCallum Cancer Centre | Analysis of the molecular functions of perforin: a critical role in tumour immunosurveillance | The aim of this dealing is to express wildtype and mutant perforin cDNAs in perforin-deficient cell lines (rat mast cell line, RBL) and primary mouse T-lymphocytes to understand the structure/function relationship of the perforin molecule. | Surrendered | 29/01/2003 | 26/10/2007 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-112 | Deakin University | Overexpression of diabetes/obesity related genes in cultured cells and animals using recombinant Adenovirus | The aim of this dealing is to study the roles of newly identified genes in the development of diabetes and obesity. | Expired | 28/01/2003 | 31/12/2007 |
| DNIR-113 | Monash University | Infectious RNA of human caliciviruses | Infection of cultured cells by calicivirus particles has not been demonstrated and the researchers hypothesise this is due to defective virus particle attachment and entry. The aim of this dealing is to bypass this block by using viral nucleic acid. | Surrendered | 29/01/2003 | 12/07/2007 |
| DNIR-114 | Institute of Medical and Veterinary Science | Generation of murine haemopoietic cells expressing human BCR/ABL | The aim of this dealing is to model human Chronic Myeloid Leukaemia (CML) in mice by delivering the leukaemogenic BCR/ABL DNA sequence to primary murine haemopoietic cells. Small molecule therapies for CML will also be examined. | Withdrawn | | |
| DNIR-115 | The Walter and Eliza Hall Institute of Medical Research | Transfection and Gene Knockout/down of Plasmodium and Mammalian Cell Lines | The researchers propose to use short sequences of dsRNA produced by stable expression vectors to silence the expression of genes in either mammalian cell lines or malaria. They also propose to study the pathogenesis of P. berghei malaria in various murine gene knockout models. | Surrendered | 14/02/2003 | 15/01/2008 |
| DNIR-116 | The Walter and Eliza Hall Institute of Medical Research | Functional Analysis of Malaria Parasite Proteins using Transfection of Plasmodium Species of Human and Rodent Origin | The aim of this dealing is to study the role of particular malaria proteins in various aspects of the parasite's lifecycle by transfecting the parasite with Plasmodium genes. | Expired | 7/02/2003 | 28/02/2015 |
| DNIR-117 | Avexa Limited | Creation of a Recombinant Baculovirus Harbouring a Greater than Genome Length of the HIV Genome Capable of Transducing Hepatoma Cell Lines | The aim of this dealing is to create a recombinant baculovirus that harbours a greater than full length copy of the HBV genome and to use this virus to transfect cell lines. The transfected cells will be used to screen for antiviral compounds. | Surrendered | 7/02/2003 | 21/11/2007 |
| DNIR-118 | Avexa Limited | Construction of Recombinant HIV Clones and Viruses | The aim of this dealing is to construct and grow molecular clones of HIV in E. coli and to produce and grow HIV and recombinant HIV in mammalian cell lines. The viruses produced will be used in assays for the development of antiviral compounds. | Surrendered | 12/02/2003 | 29/08/2011 |
| DNIR-119 | CSL Limited | Expression of Human papilloma virus antigens | The aim of this dealing is to express human papillomavirus protein antigens in E. coli and to purify these proteins in order to formulate a vaccine. | Surrendered | 12/02/2003 | 29/08/2011 |
| DNIR-120 | Peter MacCallum Cancer Centre | Role of SMC6 in cell growth, DNA damage repair, cell cycle control and chromosome stability | The aim of this dealing is to suppress the expression of SMC6 in human and mouse cells by transforming the cells with retroviruses capable of producing small interfering RNAs (SIRNAs). | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-121 | The University of Adelaide | Cereal Transformation | The researchers intend to introduce various genes into rice callus tissues. They aim to improve gene transfer efficiency and understand the effects of targeted modification of the rice glutelin gene on its expression and stability in transgenic plants. | Withdrawn | | |
| DNIR-122 | CSL Limited | Pilot scale fermentation and processing of antibody fragments expressed in GMOs | The aim of this dealing is to produce antibody fragments using GMOs and to evaluate them for the treatment of a variety of animal and human disease conditions. | Surrendered | 28/02/2003 | 26/02/2008 |
| DNIR-123 | Melbourne Health | Studies on the replication of hepatitis C virus (HCV) | The aim of this dealing is to produce a DNA copy of HCV that contains only the regions of the virus necessary for the virus to replicate. The researchers intend to study HCV replication and design and test antiviral compounds that stop this process. | Surrendered | 10/02/2003 | 22/06/2007 |
| DNIR-124 | Melbourne Health | Replication of hepatitis B virus, duck hepatitis B virus and woodchuck hepatitis virus and the testing of antiviral agents | The aim of this dealing is to study the replication of HBV, DHBV and WHV and to investigate the growth of these viruses in the presence of antiviral agents. Variants of HBV associated with resistance to antiviral agents will also be studied. | Surrendered | 21/02/2003 | 27/09/2013 |
| DNIR-125 | Melbourne Health | Studies of the replication of hepatitis B virus using recombinant HBV/adenovirus as a delivery system for mammalian cells and studies of HBV and HCV co-infection using HBV/adenovirus and HCV clones | The aim of this dealing is to study the replication of HBV by infecting liver cells with HBV using a modified adenovirus containing HBV DNA. HCV genetic material will also be introduced to HBV infected cells to investigate HBV and HCV co-infection. | Surrendered | 28/02/2003 | 27/09/2013 |
| DNIR-126 | University of New South Wales | Molecular Regulation of Cell Lifespan and Malignant Transformation | The aim of this dealing is to investigate the molecular regulation of cell lifespan and malignant transformation by genetically modifying mammalian cells with genes of interest. | Surrendered | 14/02/2003 | 21/12/2007 |
| DNIR-127 | The University of Queensland | Development of a gene transfer vector for banana | The aim of this dealing is to develop a gene transfer vector for the banana plant and other plant species. | Expired | 19/02/2003 | 28/02/2018 |
| DNIR-128 | Harry Perkins Institute of Medical Research | Expressing Hemopoietic Regulators in Cells using Amphotropic Retroviruses. | The aim of this dealing is to transfer genes associated with haemopoietic regulation into cells using a replication defective retrovirus, and to study the effects of this altered gene expression on haematopoiesis. | Surrendered | 6/03/2003 | 21/09/2007 |
| DNIR-129 | Queensland University of Technology | Cloning of Genes from Potentially Toxigenic Risk Group Two Bacteria | The aim of this dealing is to analyse genes from a variety of risk group 2 bacteria for commonalities. | Surrendered | 7/03/2003 | 7/01/2008 |
| DNIR-130 | Royal Perth Hospital | Use of retroviral and lentiviral gene delivery systems for the expression of HCV proteins in cell culture | The aim of this dealing is to use retroviruses and lentiviruses to express various HCV proteins. These viruses will be used to study the replication of HCV in cell culture. | Surrendered | 7/03/2003 | 26/02/2008 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-131 | Institute of Medical and Veterinary Science | Expression of the GM-CFS Receptor Alpha and Beta Chains from a Single Retroviral Construct | The aim of this project is to test agents known to block the action of GM-CSF on mice containing bone marrow cells that express the human GM-CSF receptor. | Withdrawn | | |
| DNIR-132 | University of Southern Queensland | Whooping Cough Vaccine VI | The aim of this dealing is to develop a genetically modified non-toxic whooping cough vaccine. | Surrendered | 13/03/2003 | 31/03/2008 |
| DNIR-133 | University of Southern Queensland | Pasturella Multocida Type A Genes and Gene Products - 1 | The aim of this dealing is to study the role of various genes and gene products in the pathogenesis of P. multocida. | Surrendered | 13/03/2003 | 31/03/2008 |
| DNIR-134 | University of Southern Queensland | Mechanisms of Immunity in Salmonellosis | The aim of this dealing is to characterise the immunoregulating factors produced by mice vaccinated with two attenuated strains of Salmonella typhimurium. | Integrated into DNIR-132 | | |
| DNIR-135 | Central Adelaide Local Health Network | Conditionally Replicative Adenoviruses for Neoplastic Disease | The aim of this dealing is to generate adenoviruses that will only replicate in the presence of specific tumour cell proteins. The adenoviruses will be tested for their impact on cell function. | Expired | 29/04/2003 | 30/04/2013 |
| DNIR-136 | Orica Australia Pty Ltd | Production of Pesticide Degrading Enzymes Using Recombinant E.coli | The aim of this dealing is to produce commercial quantities of pesticide-degrading enzymes using recombinant E. coli. | Expired | 6/03/2003 | 31/01/2008 |
| DNIR-137 | Progen Industries Limited | Geneswitch | The aim of this dealing is to produce large amounts of plasmid that will be purified and formulated into a drug product (EPO) for clinical investigation in humans. | Expired | 24/03/2003 | 31/03/2008 |
| DNIR-138 | Hospira Adelaide Pty Ltd | Large Scale Production of Recombinant Peptides or Proteins | The aim of this dealing is to produce a sufficient quantity of specific recombinant peptides or proteins to supply product for clinical trials and/or commercialisation. | Surrendered | 26/03/2003 | 25/03/2008 |
| DNIR-139 | CSIRO | Recombinant Canine Herpiesvirus as Vaccine Vector | The aim of this dealing is to construct a recombinant canine herpesvirus to be used as a vaccine vector. | Surrendered | 31/03/2003 | 26/08/2005 |
| DNIR-140 | The University of New England | Characterisation of DNA Region Associated With the Virulence of D. nodosus | The aim of this dealing is to identify genes which control virulence of D. nodosus, and to use this information to assist in the diagnosis, treatment or prevention of footrot. | Expired | 2/04/2003 | 15/05/2014 |
| DNIR-141 | CSIRO | Molecular Virology | The viruses under investigation pose a significant risk to tomato, cotton and viticulture industries. The aim of this dealing is to characterise the roles of viral genes in viral replication and to assess the use of virus derived gene constructs for preventing disease. | Withdrawn | | |
| DNIR-142 | Agen Biomedical | Thromboview Cell Culture | The aim of this dealing is to produce enough material from cell culture to support later Phase Trials and to develop large-scale manufacturing procedures. | Surrendered | 4/04/2003 | 21/12/2007 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-143 | Peter MacCallum Cancer Centre | The Role of Sialomucins in the Regulation of Haemopoiesis | The aim of this dealing is to study the role of sialomucin cell surface adhesion molecules in the regulation of haemopoiesis, by expressing them in a range of mouse and human cell types. | Surrendered | 4/04/2003 | 12/06/2007 |
| DNIR-144 | Peter MacCallum Cancer Centre | The Role of Hyaluronic Acid in Normal and Aberrant Stem Cell Biology | The aim of this dealing is to analyse the role of hyaluronic acid in leukaemiagenesis by over expressing or inhibiting hyaluronic acid synthase genes in primary human leukaemic cells. | Surrendered | 4/04/2003 | 29/06/2007 |
| DNIR-145 | CSIRO | Expression and Vaccine systems Using Viruses Expressing Zona Pellucida Genes | The aim of this dealing is to produce recombinant myxoma and vaccinia viruses that express ZP proteins for use in rabbit immunocontraceptive trials and assays respectively. | Surrendered | 8/04/2003 | 26/08/2005 |
| DNIR-146 | Monash University | Adenovirus Mediated Transient Expression of Cre Recombinase in Rodent Cells | The aim of this dealing is to transiently express Cre recombinase in rat and mouse stem cells and to use these cells to produce transgenic and knockout rats and mice. | Withdrawn | | |
| DNIR-147 | Monash University | Lentivirus Mediated RNAi Technology | The aim of this dealing is to develop lentivirus-mediated RNAi (RNA interference) technology to inactivate genes in rats and mice at the mRNA (messenger RNA) level. | Withdrawn | | |
| DNIR-148 | CSIRO | A Viral Vectored Mouse Immuno-Contraceptive | The aim of this dealing is to infect mice with a GM virus that will induce an autoimmune response which targets the developing oocyte within the ovary and renders female mice infertile. | Surrendered | 10/04/2003 | 26/08/2005 |
| DNIR-149 | Avexa Limited | Generation of Wild Type and Mutant Hepatitis B Virus (HBV) Capsid and Polymerase Proteins For Use In In Vitro Assays | The aim of this dealing is to generate HBV mutant and wild type capsid and polymerase proteins that can be used in in vitro assays to measure the sensitivity of mutant and wild type HBV polymerases to potential inhibitors of HBV replication. | Surrendered | 15/04/2003 | 21/11/2007 |
| DNIR-150 | The University of Queensland | Lentiviral Delivery of Genes and/or DNA to Cells | The aim of this dealing is to use various replication defective lentiviruses to introduce genetic information into cells. | Surrendered | 16/04/2003 | 18/10/2007 |
| DNIR-151 | Central Adelaide Local Health Network | Construction and in vitro and in vivo testing of recombinant fowlpox virus vectors that express human or rat prostatic acid phosphatase with or without co-expression of human interleukin-2, AND Induction of auto-immune prostatitis in rats and mice using recombinant vaccinia virus vectors that encode human or rat prostatic acid phosphatase. | The aim of this dealing is to investigate the immune response to recombinant fowlpox virus vectors in laboratory strains of mice and rats and in primary human peripheral blood mononuclear cell cultures. | Surrendered | 16/04/2003 | 4/07/2016 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-152 | Institute of Medical and Veterinary Science | Induction of Autoimmune Prostatitis in DA Rats and B6 Mice Using Recombinant Vaccinia Virus Vectors That Encode Human, Rat or Murine Prostatic Acid Phosphatase | The aim of this dealing is to induce experimental prostatitis in laboratory strains of rats by infecting them with recombinant vaccinia virus vectors containing the gene for human prostatic acid phosphatase. | Integrated into DNIR-151 | | |
| DNIR-153 | CSIRO | Isolation and expression of genes from endogenous soil microorganisms | The aim of this dealing is to clone various genes from soil microorganisms. The gene products will be investigated for use in the degradation of pesticide residues/toxins or for their insecticidal properties. | Expired | 23/04/2003 | 30/04/2013 |
| DNIR-154 | Monash University | Novel Virulence Determinants of Enterohemorrhagic Escherichia coli | The aim of this dealing is to identify and characterise bacterial genes in EHEC that may be required for colonisation of the host. | Expired | 24/04/2003 | 30/04/2008 |
| DNIR-155 | Progen Industries Limited | MPT64 | The aim of this dealing is to generate recombinant protein (MPT64) that will be purified and formulated into a topical drug for clinical investigation in humans. | Expired | 28/04/2003 | 30/04/2008 |
| DNIR-156 | The University of Western Australia | Gene Mediated Cell Death in Ovarian Cancer | The aim of this dealing is to study gene mediated cell death in ovarian cancer by infecting human cancer cells with viral particles containing the Y81 gene. The Y81 protein is hypothesised to slow the growth of the infected cells. | Expired | 30/04/2003 | 30/04/2006 |
| DNIR-157 | The University of Queensland | Molecular Analysis of Cucumber Mosaic Virus Host Range Factors | The aim of this dealing is to study CMV replication, symptom development and host range by inoculating plants with CMV and recombinant CMV RNA. | Surrendered | 22/04/2003 | 19/07/2017 |
| DNIR-158 | Western Sydney Local Health District | Focal Modification of Cardiac Conduction By Gene Transfer | The aim of this dealing is to introduce specific genes into human and animal cells in order to induce electrical conduction between these cells in network. | Surrendered | 1/05/2003 | 8/04/2008 |
| DNIR-159 | Australian National University | Flavivirus Host/Pathogen Interactions | The aim of this dealing is to study flaviviral host/pathogen interactions in mice and mammalian and mosquito cell lines. | Expired | 1/05/2003 | 31/05/2013 |
| DNIR-160 | The University of Queensland | Metabolic Engineering of Hyaluronic Acid (HA) Production | HA forms the capsule of some Group A and C streptococci. The aim of this dealing is to identify and study genes involved in the regulation of HA production. | Surrendered | 6/05/2003 | 6/12/2024 |
| DNIR-161 | Queensland University of Technology | Expression of Adhesins From Bacterial Pathogens in Non-Pathogenic Lactic Acid Bacteria | The aim of this dealing is to genetically modify non-pathogenic lactic acid bacteria to express adhesin molecules from pathogenic organisms. | Surrendered | 7/05/2003 | 22/01/2009 |
| DNIR-162 | Queensland University of Technology | Investigation of Host Range Determinants in Papaya Ringspot Virus | There are two types of PRSV (P & W) that differ in host range – ie. one infects papaya and another does not. The aim of this dealing is to determine the gene sequence/s that allow PRSV to infect papaya. | Expired | 8/05/2003 | 31/10/2008 |
| DNIR-163 | Queensland University of Technology | The Development of Glycine Mosaic Comovirus (GMV) as a Vactor for Heterogous Gene Expression in Plants | The aim of this dealing is to test GMV-based vectors for high level expression of genes in plants. | Expired | 8/05/2003 | 30/06/2006 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-164 | CSIRO | Small RNA viruses of insects | The aim of this dealing is to study the potential use of small RNA viruses of insects for pest control and biotechnological purposes. | Expired | 9/05/2003 | 31/05/2013 |
| DNIR-165 | Xenome Limited | Isolation and Characterisation of Venom Peptide Genes | The aim of this dealing is to investigate venom peptides for therapeutic potential. | Surrendered | 12/05/2003 | 14/10/2010 |
| DNIR-166 | Mater Research Ltd | Retroviral Expression Cloning to Discover New Molecules Expressed by Leucocytes | The aim of this dealing is to isolate novel gene sequences from leukocytes (white blood cells) to better understand immune function. | Expired | 12/05/2003 | 31/05/2008 |
| DNIR-167 | CSIRO | Production of Recombinant Proteins By Vaccinia Virus For In Vitro Uses | The aim of this dealing is to express proteins in vaccinia virus that will be used in serological assays. | Surrendered | 12/05/2003 | 26/08/2005 |
| DNIR-168 | Hunter Grain Pty Ltd | Yellow Corn Import | The applicant intends to import grain from the USA for processing as stockfeed. Since there are commercial crops of GM corn in the USA, the shipment may contain GM corn. | Expired | 2/01/2003 | 30/04/2003 |
| DNIR-169 | Hunter Grain Pty Ltd | Importation of soybeans for processing into soy oil and stockfeed | The applicant intends to import soybeans from the USA for expelling and solvent extraction to produce soybean meal to be used for stockfeed purposes and soybean oil to be used for human consumption as margarines and cooking oils (approved by FSANZ in 2000). Since there are commercial crops of GM soybeans in the USA, the shipment may contain GM soybeans. | Expired | 3/01/2003 | 30/09/2003 |
| DNIR-170 | Johnson & Johnson Research Pty Ltd | A randomized Phase II, double blind, controlled trial to evaluate the safety and efficacy of autologous CD34+ hematopoietic progenitor cells transduced with either a delivery gene construct (LNL6) or LNL6 that contains an anti-HIV-1 ribozyme (OZ1) in patients with HIV-1 infection | The proposed dealing is to modify progenitor haematopoietic cells taken from HIV-1 infected patients to carry either a retroviral vector containing an anti-HIV-1 ribozyme or only the retroviral vector. | Surrendered | 13/05/2003 | 19/01/2007 |
| DNIR-171 | Macquarie University | Comparative Genomics of Equine Herpesviruses | The aim of this dealing is to analyse gene functions of EHV-1 and EHV-4 which are genetically closely related but have different cell culture host ranges and disease outcomes. | Expired | 2/05/2003 | 31/01/2007 |
| DNIR-172 | CSIRO | Myxoma Virus/ Kunjin Replicon Vaccine System | The aim of this dealing is to produce a recombinant Myxoma/ Kunjin virus that expresses genes encoding reproductive proteins. This recombinant virus will be tested as an immuno-contraceptive delivery system in rabbits. | Surrendered | 14/05/2003 | 26/08/2005 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-173 | The University of Adelaide | Molecular Breeding Of Grapevines for Resistance to Major Root Pests | The aim of the proposed dealings is to develop transgenic grapevines that are resistant to root pests by incorporating the genes for cyanogenic glucoside biosynthesis into these plants or by altering the expression of plant genes involved in root pest feeding sites. | Expired | 15/05/2003 | 30/11/2009 |
| DNIR-174 | The University of Sydney | Cloning of Duck Hepatitis B Virus | The aim of this dealing is to clone naturally occurring variants of DHBV and to assess the infectivity of these variants in cell cultures and ducklings. | Expired | 23/05/2003 | 30/06/2007 |
| DNIR-175 | Virax Holdings Limited | Clinical Trial of Fowlpox Virus Vaccines Expressing HIV-1 Antigens and Human Interferon-gamma | The aim of this dealing is to express HIV antigens and interferon-gamma in fowlpox virus and to use this virus to elicit an immune response to these antigens in HIV infected individuals. | Expired | 10/06/2003 | 31/10/2013 |
| DNIR-176 | The University of Western Australia | Characterisation of Haemolysin produced in Vibrio alginolyticus | The aim of this dealing is to characterise the haemolysin produced by Vibrio alginolyticus and determine its relationship to other previously reported haemolysins. | Expired | 10/06/2003 | 30/06/2008 |
| DNIR-177 | Children's Medical Research Institute | Immortalisation of human cells | The aim of this dealing is to use human cells transformed with genes that may alter their growth properties to study how normal cells become cancer cells. | Surrendered | 10/06/2003 | 15/02/2008 |
| DNIR-178 | The Children's Hospital Westmead | Functional and Mollecular Analysis of Defects of the Mitochondiral Electron Transport Chain | The aim of this dealing is to study immortalised human cells that have a metabolic defect of the mitochondrial energy production pathways to determine on which chromosome the disease causing gene is located. | Expired | 6/06/2003 | 30/06/2006 |
| DNIR-179 | The Children's Hospital Westmead | Ex-Vivo Retroviral Transduction of CD34+ Selected Haemopoietic Stem Cells for Clinical Gene Therapy Trials | The aim of this dealing is to introduce genes into CD34+ haemopoietic stem cells to treat patients with X-linked Severe Combined Immunodeficiency and to provide resistance to alkylating drugs used in cancer therapy. | Expired | 10/06/2003 | 30/06/2013 |
| DNIR-180 | The University of Queensland | Functional Analysis of Cloned Avirulence/Pathogenesis Genes From Plant Pathogenic Microbes | The aim of this dealing is to determine the function of cloned genes encoding putative avirulence and pathogenesis determinants in pathogenic fungi and oomycetes. | Expired | 30/06/2003 | 30/06/2014 |
| DNIR-181 | Sugar Research Australia Limited | Transposition and Marker Exchange Mutagenesis of Leifsonia xyli Subspecies to Study Pathogenesis on Sugarcane | The aim of these dealings is to identify the genes from Leifsonia xyli involved in the interaction of this pathogen with sugarcane, in order to identify targets for antimicrobial compounds or antibodies. | Surrendered | 11/06/2003 | 5/12/2012 |
| DNIR-182 | Sugar Research Australia Limited | Development of a Virus Based Assay system to Elucidate Gene Function in Sugarcane | The aim of this dealing is to produce a virus-based vector containing sugarcane virus gene sequences that will be used in further studies to elucidate the function of sugarcane genes. | Surrendered | 11/06/2003 | 17/12/2007 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-183 | La Trobe University | Nucleotide Sequences of The Coat Protein of Johnsongrass Mosaic Virus (JMV) Determining Host Specificity | The aim of this dealing is to identify the critical changes in the amino acids of the JGMV coat protein that allowed the recent evolution of a Krish sorghum-infecting strain of JGMV. | Expired | 5/06/2003 | 31/12/2004 |
| DNIR-184 | Ludwig Institute for Cancer Research Ltd | Induction of Tumour Formation and Tumour Regression by Adenoviral -Mediated Gene Transfer | The aim of this dealing is to introduce genes that are involved in tumour formation and suppression into cultured cells and mice to mimic and/or reverse the sporadic genetic alterations that occur in adults with colorectal cancer. | Expired | 13/06/2003 | 30/06/2008 |
| DNIR-185 | CSIRO | Use of Virus Vectors For Gene Silencing in Plants (Virus Induced Gene Silencing) | The aim of this dealing is to infect plants of interest with viruses containing RNA sequences that will silence specific genes in the plants in order to identify agronomically important genes. | Expired | 16/06/2003 | 30/04/2014 |
| DNIR-186 | Macfarlane Burnet Institute for Medical Research and Public Health | Molecular Virology of HIV-1 and SIV | This dealing aims to understand the regulation and role of the various SIV, HIV-1 and HIV-2 genes in virus production and pathogenesis by comparative analysis of generated mutant variants of these viruses. | Licence issued | 13/06/2003 | 31/01/2028 |
| DNIR-187 | Macfarlane Burnet Institute for Medical Research and Public Health | Viral Assembly of MoMLV, M-PMV, HFV and ASLV | The aim of this dealing is to understand the role of various Moloney murine leukaemia virus, Mason-Pfizer monkey virus, human foamy virus or avian sarcoma/leukosis virus genes by transfecting mammalian cells with mutated or wild type clones of these retroviruses. | Licence issued | 16/06/2003 | 31/01/2028 |
| DNIR-188 | Macfarlane Burnet Institute for Medical Research and Public Health | Pathogenesis of macrophage-tropic HIV-1 | The aim of this dealing is to examine the ability of HIV-1 strains to induce cell killing by transfecting mammalian cell lines with HIV-1 DNA. | Expired | 16/06/2003 | 30/06/2006 |
| DNIR-189 | Johnson & Johnson Research Pty Ltd | In vitro Murine and Human Cell Transformation or Mouse Reconsitution for a Gene Terapy approach to Accute Myeloid leukaemia | The aim of this dealing is to develop a model for leukemia (or lymphoma) development by oncogene activation and to use the model to assess the effects of tumour suppressor genes in arresting leukemia (or lymphoma) development. | Surrendered | 17/06/2003 | 26/06/2008 |
| DNIR-190 | Macfarlane Burnet Institute for Medical Research and Public Health | Cellular immunity to HIV and HCV | The aim of this dealing is to examine cellular immunity to HIV and HCV by expressing part of the HIV or HCV genome in vaccinia virus and infecting human cells with this virus. | Expired | 16/06/2003 | 30/06/2012 |
| DNIR-191 | Australian National University | Signalling pathways for the induction and maintenance of tolerance to islet allografts and xenografts and for the re-establishment of tolerance to islet beta cells in NOD mice | The aim of this dealing is to assess the tolerance of mice to pancreatic islet transplants following the delivery of immunoregulatory genes to the donor tissue or pre-treatment of the mice with cells expressing the same genes. | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-192 | Australian National University | Immunoregulatory gene studies and vaccine vector library development | The aim of this dealing is to develop an ongoing library of vaccine vectors for use in vaccine development and the study of immunoregulatory molecules. | Licence issued | 18/06/2003 | 30/09/2028 |
| DNIR-193 | The University of Queensland | Studies on the immune response to recombinant vaccinia virus | The aim of this dealing is to use vaccinia viruses containing papillomavirus genes to study the processes governing immune activation or tolerance to DNA tumour viruses and to improve the quality of immune responses against human papillomavirus proteins. | Expired | 16/06/2003 | 30/06/2012 |
| DNIR-194 | Monash University | Evaluation of cellular immunological function with recombinant virus | The aim of this dealing is to evaluate if treatment can augment or sustain the cellular anti-HIV response of HIV positive patients and help further define the mechanisms involved. | Surrendered | 5/06/2003 | 25/11/2008 |
| DNIR-195 | Flinders University | Intracellular calcium signalling and liver disease | The aim of this dealing is to introduce genes involved in calcium channels into primary rat hepatocyte tissue culture cells. | Withdrawn | | |
| DNIR-196 | Flinders University | Transplantation of corneal and limbal stem cell allografts | The aim of this dealing is to infect the eye of rats or sheep with an adenovirus carrying genes encoding specific proteins that may prevent corneal and limbal stem cell graft rejection. | Withdrawn | | |
| DNIR-197 | CSIRO | DNA Viruses of Invertebrates | The aim of this dealing is to produce recombinant insect DNA viruses to improve understanding of their properties and characteristics and to assess their suitability as biological control agents for insect pests. | Expired | 20/06/2003 | 31/05/2013 |
| DNIR-198 | Macfarlane Burnet Institute for Medical Research and Public Health | The expression of leukocyte antigens | The aim of this dealing is study the role of a variety of leukocyte antigens, especially cell surface antigens in leukocyte function. | Expired | 18/06/2003 | 31/12/2008 |
| DNIR-199 | CSIRO | Tracking soil micro-organisms using marker genes | The aim of this dealing is to study the ecology of soil microbes that have been selected for their beneficial effects on crop plant growth using marker genes to monitor their activities. | Withdrawn | | |
| DNIR-200 | University of Canberra | Mutagenesis of vaccine antigen genes and related proteins in bacterial respiratory pathogens | The aim of this dealing is to disrupt genes encoding candidate vaccine antigens and related proteins in bacterial respiratory pathogens to gain a better understanding of their function. | Surrendered | 20/06/2003 | 30/06/2008 |
| DNIR-201 | The University of Melbourne | The Mechanisms of Tolerance and Immunity in Systemic Rheumatic Diseases | The aim of this study is to examine immunological tolerance to self antigens when they are encountered during an infection by infecting mice with vaccinia viruses containing genes encoding self or foreign antigens. | Surrendered | 20/06/2003 | 19/10/2010 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-202 | The University of Melbourne | Gene Regulation in Osteoclastogenesis | The aim of this project is to examine the action of candidate genes on the process of osteoclast generation from precursor cells by infecting these cells with adenoviruses/retroviruses containing the candidate genes. | Surrendered | 20/06/2003 | 21/08/2007 |
| DNIR-203 | The University of Melbourne | Construction and use of Herpes simplex virus mutants | The aim of this dealing is to determine how minor changes to the HSV viral protein gB will alter the response of cytotoxic T lymphocytes by infecting mice with HSV-1 gB mutants. | Surrendered | 19/06/2003 | 22/09/2011 |
| DNIR-204 | The University of Melbourne | Molecular Biology of retroviral Replication, Pathogenesis and Productive Infection | The aim of this dealing is to study the RNA elements that modulate the expression of HIV proteins and to develop drugs that target these elements. | Expired | 20/06/2003 | 20/08/2017 |
| DNIR-205 | The University of Melbourne | Nucleic Acid (DNA and RNA) and Viral Vectored Vaccines for HIV | The aim of this dealing is to develop a safe and effective vaccine against HIV by injecting animals with DNA plasmids, a recombinant fowlpoxvirus or a recombinant sindbis virus containing HIV or SIV genes. | Surrendered | 20/06/2003 | 30/11/2012 |
| DNIR-206 | CSIRO | Effect of growth hormone transgenesis on wool, meat and milk production in sheep | The aim of this dealing is to modify a growth hormone gene and insert it into the genome of sheep to determine its effects on wool, meat and milk production. | Withdrawn | | |
| DNIR-207 | The University of New England | Molecular Aspects of Plant -Pathogen Interactions - Thielaviopsis | The aim of this dealing is to identify genes in T. basicola (a pathogen causing black root disease in plants) which may be involved in virulence. | Expired | 1/07/2003 | 31/12/2008 |
| DNIR-208 | Harry Perkins Institute of Medical Research | Recombinant Murine Cytomegalovirus Encoding Hepatitis Virus C Proteins | The aim of this dealing is to use MCMV as a delivery vehicle to express HCV proteins in murine liver. | Surrendered | 20/06/2003 | 23/10/2026 |
| DNIR-209 | The University of Western Australia | Assessment of Outcrossing Under Idealised Conditions for Chickpeas | The aim of this dealing is to interplant chickpea plants containing the bar gene with non-transgenic chickpea plants and assessing the seed from non-transgenic plants for the presence of the bar gene after insect pollination. | Withdrawn | | |
| DNIR-210 | The University of Western Australia | Use of Vaccinia Virus as a Vector for Antigens and Cytokines in Murine Tumour Models | The aim of this dealing is to determine if recombinant Vaccinia virus can induce long term protection against tumour growth and induce tumour regression. | Licence issued | 20/06/2003 | 31/05/2027 |
| DNIR-211 | The University of Sydney | Construction and Manipulation of an Infectious cDNA clone of Enterovirus 71 and Coxsackievirus A16 | The aim of this dealing is to investigate the molecular basis of human enterovirus 71 virulence by inserting genome regions from related viruses of low virulence into its genetic background. The virulence of these chimeras will be studied in the mouse model. | Expired | 18/06/2003 | 20/02/2018 |
| DNIR-212 | The University of Adelaide | Pathogenicity and virulence genes of the barley pathogen Rhynchosporium secalis | The aim of this dealing is to identify and isolate pathogenicity determinant genes from the barley pathogen R. secalis. | Surrendered | 20/06/2003 | 20/09/2004 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-213 | Alpharma Animal Health Pty Ltd | Porcine growth hormone | The aim of this dealing is to continue the commercial production of porcine somatotropin which is sold into Australian and international markets under the tradename Reporcinâ. | Surrendered | 15/08/2003 | 7/01/2008 |
| DNIR-214 | CSIRO | Adenoviruses as Gene Delivery Vectors | The aim of the proposed dealings is to develop and characterise human and ovine adenovirus vectors for use in gene therapy and vaccine development. | Expired | 20/06/2003 | 30/06/2011 |
| DNIR-215 | The University of Queensland | Gene therapy of hypertension tumor sensitisation to radiotherapy | The aim is to develop gene therapy strategies using replication defective viral vectors for the treatment of hypertension and tumours. | Surrendered | 19/03/2003 | 9/07/2015 |
| DNIR-216 | The University of Melbourne | Development of Trichoderma harzianum for biocontrol of plant pathogens | The aim of this dealing is to improve the biocontrol efficacy of Trichoderma harzianum by inserting the chitinase gene into its genome. | Expired | 28/07/2003 | 31/03/2004 |
| DNIR-217 | The University of Western Australia | Structure/activity of novel toxins from native venomous organisms (jellyfish) | The aim of this dealing is to produce milligram quantities of toxic jellyfish and snake venom proteins by expressing them in Escherichia coli. The structure and activity of these proteins will then be investigated. | Surrendered | 1/08/2003 | 4/01/2007 |
| DNIR-218 | CSIRO | Generation of Recombinant Canine Herpesvirus | The aim of this dealing is to develop recombinant CHVs that express heterologous antigens derived from genomic, viral, protozoan or bacterial genes. These viruses will be used as experimental vaccines to immunise foxes, dogs and ferrets against infectious diseases and/or to reduce their fertility. | Surrendered | 4/08/2003 | 26/08/2005 |
| DNIR-219 | Centenary Institute of Cancer Medicine and Cell Biology | Recombinant mycobacteria as new anti-tuberculosis vaccines | The aim of this dealing is to express mycobacterium tuberculosis antigens in the vaccine strain Mycobacterium bovis BCG to develop a potential tuberculosis vaccine. | Surrendered | 4/08/2003 | 21/12/2007 |
| DNIR-220 | Menzies School of Health Research | Cloning of Streptococcal DNA to and from Streptococcal species | The aim of this dealing is to understand how streptococcal gene products contribute to the pathogenesis of streptococcal infections by inserting the genes of interest into strains of streptococci that do not normally harbour these genes. | Surrendered | 6/08/2003 | 3/06/2008 |
| DNIR-221 | QIMR Berghofer | Cloning of DNA Between Group A Streptococcal Strains | The aim of this dealing is to understand how group A streptococcal (GAS) gene products contribute to the pathogenesis of streptococcal infections by inserting the genes of interest into GAS strains that do not normally harbour these genes. | Expired | 6/08/2003 | 31/05/2021 |
| DNIR-222 | QIMR Berghofer | Expression of Virus Encoded Antigens Using Vaccinia Expression System | The aim of this dealing is to study in vitro T lymphocyte responses to cells infected with recombinant vaccinia viruses expressing Cytomegalovirus (CMV) or Epstein-Barr Virus (EBV) proteins. | Licence issued | 6/08/2003 | 31/05/2028 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-223 | Central Adelaide Local Health Network | Identification of novel molecular targets in angiogenesis | The aim of this dealing is to identify genes involved in endothelial cell function by overexpressing genes of interest in human endothelial cells and mice using viral vectors. | Surrendered | 8/07/2003 | 20/01/2012 |
| DNIR-224 | Macfarlane Burnet Institute for Medical Research and Public Health | Molecular virology of hepatitis A, B and E viruses | The aim of this dealing is to investigate the role of various hepatitis genes and gene products in the gene expression, replication, virus particle assembly and pathogenesis of hepatitis A, B and E. | Expired | 14/07/2003 | 24/12/2019 |
| DNIR-225 | Ludwig Institute for Cancer Research Ltd | Mouse models of colorectal cancer using a TVA-based retroviral gene transfer system | The aim of this dealing is to investigate the role of various genes in colorectal cancer by transferring candidate oncogenes and a tumour suppressor gene directly into the intestinal epithelium of mice using an avian retrovirus. | Surrendered | 13/08/2003 | 29/11/2012 |
| DNIR-226 | Department of Jobs, Precincts and Regions | Molecular Breeding Of Grapevines for Resistance to Major Root Pests | The aim of the proposed dealings is to challenge transgenic grapevines with root pests and monitor their response. | Expired | 15/05/2003 | 30/06/2005 |
| DNIR-227 | The University of Western Australia | Structure/activity of novel toxins from native venomous organisms (Brownsnake) | The aim of this dealing is to introduce genes encoding brown snake venom proteins into bacterial and/or eukaryotic hosts to produce milligram quantities of these proteins for biophysical and functional studies. | Integrated into DNIR-217 | | |
| DNIR-228 | Queensland University of Technology | The development of tobacco mosaic virus (TMV) as a vector for heterologous gene expression | The researchers intend to use TMV to deliver heterologous genes to plants with the purpose of expressing high levels of these genes in the plants. | Withdrawn | | |
| DNIR-229 | Queensland University of Technology | Development of a tobacco rattle virus-based RNA amplification system in tobacco | The researchers intend to use non-infectious RNA components of Tobacco rattle virus to deliver heterologous genes to tobacco plants with the purpose of enhancing the expression of these genes in the plants. | Withdrawn | | |
| DNIR-230 | Adelaide University | Pathogenesis, prevention and treatment of Shiga toxigenic Escherichia coli (STEC) infections | The aim of this dealing is to clone and characterise STEC genes involved in the pathogenesis of disease in order to identify novel drug targets and develop vaccines against STEC infection. | Licence issued | 26/06/2003 | 31/05/2029 |
| DNIR-231 | The University of Adelaide | Pathogenesis and prevention of pneumococcal disease | The aim of this dealing is to clone and characterise Streptococcus pneumoniae genes involved in the pathogenesis of pneumococcal disease in order to identify novel drug targets and develop vaccines against pneumococcal disease. | Integrated into DNIR-230 | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-232 | The University of Newcastle | HIV vaccine design and development teams | The aim of this dealing is to develop a safe and effective vaccine against HIV using a mouse model using DNA vaccines and recombinant fowlpoxvirus vaccines to induce both mucosal and systemic HIV-specific immune responses. | Surrendered | 7/07/2003 | 3/05/2004 |
| DNIR-233 | Murdoch University | Mutation of an infectious clone of BIV R29 | The aim of this dealing is to identify the role of the bovine immunodeficiency virus (BIV) genes vif and tmx in viral replication and pathology and to assess the ability of homologous genes from the related Jembrana disease virus (JDV) to act as functional homologues. | Expired | 28/08/2003 | 31/08/2008 |
| DNIR-234 | Murdoch University | Transomplementation of vif deleted BIV with bovine lentivirus | The aim of this dealing is to identify the role of the bovine immunodeficiency virus (BIV) genes vif and tmx in viral replication and pathology and to assess the ability of homologous genes from the related Jembrana disease virus (JDV) to act as functional homologues. | Integrated into DNIR-233 | | |
| DNIR-235 | Murdoch University | Use of an infectious clone of BIV R29 | The aim of this dealing is to identify the role of the bovine immunodeficiency virus (BIV) genes vif and tmx in viral replication and pathology and to assess the ability of homologous genes from the related Jembrana disease virus (JDV) to act as functional homologues. | Integrated into DNIR-233 | | |
| DNIR-236 | Women's and Children's Health Network Incorporated | Functional analysis of genes involved in haemopoiesis by retroviral expression in human cells and cell lines | This project aims to investigate the function of various genes involved in normal and abnormal growth of human blood cells. | Expired | 9/07/2003 | 31/07/2008 |
| DNIR-237 | Department of Primary Industries | Vaccination of cattle with recombinant bovine herpesvirus 1 | DNA from bovine pestivirus will be inserted into the genome of bovine herpesvirus 1 and cattle will be inoculated with the modified virus in order to elicit protective immune responses to both viruses. | Withdrawn | | |
| DNIR-238 | Murdoch University | Mutational Analysis of the Australian Strain of Procine circovirus type 1 | The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2. | Expired | 16/09/2003 | 31/08/2007 |
| DNIR-239 | Murdoch University | Production of an infectious clone from the Australian Strain of Procine circovirus type 1 | The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2. | Integrated into DNIR-238 | | |
| DNIR-240 | Murdoch University | Mutational Analysis of the Australian Strain of Procine circovirus type 2 | The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2. | Integrated into DNIR-238 | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-241 | Murdoch University | Production of an infectious clone from the Australian Strain of Procine circovirus type 2 | The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2. | Integrated into DNIR-238 | | |
| DNIR-242 | The University of Queensland | Investigating the molecular pathways controlling cell survival in acute and chronic renal failure | The aim of this dealing is to modify renal disease processes by using replication defective lentiviruses to overexpress various genes associated with apoptosis (programmed cell death) in the rats and mice. | Surrendered | 7/07/2003 | 28/07/2016 |
| DNIR-243 | The University of Melbourne | Investigating the biological requirements for prion formation | The aim of this dealing is to transform bacterial, fungal and mammalian cells with the gene encoding the prion protein (PrP) and use these cells to study PrP function and metabolism. | Expired | 12/08/2003 | 30/06/2007 |
| DNIR-244 | CSIRO | Development of daughterless carp technology (Zebrafish) | The aim of these dealings is to use RNA interference technology in zebrafish, carp and mosquito fish to sex bias these fish as a means of controlling their population. | Withdrawn | | |
| DNIR-245 | CSIRO | Development of daughterless carp technology (Mosquitofish) | The aim of these dealings is to use RNA interference technology in zebrafish, carp and mosquito fish to sex bias these fish as a means of controlling their population. | Withdrawn | | |
| DNIR-246 | CSIRO | Development of daughterless carp technology (Medaka) | The aim of these dealings is to use RNA interference technology in zebrafish, carp and mosquito fish to sex bias these fish as a means of controlling their population. | Withdrawn | | |
| DNIR-247 | Virax Holdings Limited | GMP Manufacturing of recombinant fowlpox viruses vectored vaccines | The researchers intend to undertake large-scale production of recombinant fowlpox virus vector-based vaccines from tissue cultured avian cells. | Expired | 30/09/2003 | 30/09/2008 |
| DNIR-248 | Pfizer Australia Pty Ltd | Production of Neovac antigens | The aim of this dealing is to produce four types of recombinant pili antigens to be used in the manufacture of a vaccine against neonatal scours in pigs. | Expired | 30/09/2003 | 30/09/2012 |
| DNIR-249 | The University of Adelaide | Studies of avian hepatitis B viruses - virulence, replication and pathogenesis | The aim of this dealing is to introduce mutations into cloned genomes of avian hepatitis B virus isolates and then compare the replication and pathogenesis of the wild type and mutant strains in vitro and in vivo. | Expired | 1/07/2003 | 30/06/2013 |
| DNIR-250 | The University of Adelaide | Cellular interactions between HBV and HCV | The aim of this dealing is to transfect cultured liver cells containing a non-infectious hepatitis C virus (HCV) replicon with hepatitis B virus (HBV) and investigate the effect of HBV replication on HCV replication, cell growth, cell viability and cellular gene expression. | Expired | 2/10/2003 | 31/07/2013 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-251 | Monash University | Function of Dichelobacter nodosus genes | The aim of this dealing is to isolate and characterise genes that may have a role in conferring virulence and pathogenesis in Dichelobacter nodosus the causative agent of footrot in sheep, cattle and goats. | Surrendered | 23/06/2003 | 24/06/2008 |
| DNIR-252 | University of Technology Sydney | Paralysis Tick Vaccine Development | The aim of this dealing is to produce recombinant forms of Australian paralysis tick (Ixodes holocyclus) salivary proteins for the development of a veterinary vaccine. | Expired | 9/07/2003 | 30/11/2011 |
| DNIR-253 | St Vincent's Hospital Sydney Limited | HIV biology | The aim is to understand the biology of the human immune deficiency virus as the basis for better drug and vaccine development. | Expired | 21/10/2003 | 31/10/2017 |
| DNIR-254 | The University of Western Australia | Evaluation on the effects of apoptosis and necrosis on tumour antigen presentation and anti-tumour response | The aim of this dealing is to determine whether induction of different types of cell death mechanisms in tumours can increase the immune response to these tumours. | Surrendered | 3/10/2003 | 4/04/2007 |
| DNIR-255 | Griffith University | Studies on the virulence and physiology of Burkholderia psudomallei | The aim of this dealing is to identify and characterise virulence genes in the pathogen B. pseudomallei, including those involved in adherence to epithelial cells, and to develop diagnostic and preventative strategies. | Expired | 8/08/2003 | 30/09/2015 |
| DNIR-256 | CSIRO | Genetics of Clostridium perfringens pathogenesis | The aim of this dealing is to investigate the role of specific, defined toxin proteins in the pathogenesis of C. perfringens. | Expired | 6/11/2003 | 30/06/2008 |
| DNIR-257 | CSIRO | Live bacterial vectors for delivery of recombinant proteins to the chicken gut | The aim of this dealing is to use benign bacterial strains isolated from the chicken gut to deliver therapeutic proteins such as cytokines, bacteriocins, single chain antibodies and vaccine antigens to the chicken gut. | Withdrawn | | |
| DNIR-258 | Australian Red Cross Blood Service - Endeavour | Cell mediated immune responses against blood borne viral pathogens | This study aims to express genes from the human pathogenic viruses HIV and HCV in mammalian cell cultures for use as targets in cytotoxic T lymphocyte (CTL) activity assays or antigen presenting cells to stimulate virus-specific CTLs in vitro. | Surrendered | 5/08/2003 | 31/07/2008 |
| DNIR-259 | Department of Primary Industries | Study of plant Virus interactions using fluorescence tagged viruses | The aim of this dealing is to study the function of viral genes in virus movement and host interaction in resistant and susceptible plants. | Surrendered | 30/10/2003 | 22/02/2005 |
| DNIR-260 | Royal Perth Hospital | Use of Adenovirus and Adenovirus associated virus gene delivery systems for the expression of HCV proteins | Recombinant adenovirus and adeno-associated viruses carrying hepatitis C virus (HCV) genes will be used to produce HCV proteins in cell cultures and mice. This will enable studies on the structure and function of the proteins and act as a source of HCV protein for immune studies. | Surrendered | 30/10/2003 | 3/09/2013 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-261 | EnGeneIC Limited | Novel Gene Delivery Vector | The aim of this dealing is to develop a novel drug delivery vector that combines drug biosynthesis and targeted delivery. | Expired | 31/10/2003 | 30/04/2017 |
| DNIR-262 | Peter MacCallum Cancer Centre | Molecular analysis of cell cycle and polarity in development and tumourigenesis | The aim of this dealing is to generate cells and mouse tissues modified to express or down-regulate genes involved in the pRB/E2F and Scrib/Dlg/Lgl pathways and study their role in tumour development. | Withdrawn | | |
| DNIR-263 | University of Technology Sydney | Development of recombinant immunotoxins | The aim of this dealing is to develop a recombinant cytotoxic agent (which is not a GMO) that can be tested as a therapeutic agent for cancer. | Expired | 9/09/2003 | 31/01/2008 |
| DNIR-264 | Western Sydney Local Health District | Liver cell biology and liver injury, metabolic liver disease and mitochondrial dysfunction in drug-induced liver disease | The aim of this dealing is to use mice and rats with experimentally induced liver injury to identify cellular proteins that mediate important liver injury resulting from medical conditions or after exposure to alcohol and drug toxins. | Surrendered | 19/09/2003 | 30/09/2008 |
| DNIR-265 | University of New South Wales | Transformation of human cells by human Papillomavirus transforming genes | The aim of this study is to discover the functions of human papillomavirus E6 and E7 proteins by introducing the genes encoding these proteins into normal and/or immortalised human cells. | Withdrawn | | |
| DNIR-266 | Melbourne Health | Construction of influenza viruses by reverse genetics for diagnostic and research purposes. | The aim of this project is to employ a technique known as reverse genetics to produce Influenza viruses synthetically in order to derive potential Influenza virus vaccine candidates in a more rapid and reproducible manner. | Surrendered | 27/11/2003 | 14/10/2013 |
| DNIR-267 | Queensland University of Technology | Chimeric Dengue vaccines | The aim of this dealing is to elicit an immune response against multiple Dengue virus serotypes in mice using a recombinant Dengue virus or a plasmid containing Dengue virus envelope protein genes from two or more serotypes. | Surrendered | 18/11/2003 | 16/05/2007 |
| DNIR-268 | Queensland University of Technology | The development of a novel resistance strategy against ssDNA plant viruses | The aim of this dealing is to develop resistance to single stranded DNA viruses in several plant species by introducing a gene to these plants that will trigger the death of infected cells when exposed to a particular viral protein. | Surrendered | 27/11/2003 | 30/04/2007 |
| DNIR-269 | Murdoch Children's Research Institute | Characterisation of genes involved in haematopoietic stem cell growth and regulation | This project will examine the role of known and novel genes in human blood cell growth with the aim of learning more about normal blood cell development and what goes wrong in this process to cause leukaemia. | Surrendered | 12/12/2003 | 25/11/2008 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-270 | The Walter and Eliza Hall Institute of Medical Research | Retroviral and adenoviral mediated gene transfer into murine mammary cells and breast cancer cell lines | The aim of this dealing is to study the role of specific genes in cell growth, mammary gland development and oncogenesis. | Surrendered | 18/12/2003 | 28/09/2007 |
| DNIR-271 | University of Technology Sydney | Investigations on parasite virulence using cross complementation | The goal of this project is to use a genetic approach to investigate the regions of the parasitic proteins GRA2 and GRA6 involved in Toxoplasma gondii and Neospora caninum virulence. | Expired | 10/12/2003 | 31/12/2008 |
| DNIR-272 | The University of Queensland | Delivery of replication defective lentiviruses into mice | The aim of this dealing is to develop novel anticancer treatments against both skin cancers and cancers caused by viruses, using a mouse model. | Surrendered | 10/12/2003 | 8/10/2008 |
| DNIR-273 | Western Sydney Local Health District | Repression of hepatic drug metabolism by solid tumours | The aim of this dealing is to investigate how the inflammatory factors released by tumours into the blood reduce hepatic levels of enzymes involved in drug metabolism. | Surrendered | 9/12/2003 | 13/06/2007 |
| DNIR-274 | Australian Defence Force Malaria and Infectious Disease Institute | Experimental Infection of Culex annulirostris, Ochlerotatus vigilax and Culex gelidus with Japanese encephalitis virus vaccine candidate ChimeriVax™-JE | The aim of this dealing is to assess the potential of the ChimeriVax™-JE vaccine to infect and replicate in Australian mosquitoes. | Surrendered | 29/01/2004 | 12/02/2007 |
| DNIR-275 | Biotron Limited | Viral protein gene function in whole virus for screening anti-viral compounds | The aim of this dealing is to screen for novel compounds which disrupt viral replication using whole recombinant viruses. | Surrendered | 22/01/2004 | 11/03/2011 |
| DNIR-276 | QIMR Berghofer | Functional analysis of DNA damage responsive genes by retroviral transfections | The aim of this dealing is to overexpress or inhibit the expression of genes encoding proteins involved in DNA damage repair. This will allow the proponents to determine the function and importance of these genes in keeping the genome intact and preventing cancer. | Surrendered | 18/12/2003 | 17/10/2007 |
| DNIR-277 | Cargill Australia Limited | Importation and Processing Soybeans | The applicant intends to import soybeans from the USA, Argentina, and Brazil for processing as oil and stockfeed. Since there are commercial crops of GM soybeans in these countries, the shipment may contain GM soybeans. | Expired | 19/12/2003 | 31/07/2023 |
| DNIR-278 | The University of Newcastle | Analysis of oncogenes and their protein products, and investigation of drug resistance mechanisms. | The purpose of this dealing is to investigate specific genes involved in the onset of cancers and characterise various mechanisms of cancer cell drug resistance to conventional and new cancer therapies. | Surrendered | 23/12/2003 | 17/12/2008 |
| DNIR-279 | QIMR Berghofer | Expression of virus encoded antigens using vaccinia/fowlpox expression system | The aim of this dealing is to study cell lines infected with vaccinia and fowlpox viruses containing genes encoding Epstein-Barr virus (EBV) and cytomegalovirus antigens. | Withdrawn | | |
| DNIR-280 | University of New South Wales | Production of Recombinant Proteins in Chinese Hamster Ovary (CHO) cells | The aim of this dealing is to produce large-scale amounts of recombinant proteins of commercial value in Chinese hamster ovary (CHO) cells. | Surrendered | 10/03/2004 | 21/12/2007 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-281 | Murdoch University | Development of a subterranean clover mottle virus as a gene-silencing vector | The aim of this dealing is to use subterranean clover mottle virus as a vector for silencing plant genes in vivo and in vitro. | Expired | 27/02/2004 | 31/10/2008 |
| DNIR-282 | Monash University | Modification of the HIV-1 genome in order to visualize the HIV-1 preintegration complex (PIC) and HIV-1 component subcellular trafficking | The aim of this dealing is to elucidate the mechanism used by HIV-1 to gain access to the nucleus of infected cells by investigating a nucleoprotein (PIC) that mediates entry of HIV-1 DNA into the nucleus. | Withdrawn | | |
| DNIR-283 | Queensland University of Technology | Generation of an infectious clone of taro bacilliform virus (TaBV) | The aim of this dealing is to determine if taro plant disease can be caused by infection with TaBV alone by infecting taro plant with infectious clones of this virus. | Expired | 2/02/2004 | 30/06/2007 |
| DNIR-284 | Griffith University | Cloning and characterisation of Campylobacter spp pathogenicity genes in E.coli and construction of a vector dedicated to cloning and expression of Campylobacter spp. Dna functional in E.coli and Campylobacter spp | The aim of this dealing is to develop a system for the expression of Campylobacter spp. genes functional in both Campylobacter spp. and E. coli and to characterise genes from C. jejuni that encode potential pathogenicity determinants. | Surrendered | 10/03/2004 | 2/12/2008 |
| DNIR-285 | Centenary Institute of Cancer Medicine and Cell Biology | Gene transfer into cells of human, non-human primate or rodent origin using replication-incompetent lentiviral vectors | The proponents intend to transfer genes of interest into human or animal cells using lentiviral-based gene delivery systems with the aim of applying these techniques to gene therapy. | Withdrawn | | |
| DNIR-286 | The University of Queensland | Retroviral expression of known and potential growth-regulatory genes in human and murine cell lines | The aim of this dealing is to understand how certain oncogenes actively cause or contribute to cancer and to identify new oncogenes involved in leukaemia and breast cancer. | Surrendered | 22/04/2004 | 18/10/2007 |
| DNIR-287 | Monash University | Subcellular trafficking of the Dengue virus NS5 protein | The aim of this research is to describe the localisation of the Dengue virus non-structural protein 5 (NS5) during infection of cultured mammalian and insect cells. | Expired | 28/05/2004 | 31/05/2009 |
| DNIR-288 | Avexa Limited | Cell Lines Expressing Hepatitis B Virus | The aim of this dealing is to study the formation and release of lamivudine resistant and normal Hepatitis B virus in liver cells. | Expired | 24/05/2004 | 30/06/2009 |
| DNIR-289 | Flinders University | Asexual Genetic Exchange in Rhynchosporium secalis, the causal agent of barley scald | The aim of this dealing is to investigate whether genes can be exchanged between isolates of R. secalis in the absence of a sexual cycle. | Surrendered | 25/05/2004 | 8/05/2007 |
| DNIR-290 | Australian National University | Temporary storage of Ross River virus mutants | The proponents intend to store Ross River virus mutants for future use. | Expired | 20/07/2004 | 31/07/2009 |
| DNIR-291 | South Eastern Sydney Local Health District | Analysis of cytomegalovirus (CMV) genes involved in antiviral susceptibility, replication and cell tropism. | The aim of this dealing is to determine the role of different gene regions of CMV in infection and growth of the virus and inhibition of growth by antiviral drugs, focussing on the DNA polymerase and protein kinase mutations. | Licence issued | 26/05/2004 | 18/09/2030 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-292 | QIMR Berghofer | Kunjin replicon virus like particles for delivery of cytokines into mice | The proponents intend to deliver immune response modulating genes into mice using Kunjin replicons with the aim of effecting tumour regression and preventing transplant rejection. | Expired | 30/07/2004 | 31/07/2014 |
| DNIR-293 | The University of Queensland | Viral delivery of genes or siRNA involved in adipogenesis or insulin signaling to cells | The aim of this dealing is to examine the effect of increasing or reducing the expression of factors involved in the body's response to insulin and in human fat tissue development in mammalian cells. | Surrendered | 30/07/2004 | 18/10/2007 |
| DNIR-294 | CSIRO | Expression of alpha mannosidase in human RD rhabdasomyosarcoma cells | The aim of this dealing is to produce RD rhabdasomyosarcoma cells expressing alpha mannosidase that can be encapsulated and used in guinea pig trials of an experimental enzyme replacement therapy. | Withdrawn | | |
| DNIR-295 | Murdoch Children's Research Institute | Somatic cell genetic studies of mitochondrial respiratory chain disorders | The aim of this dealing is to determine the genetic basis of human diseases caused by mitochondrial energy generation disorders. | Expired | 30/07/2004 | 31/10/2011 |
| DNIR-296 | University of Technology Sydney | Characterisation of vaccine, drug and diagnostic targets in apicomplexan parasites | The aim of this dealing is to characterise molecules implicated in the survival and infection of apicomplexan parasites and to determine their suitability as targets for drug and vaccine development. | Withdrawn | | |
| DNIR-297 | Australian Defence Force Malaria and Infectious Disease Institute | Development of in vitro liver stage drug susceptibility assays for Plasmodium vivax. P. falciparum, P. yoelii, and P. cynomolgi. | The aim of this dealing is to develop an in vitro assay for evaluating the effectiveness of new drugs and vaccines against the liver stage of malarial parasites. | Expired | 30/08/2004 | 30/06/2009 |
| DNIR-298 | CSIRO | A Phase I/IIa, two centre, open-label, dose escalation study to assess the safety, tolerability and efficacy of FP253 in combination with fludarabine phosphate. | The aim of this dealing is to assess the safety, tolerability and efficacy of a candidate cancer therapeutic in a Phase I/IIa clinical trial in prostate cancer patients. | Expired | 23/09/2004 | 28/02/2015 |
| DNIR-299 | Monash University | Characterisation of replication competent hepatitis B viruses | The aim of this dealing is to characterise HBV viral DNA sequences present in blood samples from different animal species. | Expired | 22/09/2004 | 30/09/2014 |
| DNIR-300 | Western Sydney Local Health District | Expression of CD44 variants in ALL cells | The aim of this dealing is to examine the roles of the cell surface proteins CD44 and VLA-4 in the interaction of leukemic cells with the bone marrow. | Withdrawn | | |
| DNIR-301 | Intervet Australia Pty Ltd | Fermentation, processing and inactivation of M.haemolytica cultures | The aim of this dealing to produce large-scale quantities of recombinant M. haemolytica for use in an inactivated veterinary vaccine. | Licence issued | 28/06/2004 | 30/06/2027 |
| DNIR-302 | Avexa Limited | Generation of stable cell lines expressing Hepatitis B Virus using the ViraPower lentiviral expression system. | The aim of this dealing is to generate recombinant liver cells that express hepatitis B virus. | Surrendered | 3/09/2004 | 29/08/2011 |
| DNIR-303 | Westmead Institute for Medical Research | Production of recombinant Vaccinia viruses for viral disease: immunogenicity studies and vaccine development | The purpose of the dealing is to study the immunogenicity of HIV and Herpes simplex virus proteins in vitro | Expired | 3/09/2004 | 30/09/2024 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-304 | Western Sydney Local Health District | Storage of GMOs | The proponents intend to store recombinant mouse and human cell lines for future use. | Withdrawn | | |
| DNIR-305 | Peter MacCallum Cancer Centre | Wnt/FZD in human cancer | The aim of this dealing is to define the role of two particular proteins in colon cancer metastasis by modulating the expression of these proteins in colon cancer cell lines in vitro. | Surrendered | 5/10/2004 | 12/06/2007 |
| DNIR-306 | University of New South Wales | Study of human immunity against Hepatitis C virus | The aim of this dealing is to investigate specific immune responses against hepatitis C virus that allow some individuals to clear infection, others to become chronically infected and others to have a rapid disease progression. | Surrendered | 3/09/2004 | 20/08/2012 |
| DNIR-307 | Macfarlane Burnet Institute for Medical Research and Public Health | Molecular studies of HIV and HCV replication | The proponents intend to study the fusion and entry of human immunodeficiency virus and hepatitis C virus into human cell lines in vitro in order to develop antivirals and vaccines targeting this process. | Licence issued | 5/11/2004 | 30/11/2029 |
| DNIR-308 | University of Canberra | Storage and maintenance of bacterial strains and plasmids for future use | The aim of this dealing is to store and maintain an array of bacterial strains and plasmids for future use. | Surrendered | 5/11/2004 | 30/06/2008 |
| DNIR-309 | The University of Adelaide | Diagnosis and management of eutypa dieback | The aim of this dealing is to improve disease management strategies for the grapevine pathogen Eutypa lata by using DNA probes to detect the pathogen in infected grapevines and to analyse variations in the fungus. | Withdrawn | | |
| DNIR-310 | Institute of Medical and Veterinary Science | Mechanisms of cell survival and apoptosis in multiple myeloma | The aim of this dealing is to investigate the role of various proteins involved in apoptosis and cell survival in multiple myeloma cells and to identify potential targets for therapy. | Surrendered | 9/11/2004 | 30/06/2008 |
| DNIR-311 | Department of Primary Industries and Regional Development | DNA adenine methylase salmonella vaccines | The aim of this dealing is to evaluate the cross protective efficacy of the DNA adenine methylase deficient Salomonella typhimurium vaccine strain in calves. | Withdrawn | | |
| DNIR-312 | The University of New England | Interactions between beneficial bacteria and wheat | The aim of this dealing is to investigate the interactions between wheat and beneficial bacteria that suppress fungal diseases of wheat. | Withdrawn | | |
| DNIR-313 | Institute of Medical and Veterinary Science | Study of breast cancer tumour suppressor genes | The aim of this dealing is to investigate the function of breast tumour suppressor genes and their interacting proteins in human breast cell lines in vitro. | Surrendered | 18/11/2004 | 30/06/2008 |
| DNIR-314 | Peter MacCallum Cancer Centre | Viral mediated approaches to examine cell growth, cell proliferation and cell death. | The aim of this dealing is to use viral vectors to introduce genes into cultured cells and animals to determine their role in cancer. | Expired | 19/11/2004 | 30/11/2019 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-315 | Peter MacCallum Cancer Centre | Expression and function of HIN 200 proteins. | The aim of this dealing is to use viral vectors to introduce genes encoding HIN-200 proteins into mice and cultured cells to determine their role in cellular differentiation. | Surrendered | 26/11/2004 | 26/10/2007 |
| DNIR-316 | The University of Adelaide | Storage (Salmonella GMOs) | The storage of genetically modified Salmonella enterica Serovar Typhimurium. | Surrendered | 29/11/2004 | 3/07/2008 |
| DNIR-317 | Progen Industries Limited | Deltavasc | The aim is to generate large amounts of plasmid that will be formulated into a drug product for a US based Biotechnology company. | Expired | 22/09/2004 | 28/02/2006 |
| DNIR-318 | Flinders University | Analysis of the M-flax rust resistance gene in transgenic flax and tobacco. | The aim is to use transgenic plants to study the control of expression and function of disease resistance proteins. | Withdrawn | | |
| DNIR-319 | IDT Australia Limited | Randomised, double blind, placebo controlled phase II dose-ranging study of the safety, tolerability and immunogenicity of live attenuated ChimeriVax™-JE vaccine (lyophilised). | The aims of this study are to assess the safety, tolerability and immunogenicity of a new formulation of lyophilised ChimeriVax™-JE, given at three dose levels, compared with the placebo. | Surrendered | 5/11/2004 | 17/10/2006 |
| DNIR-320 | Melbourne Health | Randomised, double blind, placebo controlled phase II dose-ranging study of the safety, tolerability and immunogenicity of live attenuated ChimeriVax™-JE vaccine (lyophilised). | The aims of this study are to assess the safety, tolerability and immunogenicity of a new formulation of lyophilised ChimeriVax™-JE, given at three dose levels, compared with a placebo. | Surrendered | 5/11/2004 | 17/10/2006 |
| DNIR-321 | The Walter and Eliza Hall Institute of Medical Research | Storage of GM Cell Lines that would require a licence if dealings with those GMOs were undertaken. | Storage of GM cell lines that would require a licence if dealt with. The GMOs will be stored in certified facilities or in other restricted access areas (such as a locked freezer or liquid nitrogen store). | Surrendered | 3/12/2004 | 28/09/2007 |
| DNIR-322 | CSL Limited | Pilot scale fermentation and processing of merozoite surface proteins (MSP) expressed in recombinant Escherichia coli (E.coli) | The aim is to use genetically modified bacteria to express proteins normally made by the malaria parasite to test as anti-malarial vaccines. | Expired | 4/01/2005 | 31/07/2008 |
| DNIR-323 | Griffith University | Development of novel gene transfer vectors for gene therapy. | The aims are to develop new mechanisms and vectors for gene therapy of respiratory diseases and cancers. | Expired | 7/01/2005 | 31/08/2013 |
| DNIR-324 | The University of Queensland | Complementation of mutations to genes that play a role in virulence in intestinal and extraintestinal bacteria. | This work will examine the processes important to adherance, colonisation, survival and pathogenesis employed by bacteria that cause enteric and urinary tract infections in humans. | Surrendered | 7/01/2005 | 18/10/2007 |
| DNIR-325 | The University of Queensland | Genetic analysis of X. albilineans. | This project explores the molecular basis for albicidin antibiotic biosynthesis and resistance in Xanthomonas albilineans. | Surrendered | 7/01/2005 | 18/10/2007 |
| DNIR-326 | St Vincent's Hospital (Melbourne) | Storage of GMOs that are a licensed dealing. | Storage of GMOs related to licenced dealings | Withdrawn | | |
| DNIR-327 | Mater Research Ltd | Retroviral expression of genes and small inhibitory RNA. | This study aims to use retroviral vectors to generate stable and transient expression of human and rodent genes in human and rodent cell lines. | Expired | 7/01/2005 | 31/01/2010 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-328 | Macfarlane Burnet Institute for Medical Research and Public Health | Immunotherapy for hepatitis C virus infection. | The aim is to treat HCV-infected individuals who have failed conventional interferon-based therapy, with activated dendritic cells. | Expired | 27/01/2005 | 31/01/2015 |
| DNIR-329 | The University of Melbourne | Identification of virulence determinants of Leptosphaeria maculans and sclerotinia sclerotiorum. | The aims are to identify the genes that allow L. maculans and S. sclerotiorum, two fungal pathogens, to cause disease in canola. | Surrendered | 25/01/2005 | 21/08/2007 |
| DNIR-330 | The University of Melbourne | Novel approaches to vaccination against bacterial diseases. | The purpose of this dealing is to construct attenuated Salmonella strains for use as potential Salmonella vaccines and to study the immunobiology of Salmonella infection and the efficacy of the attenuated Salmonella strains as vaccine delivery vehicles for foreign antigens. | Surrendered | 22/07/2005 | 23/08/2007 |
| DNIR-331 | The University of Melbourne | Investigation of the virulence of Klebsiella pneumoniae: development of a vaccine and immunotherapeutics. | The aims are to investigate the properties of the bacterium K. pneumoniae which allow it to cause pneumonia, urinary tract infections and sepsis. | Surrendered | 24/01/2005 | 21/08/2007 |
| DNIR-332 | The University of Melbourne | Identification of virulence-associated determinants and protective antigens in bacterial pathogens. | This dealing aims to identify novel virulence-associated determinants in several bacterial pathogens of humans and to investigate whether these factors can be used as targets for therapeutic or prophylactic vaccines. | Surrendered | 27/01/2005 | 28/08/2007 |
| DNIR-333 | The University of Melbourne | Manipulation of Influenza A viruses using reverse genetics to study both cellular, humoral and molecular characteristics of viral immunity. | The aims are to use reverse genetics on Influenza A virus to determine the cellular, humoral and molecular characteristics of anti-viral immunity. | Surrendered | 28/01/2005 | 23/08/2007 |
| DNIR-334 | University of New South Wales | Storage of GMOs that are a licensed dealing. | The aim of this dealing is to store or dispose of pre-existing GMOs generated by several GMAC dealings. | Surrendered | 27/01/2005 | 21/12/2007 |
| DNIR-335 | University of New South Wales | The role of quorum sensing in biofilm formation, virulence factor expression and environmental adaptation. | The aims are to study the role of quorum sensing, quorum sensing genes and quorum sensing controlled factors in the processes of biofilm formation, environmental adaptation and infection | Surrendered | 27/01/2005 | 21/12/2007 |
| DNIR-336 | University of Technology Sydney | Use of wild type, gene knock-out, and transgenic mice, and recombinant viruses to study cytokine biology. | The aims are to investigate the roles of immune cell activating proteins in the immune response to virus infection. | Expired | 28/01/2005 | 31/01/2020 |
| DNIR-337 | CSL Limited | Pilot scale fermentation and processing of hepatitis C polyprotein expressed in recombinant saccharomyces cerevisiae. | The aims are to produce pilot-scale quantities of Hepatitis C virus polyprotein from S. cerevisiae for purification and vaccine formulation. | Surrendered | 25/01/2005 | 8/10/2009 |
| DNIR-338 | Western Sydney Local Health District | Use of transgenic and gene knock-out mice and recombinant viruses to study tumour necrosis factor (TNF)-family molecule biology. | The aims are to investigate the role of TNF-related apoptosis inducing ligand (TRAIL) in the immune system. | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-339 | The University of Melbourne | Virulence genes of avian pathogenic Escherichia coli. | This study aims to identify the genes responsible for virulence in avian pathogenic Escherichia coli and to examine the efficacy of mutants with these genes deleted or disrupted as vaccine candidates.. | Surrendered | 8/02/2005 | 21/08/2007 |
| DNIR-340 | Western Sydney Local Health District | (1) Regulation of secretion of the fungal virulence determinant, phospholipase B. (2) Fungal phospholipases: exploring a new target for drug discovery. | The aims are to determine the mechanisms regulating cryptococcal Phospholipase B (PLB) synthesis and secretion and to develop new antifungals based on the inhibition of PLB. | Withdrawn | | |
| DNIR-341 | Women's and Children's Health Network Incorporated | Functional analysis of genes involved in haemopoiesis by retroviral expression in human cells and cell lines. | This project aims to investigate the function of various genes with regard to the normal and abnormal growth of human blood cells. | Surrendered | 24/02/2005 | 7/11/2008 |
| DNIR-342 | The Children's Hospital Westmead | Use of wild type, gene knock-out, and transgenic mice, and recombinant viruses to study cytokine biology. | The aims are to investigate the roles of immune cell activating proteins in the immune response to virus infection. | Surrendered | 28/01/2005 | 22/09/2009 |
| DNIR-343 | Macquarie University | Production of TMV-GFP viral vector. | The aim of this project is to produce assembled TMV-GFP viral vector from RNA transcript in young plants. | Withdrawn | | |
| DNIR-344 | Harry Perkins Institute of Medical Research | Studying the regulation of gene transcription using amphotropic retroviruses. | The aims of this project are to use replication defective amphotropic retroviruses to transfer genes into mammalian cell lines and primary cells. | Surrendered | 30/03/2005 | 21/09/2007 |
| DNIR-345 | The University of Sydney | Function of Dichelobacter nodosus genes and production of recombinant antigens. | The purpose of the dealings is to investigate the function of potential virulence genes in Dichelobacter nododus, the causative agent of footrot and, to produce recombinant antigens. | Expired | 6/04/2005 | 30/04/2015 |
| DNIR-346 | South Eastern Sydney Local Health District | Cellular Antiviral Immunity (including HIV and HCV) | The aim of this dealing is to study cellular immunity of human peripheral blood mononuclear cells to Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) by expressing HIV and HCV antigens using Vaccinia virus (VV) recombinant vectors and conducting in vitro assays that measure cytotoxic T cell activity, lymphoproliferative activity and cytokine production. | Surrendered | 4/05/2005 | 25/05/2009 |
| DNIR-347 | University of Wollongong | Storage of GMOs that are GMAC, NLRD and DNIR dealings | The purpose of this dealing is to store GMOs that were previously covered under GMAC, NLRDs and DNIRs. | Expired | 5/05/2005 | 30/11/2010 |
| DNIR-348 | CSIRO | Production of anti-CD59 Fab fragments using recombinant E. coli | The purpose of this dealing is to produce large-scale quantities of recombinant Escherichia coli expressing anti-CD59 antibody fragments and to purify the recombinant protein. | Surrendered | 14/04/2005 | 15/03/2010 |
| DNIR-349 | The University of Queensland | Investigation into the role of novel genes at the level of the cell and animal | The purpose of this dealing is to understand the role of genes of interest in disease specifically inflammation, tissue regeneration and congenital abnormalities. | Expired | 12/05/2005 | 31/05/2010 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-350 | University of Technology Sydney | Development of Chimeric and Humanized forms of a mouse monoclonal antibody | The aims of this dealing are to produce large-scale quantities of chimeric and humanised forms of the murine monoclonal antibody mKap. | Expired | 27/05/2005 | 31/05/2007 |
| DNIR-351 | The University of Melbourne | Cell wall metabolism in mycobacteria | The aim of this dealing is to investigate the cell wall metabolism of Mycobacterium tuberculosis, the causative agent of tuberculosis. | Surrendered | 27/06/2005 | 11/09/2014 |
| DNIR-352 | Seqirus Pty Ltd | Preparation of influenza vaccines of genetically modified, attenuated influenza A strains with a PR8 [A/Puerto Rico/8/1934 (H1N1)] background | The aim of the dealing is to prepare batches of inactivated human influenza vaccine from strains of attenuated avian influenza | Licence issued | 6/04/2005 | 31/03/2030 |
| DNIR-353 | Queensland University of Technology | Investigation of Host Range Determinants in Papaya Ringspot Virus | To use an artificial infection system for PRSV-P and W using cloned components to identify amino acids involved in host range through generation of recombinants representing mixtures of different regions of the two genomes and in vitro mutagenesis | Withdrawn | | |
| DNIR-354 | Murdoch Children's Research Institute | Analysis of telometric structure and function in human marker chromosomes. | This project aims to determine the structure and function of the ends (telomeres) of human cytogenetic marker chromosomes | Withdrawn | | |
| DNIR-355 | Department of Primary Industries and Regional Development | Function of Dichelobacter nodosus genes. | The purpose of this dealing is to examine the function of potential virulence genes in Dichelobacter nodosus, the causative agent of footrot, through in vivo testing on sheep (Ovis aries). | Expired | 3/06/2005 | 30/06/2010 |
| DNIR-356 | QIMR Berghofer | Expression and characterization of novel genes from Australian snakes. | The aims of this research are to clone and express venom proteins from Australian elapid snakes in relation to the treatment of envenomation victims or as therapeutic agents. | Expired | 16/08/2005 | 31/08/2015 |
| DNIR-357 | The University of Queensland | Investigation into the role of genes in neural development and repair. | The aims of this research are to use replication defective lentiviral vectors as a tool to investigate the function of genes that are involved in neural development and repair. | Expired | 22/08/2005 | 31/08/2015 |
| DNIR-358 | CSIRO | Immunocontraceptive effects of recombinant murine cytomegaloviruses expressing mouse zona pellucida subunit 3 protein. | The purpose of this dealing is to test the efficacy and safety of recombinant Murine cytomegalovirus expressing immunocontraceptive proteins. | Expired | 30/06/2005 | 30/11/2013 |
| DNIR-359 | CSIRO | Storage of GMOs that are licensed dealings. | The purpose of this dealing is to store GM cell lines that are no longer being worked on but for which the researchers wish to maintain stocks. | Expired | 30/06/2005 | 30/11/2013 |
| DNIR-360 | The University of Queensland | Identification of virulence determinants in encephalitic flaviviruses | The aims of this research are to investigate the role of flaviviral genes and untranslated genomic regions in the virulence and pathogenicity of encephalitic flaviviruses. | Surrendered | 7/10/2005 | 15/06/2010 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-361 | Peter MacCallum Cancer Centre | Viral mediated approaches to examine cell proliferation, differentiation transformation and death. | The aim of this research is to utilise replication defective viral vectors for the delivery of tumour-suppressor genes and oncogenes in order to study the proliferation, differentiation, transformation and death of mammalian cultured cells. | Withdrawn | | |
| DNIR-362 | University of New South Wales | The role of quorum sensing and biofilm related genes in environmental adaptation by marine Vibrio spp. | The aim of this project is to study those genes that appear, under laboratory conditions, to be essential for biofilm development and grazing resistance under real life conditions in the marine environment where the bacteria are exposed to natural variations in nutrients, light, and temperatures. | Withdrawn | | |
| DNIR-363 | Flinders University | Storage of GMO's associated with the DNIR project. | | Withdrawn | | |
| DNIR-364 | University of Technology Sydney | Generation and characterisation of poxvirus Tumour Necrosis Factor Receptor (TNF-R) homologues orfs in subversion of cellular TNF-R signalling. | The aims of this research are to investigate how poxvirus tumour necrosis factor receptor-like proteins are able to inhibit the death of infected cells. | Surrendered | 25/10/2005 | 12/12/2024 |
| DNIR-365 | Western Sydney Local Health District | Infusion of Ad5F35pp65-stimulated, donor-derived cytotoxic T lymphocytes for the prevention of CMV reactivation and infection following allogeneic stem cell transplantation. | The aim of this dealing is to conduct a clinical trial in patients undergoing blood or bone marrow transplantation. The trial will involve the use of a recombinant adenovirus as an antigen source | Withdrawn | | |
| DNIR-366 | PPD Australia Pty Ltd | Phase III clinical trials of ChimeriVax™-JE | The aims of this dealing are to conduct two phase III clinical trials of ChimeriVax™-JE a live, attenuated, genetically modified vaccine against Japanese encephalitis (JE). | Expired | 26/09/2005 | 30/06/2009 |
| DNIR-367 | Australian National University | Molecular characterisation of the biogenesis and action of cholera toxin and related enterotoxins | The purpose of this dealing is to clone and express the cholera toxin of Vibrio cholerae and related enterotoxins of Escherichia coli, and to analyse their interactions with mammalian cells, for potential use in therapeutics. | Expired | 30/11/2005 | 30/11/2010 |
| DNIR-368 | Monash University | Measurement of cell entry mediated by HIV-1 particles pseudotyped with hepatitis C virus (HCV) envelope proteins. | The aims of this dealing are to investigate the entry into human liver cells in vitro of HIV-1 particles pseudotyped with Hepatitis C virus (HCV) envelope proteins | Surrendered | 6/12/2005 | 25/08/2016 |
| DNIR-369 | St Vincent's Hospital Sydney Limited | A Multicentre, Double-blind, randomised, placebo-controlled phase II proof-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Merck adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in adults at high risk of HIV-1 infection | The aims of the dealing are to test the safety, efficacy and tolerability of a recombinant adenovirus vaccine containing genes from HIV-1 to act as a prophylactic vaccine to prevent HIV-1 infection of HIV-1 seronegative individuals. | Expired | 6/02/2006 | 31/01/2011 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-370 | St Vincent's Hospital Sydney Limited | A randomised study of theraputic immunization and treatment interruption among subjects who began potent antiretroviral therapy within 16 days of diganosis of acute or recent HIV infection | The aims of the dealing are to test the safety, efficacy and tolerability of a recombinant adenovirus containing genes from HIV-1 as a therapeutic vaccine to suppress viral replication and lower the viral load in patients who have been diagnosed with acute or recent HIV-1 infection and who have been receiving antiretroviral therapy. | Integrated into DNIR-369 | | |
| DNIR-371 | Harry Perkins Institute of Medical Research | Generation of assay cell lines | | Withdrawn | | |
| DNIR-372 | Melbourne Health | The Effect of Hepatitis B Virus surface antigen mutations on Hepatitis Delta Virus assembly and release. | The aims of this research are to study the effect of mutations encoded by the Hepatitis B virus envelope genes on the assembly and release of Hepatitis delta virus. | Expired | 9/02/2006 | 28/02/2011 |
| DNIR-373 | The Children's Hospital Westmead | Studies of human cell immortalisation using adeno-associated virus (AAV) vectors | | Withdrawn | | |
| DNIR-374 | CSL Limited | Fermentation and Processing of a Recombinant Antibody Expressed in Recombinant Chinese Hamster Ovary Cells. | The purpose of this dealing is to produce and purify pilot-scale quantities of recombinant, chimeric anti-cancer antibodies from Chinese Hamster Ovary cells | Expired | 20/02/2006 | 31/05/2011 |
| DNIR-375 | The University of Adelaide | Adenoviruses as a delivery vector of exogenous protein expression in cultured cells and livers of mice | The aim of the proposed dealing is to use an adenovirus gene-delivery and over-expression system to evaluate the role that several cellular gene products, previously identified through microarray analysis of HCV-infected tissue, play in the progression of HCV-related liver disease | Withdrawn | | |
| DNIR-376 | The University of Sydney | RCAS gene transmission to TVA transgenic mice and cells | This study aims to identify human and mouse genes that are responsible for maintaining a normal differentiation program in keratinocytes. | Expired | 10/04/2006 | 30/04/2016 |
| DNIR-377 | The University of Sydney | Regulation of keratinocyte differentiation | The aim of the proposed dealings is to identify genes that are responsible for maintaining a normal differentiation program in keratinocytes, determine whether they are aberrantly expressed in cancers of the skin and head and neck region and to assess the carcinogenic consequences of aberrantly expressing themThe aim of the proposed dealings is to identify genes that are responsible for maintaining a normal differentiation program in keratinocytes, determine whether they are aberrantly expressed in cancers of the skin and head and neck region and to assess the carcinogenic consequences of aberrantly expressing them | Withdrawn | | |
| DNIR-378 | University of Tasmania | Therapeutic Potential of shRNA's in Leukemic Cells | | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-379 | University of Tasmania | Storage of GMO's that are licenced dealing | | Withdrawn | | |
| DNIR-380 | Griffith University | Engineering anaerobic bacteria for multimodal cancer therapy | The aims of this study are to investigate the potential of utilising anaerobic bacteria that express recombinant immunotoxins as treatments for solid tumours in animal models. | Expired | 9/05/2006 | 31/10/2011 |
| DNIR-381 | The University of Melbourne | Biological requirements for prion formation | The aims of this research are to express isoforms of human, mouse and hamster prion protein to identify regions of the protein that modulate the infection process. | Surrendered | 16/05/2006 | 31/05/2011 |
| DNIR-382 | The University of Melbourne | Mutations in humans prion diseases | The aims of this research are to express isoforms of human, mouse and hamster prion protein to identify regions of the protein that modulate the infection process. | Integrated into DNIR-381 | | |
| DNIR-383 | The University of Melbourne | Analysis of HIV vaccination strategies | The aims of the dealing are to compare the efficacy of HIV vaccination strategies by the use of live recombinant vaccinia and influenza viruses expressing HIV antigens in mice in vivo and to develop a vaccination strategy based on the influenza virus | Withdrawn | | |
| DNIR-384 | Peter MacCallum Cancer Centre | Analysis of molecular signalling for growth of blood vessels and lymphatic vessels using adenoviral gene transfer | The purpose of this dealing is to transfer genes using adenoviral vector and to analyse the expressed proteins for growth of blood and lymphatic vessels in cultured mammalian cells and mice. | Expired | 31/05/2006 | 31/05/2021 |
| DNIR-385 | Royal Perth Hospital | Construction of recombinant plasmids carrying HCV viral genome inserts. | | Withdrawn | | |
| DNIR-386 | Sanofi-Aventis Australia Pty Ltd | Clinical trials of ChimeriVax™ Tetravalent Dengue Vaccine | The purpose of this dealing is to conduct a Phase IIa clinical trial of ChimeriVax™-DEN, a tetravalent, live, attenuated, chimeric, genetically modified vaccine against dengue virus. | Expired | 24/07/2006 | 31/12/2012 |
| DNIR-387 | CSIRO | Identification of virulence factors for infectious bursal disease virus (IBDV) | Recombinant strains of infectious bursal disease virus (IBDV) will be used to identify the virulence factors that make IBDV pathogenic to chickens. | Licence issued | 21/07/2006 | 31/07/2029 |
| DNIR-388 | Baker Heart & Diabetes Institute | Virus-mediated approaches to examine cardiovascular disease in vitro and in vivo | This project utilises virus-based gene delivery to examine the processes that control the function of the heart and circulation in health and disease. | Expired | 1/09/2006 | 31/08/2012 |
| DNIR-389 | Griffith University | Mechanisms of Ross River viral disease | The aim of the proposed dealings is to study the pathogenesis of Ross River virus-induced polyarthritis in a mouse model. | Licence issued | 1/09/2006 | 19/12/2026 |
| DNIR-390 | La Trobe University | Identification of virulence determinants of Venturia inaequalis,Botrytis cinerea and Sclerotinia sclerotiorum | | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-391 | Bioproperties Pty Ltd | Production of Neovac antigens | The aim of this dealing is to produce four types of recombinant pili antigens to be used in the manufacture of a vaccine against neonatal scours in pigs. | Expired | 16/10/2006 | 31/10/2012 |
| DNIR-392 | The University of Western Australia | Plasmids in Neisseria sp | The aims of this dealing are to identify and study the expression and function of genes involved in pathogenicity/virulence of Neisseria meningitidis and N. gonorrhoeae. | Surrendered | 2/11/2006 | 4/10/2011 |
| DNIR-393 | University of New South Wales | Evolution of Hepatitis C Virus (HCV) in Cell Culture | | Withdrawn | | |
| DNIR-394 | The University of Newcastle | Generation of low-pathogenic enteroviral full-length infections clones | The purpose of this dealing is to generate full-length infectious clones of several low-pathogenic enteroviruses of the picornaviridae for characterisation of the virus genome(s) by in vitro studies. | Surrendered | 10/11/2006 | 30/11/2010 |
| DNIR-395 | Institute of Medical and Veterinary Science | The use of lenti-viral vectors as delivery systems for the knock-down of proteins involved in gastric vagal afferent mechanosensitivity | | Withdrawn | | |
| DNIR-396 | The University of Queensland | Analysis of invertebrate virus genomes | This dealing aims to analyse the function of various invertebrate viral genomes by mutagensis and subsequent analysis of virus function in vitro and in vivo. | Surrendered | 21/11/2006 | 8/06/2016 |
| DNIR-397 | Seqirus Pty Ltd | Development of improved attenuated H5 influenza virus for production of killed influenza vaccine | The aim of the proposed dealings is to use reverse genetics to produce an improved, attenuated H5 influenza vaccine strain with increased levels of surface haemagglutinin (HA) through modification of the HA gene. | Surrendered | 28/11/2006 | 19/12/2014 |
| DNIR-398 | QIMR Berghofer | Large Scale Production of a Human/Chimeric IgG4 Antibody for Clinical trials | The purpose of this dealing is to produce large scale quantities of a chimeric IgG4 antibody via cell culture for clinical use | Expired | 9/11/2006 | 30/11/2011 |
| DNIR-399 | La Trobe University | Mechanisms of cell death | | Withdrawn | | |
| DNIR-400 | Cargill Australia Limited | Canadian canola seed import for further processing at Newcastle | The aim of the dealing is to import Canadian canola seed into Newcastle, NSW, Australia for crushing in order to supply domestic oil and meal demands. | Expired | 22/09/2006 | 30/09/2021 |
| DNIR-401 | Westmead Institute for Medical Research | Transmissible genetic elements in bacteria | The purpose of this dealing is to characterise antibiotic resistance-associated genetic loci such as resistance genes and mobile genetic elements in bacteria. | Licence issued | 23/01/2007 | 20/01/2027 |
| DNIR-402 | Clinical Network Services (CNS) Pty Ltd | Single armed, multicentre, open label clinical study evaluating the safety and tolerability of NovaCaps in patients with inoperable pancreatic carcinoma | The aim of this dealing is to conduct a phase I clinical trial of an encapsulated cell therapy product (NovaCaps) that activates the prodrug ifosfamide in patients with inoperable pancreatic carcinoma. | Surrendered | 16/01/2007 | 7/11/2008 |
| DNIR-403 | Progen Industries Limited | Large scale production of Mannan Fusion Protein | | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-404 | The University of Sydney | A Gene Therapy Strategy for Prion Disease using Lentiviral Vector Delivery of Short Hairpin RNA (shRNA) Targeting the PrPc Gene | | Withdrawn | | |
| DNIR-405 | The University of Queensland | Overexpression and mutant complementation in Cryptococcus | The aim of this dealing is to investigate mating and growth regulators in Cryptococcus species. | Surrendered | 5/03/2007 | 22/01/2009 |
| DNIR-406 | Imugene Limited | Construction and testing of porcine adenovirus (PAV) vectors expressing foreign DNA | The aim of this dealing is to develop and conduct in vitro tests of potential vaccines and therapeutics for the poultry and pork industries | Surrendered | 5/04/2007 | 25/01/2013 |
| DNIR-407 | Imugene Limited | Construction and testing of fowl adenovirus (FAV) vectors expressing foreign DNA | The aim of this dealing is to develop and conduct in vitro tests of potential vaccines and therapeutics for the poultry and pork industries | Surrendered | 5/04/2007 | 25/01/2013 |
| DNIR-408 | Institute of Medical and Veterinary Science | Binding and replication studies of Norovirus | | Withdrawn | | |
| DNIR-409 | The University of New England | Is XprG a global regulator of fungal virulence? | | Withdrawn | | |
| DNIR-410 | Women's and Children's Health Network Incorporated | New approaches to understanding bone fusion | | Withdrawn | | |
| DNIR-411 | Murdoch University | Pathogenicity determinants of Septoria (Stagonospora) nodorum | | Withdrawn | | |
| DNIR-412 | Queensland University of Technology | Population dynamics of arboviruses | | Not Issued | | |
| DNIR-413 | The University of Melbourne | Analysis of malaria proteins and regulatory DNA sequences through disruption and complementation | | Withdrawn | | |
| DNIR-414 | The University of Queensland | Characterisation of Cytomegalovirus chemokine receptor homologues | The purpose of this dealing is to investigate the function of mouse and human viral chemokine receptors in promoting virus replication and dissemination during infection | Surrendered | 13/06/2007 | 3/03/2025 |
| DNIR-415 | The University of Western Australia | A phase I/II human gene therapy trial to establish the base line safety and efficacy following a single subretinal injection of rAAV.sFlt-1 for the treatment of exudative age related macular degeneration (AMD) | The purpose of this dealing is to conduct a phase I/II clinical trial of a genetically modified replication defective Adeno-associated virus in patients suffering exudative age related macular degeneration | Surrendered | 2/07/2007 | 12/05/2015 |
| DNIR-416 | Ludwig Institute for Cancer Research Melbourne-Austin Branch | Dissecting the mechanism of immunodominance hierarchy | | Withdrawn | | |
| DNIR-417 | Macfarlane Burnet Institute for Medical Research and Public Health | Studies of dengue type 2 virus replication | | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-418 | Biotron Limited | Anti Viral Drugs | The purpose of this dealing is to use GM viruses to understand how novel anti-HIV drugs act against HIV-1 and confirm the target site of drug activity | Expired | 17/09/2007 | 15/02/2015 |
| DNIR-419 | Institute of Medical and Veterinary Science | Designing novel vaccination approaches to provide protection against vaccinia virus infection | | Withdrawn | | |
| DNIR-420 | Central Adelaide Local Health Network | Determining the relative packaging efficiency of HIV-1 and HIV-1 derived vector genomes | The purpose of the dealing is to determine the relative packaging efficiencies of wild-type HIV-1 genomic RNA and the genomic RNA of attenuated HIV-1 derived gene vectors | Surrendered | 5/10/2007 | 22/09/2011 |
| DNIR-421 | Sanofi Pasteur Pty Ltd | Recombinant, live attenuated Japanese encephalitis vaccine (ChimeriVax™-JE) | | Withdrawn | | |
| DNIR-422 | Westmead Institute for Medical Research | Pathogenesis of hepatitis C virus | The aim of the project is to understand how hepatitis C virus causes disease in infected people, including fatty liver, inflammation and scarring of the liver, liver failure and liver cancer | Licence issued | 8/11/2007 | 31/08/2027 |
| DNIR-423 | QIMR Berghofer | The biology of arbovirus fitness in arthropod hosts | The purpose of this dealing is to study the replication of genetically modified Ross River virus strains in mosquitoes | Expired | 16/11/2007 | 30/11/2012 |
| DNIR-424 | Women's and Children's Health Network Incorporated | Evolution and selection of complement-resistant VSV-G variants | The purpose of this dealing is to isolate a complement-resistant variant of the Vesicular stomatitis virus (VSV)-G glycoprotein that can be used to pseudotype lentiviral vectors | Surrendered | 16/11/2007 | 22/09/2011 |
| DNIR-425 | Seqirus Pty Ltd | Influenza viruses | The aim of the dealing is to construct influenza viruses by reverse genetics for research purposes | Licence issued | 16/11/2007 | 30/06/2031 |
| DNIR-426 | Griffith University | Characterising virulence in enteric pathogens | The purpose of these dealings is to study the function of bacterial molecules that enter into and alter host cells in order to understand disease progression and identify targets for therapeutics | Surrendered | 21/12/2007 | 9/02/2011 |
| DNIR-427 | CSIRO | Molecular identification and characterisation of the virulence and host range determinants of SARS and SARS-like coronaviruses | The aims of this dealing are to investigate the role of virulence and host-range determinants in vitro in Severe Acute Respiratory Syndrome (SARS) and SARS-like coronaviruses | Licence issued | 7/02/2008 | 30/11/2027 |
| DNIR-428 | CSIRO | Identification of virulence factors for Henipaviruses | This study aims to generate recombinant Hendra virus and Nipah virus that include mutations or deletions in viral genes or the non-coding regions to determine their role in Henipavirus pathogenesis and transmission | Surrendered | 7/02/2008 | 15/11/2011 |
| DNIR-429 | Cargill Australia Limited | Importation of US Corn for further processing into stockfeed | The aim of this dealing is to import corn which potentially includes GM lines into Newcastle and Melbourne for processing to produce domestic stockfeed. | Surrendered | 21/02/2008 | 15/08/2025 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-430 | The University of Melbourne | Gene transfer of neurotrophins for survival and reconnection of regenerating auditory nerves | | Withdrawn | | |
| DNIR-431 | Women's and Children's Health Network Incorporated | Lentiviral-mediated gene therapy | Development and testing of lentiviral HIV-1 vector systems for the treatment of monogenic diseases | Surrendered | 11/03/2008 | 10/11/2016 |
| DNIR-432 | University of Technology Sydney | Insulin storage and release from liver hepatocytes | The purpose of the proposed dealings is to develop a somatic cell gene therapy system using lentiviral vectors for the treatment of diabetes. | Licence issued | 31/03/2008 | 31/08/2027 |
| DNIR-433 | University of Technology Sydney | Insulin storage and release from liver hepatocytes using a new lentiviral vector | | Withdrawn | | |
| DNIR-434 | CSIRO | Generation of new vaccines to Marek's disease virus | | Withdrawn | | |
| DNIR-435 | Flinders University | Lentivirus-mediated gene transfer to prolong corneal graft survival | The aims of these dealings are to investigate the potential for lentiviral and adenoviral (var-6526) mediated gene therapy to improve the survival of corneal grafts in animal models | Surrendered | 2/04/2008 | 1/12/2015 |
| DNIR-436 | Institute of Medical and Veterinary Science | The effects of BCR-ABL and BCR-ABL mutants on transporter expression and function | | Withdrawn | | |
| DNIR-437 | QIMR Berghofer | Cleanroom manufacturing of a chemotherapeutic drug delivery technology for use in cancer therapy | The purpose of this dealing is to produce large scale preparations of a drug delivery vehicle for use in cancer therapy | Surrendered | 29/04/2008 | 25/05/2009 |
| DNIR-438 | Royal Prince Alfred Hospital | Phase 1 safety study in subjects with severe Hemophilia B (Factor IX Deficiency) using adeno-associated viral vector to deliver the gene for Human Factor IX into the liver coupled with transient immunomodulation. | The purpose of this dealing is to conduct a phase I clinical trial of a genetically modified, replication defective Adeno-associated viral vector in patients suffering Hemophilia B in combination with immunosuppressive therapy. | Surrendered | 20/06/2008 | 7/01/2013 |
| DNIR-439 | The University of Queensland | Virus-mediated approaches to examine cardiovascular disease in vitro and in vivo | The aim of the proposed dealings is to investigate the regulation of cardiac function in vivo by the delivery of cardiac regulatory genes into rodents using replication-defective viral vectors. | Licence issued | 30/06/2008 | 31/03/2028 |
| DNIR-440 | The University of Queensland | Mechanisms of growth hormone signalling II | This project will investigate how growth hormone signals via the growth hormone receptor and other genes to control growth and metabolism, and its role in the development of cancer. | Licence issued | 30/06/2008 | 30/04/2028 |
| DNIR-441 | QIMR Berghofer | Characterizing Host Immunity to Plasmodium | The aims of this dealing are to characterise Plasmodium antigens in vitro and in vivo, to assess their suitability in the development of a malaria vaccine | Expired | 15/07/2008 | 31/07/2019 |
| DNIR-442 | Women's and Children's Health Network Incorporated | Lentivirus Gene Transfer to Treat Cystic Fibrosis Airway Disease | The purpose of this dealing is to test lentiviral HIV-1 vector systems for the treatment of cystic fibrosis. | Surrendered | 21/07/2008 | 10/11/2016 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-443 | CSIRO | Avian Influenza: A Study of Molecular Pathogenesis | The purpose of this dealing is to identify sequence changes in H5N1 influenza viral genes that cause differences in the severity of disease symptoms in avian and mammalian hosts. | Expired | 7/08/2008 | 31/10/2021 |
| DNIR-444 | The Bionics Institute of Australia | Gene transfer of neurotrophins for survival and reconnection of regenerating auditory nerves | This study aims to utilise adenoviral and adeno-associated viral vector gene therapy to determine whether locally expressed neurotrophins can promote nerve survival and nerve regeneration in the inner ear of animals | Expired | 4/04/2008 | 30/04/2013 |
| DNIR-445 | CSIRO | Characterisation of pathogenicity determinants of Fusarium oxysporum | | Withdrawn | | |
| DNIR-446 | The Queen Elizabeth Hospital | Transduction of islets with Adenovirus and Adeno associated virus expressing marker and/or therapeutic genes to improve islet survival and function following transplantation | | Withdrawn | | |
| DNIR-447 | CSIRO | Characterisation of putative pathogenicity determinants in Fusarium species by gene knockout and complementation | | Withdrawn | | |
| DNIR-448 | O'Brien Institute | Targeting NADPH oxidase in angiogenesis in vivo | | Withdrawn | | |
| DNIR-449 | Peter MacCallum Cancer Centre | Phase I study of autologous T lymphocytes with an anti LeY chimeric receptor gene for patients with Multiple Myeloma, AML or high-risk MDS | The purpose of this dealing is to analyze the safety and efficacy of autologous administration of genetically modified T-lymphocytes expressing an anti-Lewis Y antibody for the treatment of cancer in patients enrolled in a Phase I clinical trial. | Expired | 6/11/2008 | 31/12/2012 |
| DNIR-450 | Monash University | Polymyxin resistance in Gram-negative bacteria | | Withdrawn | | |
| DNIR-451 | Central Adelaide Local Health Network | Expression of lysosomal enzymes and shRNA from a lentiviral vector and gene therapy for MPS | The purpose of this dealing is the development of gene therapies for the treatment of lysosomal storage diseases using lentiviral vectors. | Expired | 11/12/2008 | 4/04/2014 |
| DNIR-452 | The University of Queensland | Genome wide overexpresion and knockdown of mRNA transcripts at the level of the cell | The purpose of this dealing is to use replication defective lentiviral vectors encoding gene silencing constructs to study gene expression in mammalian cells in vitro | Surrendered | 22/12/2008 | 20/08/2012 |
| DNIR-453 | The University of Queensland | Investigations into the role of novel genes at the level of the cell and animal | The purpose of this dealing is to use replication defective lentiviral vectors in vitro and in vivo as a tool to investigate the function of genes involved in eukaryotic tissue, organ and organism development. | Surrendered | 19/04/2009 | 11/01/2016 |
| DNIR-454 | University of New South Wales | Development of a pseudo-typed NoV to investigate NoV replication in cell culture | The purpose of this dealing is to develop a pseudo-typed murine Norovirus to investigate Norovirus replication in cell culture. | Expired | 24/02/2009 | 13/06/2014 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-455 | PPD Australia Pty Ltd | Clinical Study MI-CP178 - A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenze Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants | | Withdrawn | | |
| DNIR-456 | The University of Western Australia | Development of a prime-boost anti-cancer vaccine | The purpose of this dealing is to test prime-boost anti-cancer vaccines using in vivo murine tumour models. | Expired | 19/03/2009 | 31/03/2019 |
| DNIR-457 | The Walter and Eliza Hall Institute of Medical Research | Knockdown of gene expression in human and mouse cells using lentiviral libraries | The purpose of these dealings is to use replication defective lentiviral vectors encoding gene silencing constructs to study cellular behaviour in vitro. | Surrendered | 20/03/2009 | 20/08/2012 |
| DNIR-458 | CSIRO | Pathogenicity of J paramyxovirus (JPV) and Beilong paramyxovirus (BeiPV) | The purpose of this dealing is to generate recombinant J Paramyxovirus and Beilong Paramyxovirus that including changes in viral genes or non-coding regions to determine their influence on pathogenicity | Expired | 6/04/2009 | 30/04/2014 |
| DNIR-459 | Women's and Children's Health Network Incorporated | Molecular mechanisms of bone growth | The purpose of this dealing is to use replication defective lentiviral vectors in vitro and in vivo as a tool to investigate the function of genes involved in bone growth or repair. | Expired | 14/04/2009 | 30/04/2014 |
| DNIR-460 | Peter MacCallum Cancer Centre | Use of a short hairpin microRNAi (shRNA-mir) lentiviral based library for small and large scale functional genomics screens | The purpose of these dealings is to use replication defective lentiviral vectors encoding gene silencing constructs to study cellular behaviour in vitro. | Expired | 20/03/2009 | 31/03/2024 |
| DNIR-461 | Amgen Australia Pty Ltd | Clinical trials to evaluate the efficacy and safety of treatment with GM human herpes virus 1 (talimogene laherparepvec) | The purpose of the dealings is to undertake the Australian arm of multi-national clinical trials in melanoma patients. | Expired | 26/06/2009 | 31/03/2019 |
| DNIR-462 | University of Technology Sydney | Roles for TNF-family molecules in anti-viral immunity | | Withdrawn | | |
| DNIR-463 | Griffith University | Engineering anaerobic bacteria for multimodal cancer therapy | The purpose of the dealings is to generate anaerobic bacteria that express recombinant immunotoxins specific for solid tumours and to test the oncolytic activity of the GMO in vitro and in vivo. | Expired | 30/09/2009 | 30/09/2025 |
| DNIR-464 | QIMR Berghofer | Investigation of malaria parasite proteins | | Withdrawn | | |
| DNIR-465 | South Eastern Sydney Local Health District | Investigation of polymerase (PB1) fidelity from different influenza strains | The purpose of the dealing is to construct reassorted influenza viruses by reverse genetics for research purposes. | Licence issued | 6/09/2009 | 30/09/2027 |
| DNIR-466 | Peter MacCallum Cancer Centre | Regulation of Tumor Suppression | | Withdrawn | | |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-467 | St Vincent's Institute of Medical Research | The role of LIMK1 and its interacting proteins in cancer metastasis | The purpose of this dealing is to identify novel proteins involved in cancer metastasis and explore the role of these and LIM kinases in tumour cell invasiveness. | Surrendered | 13/10/2009 | 13/11/2013 |
| DNIR-468 | QIMR Berghofer | Investigation of malaria parasite proteins | The aim of the proposed dealings is to investigate the function of characterised and uncharacterised DNA sequences in the erythrocytic stage rodent and human malaria parasite Plasmodium. | Expired | 30/10/2009 | 31/10/2019 |
| DNIR-469 | The University of Melbourne | Complementation of Mycobacterium spp and Streptomyces spp with genes required for the synthesis of mycolactones | The aim of the proposed dealing is to understand how mycobacteria produce mycolactones | Expired | 26/10/2009 | 31/10/2024 |
| DNIR-470 | The University of Melbourne | Pathogenesis in Staphylococcus aureus | The purpose of this dealing is to understand: 1) how S. aureus strains develop low-level resistance to the antibiotic vancomycin; and 2) the role of S. aureus protein toxins in disease. | Licence issued | 13/11/2009 | 30/11/2029 |
| DNIR-471 | The University of Sydney | Adeno-associated virus expression of immunosuppressive genes in rodent livers | This study aims to utilise adeno-associated viral vector gene therapy to determine whether a locally expressed immunosuppressive genes can promote the acceptance of transplanted organs in animal transplant models. | Expired | 16/10/2009 | 30/10/2019 |
| DNIR-472 | The University of Queensland | Identification of virulence determinants of flaviviruses | The aims of this dealing are to investigate the role of flaviviral genes and untranslated genomic regions in the neurovirulence and/or pathogenicity of flaviviruses | Licence issued | 9/11/2009 | 30/11/2029 |
| DNIR-473 | The University of Melbourne | Cardiovascular reactivity to stress: role of redox signaling in the hypothalamus and brainstem | The purpose of this dealing is to use replication defective lentiviral vectors in vivo to investigate the role of redox signalling genes in the cardiovascular response to stress. | Surrendered | 21/12/2009 | 25/03/2013 |
| DNIR-474 | The University of Melbourne | The Impact of influenza A virus PB1-F2 protein on host immunity and potential for therapeutic targeting | The purpose of this dealing is to determine the mechanisms by which the protein PB1 F2 contributes to the virulence of Influenza A virus. | Expired | 15/01/2010 | 31/01/2015 |
| DNIR-475 | O'Brien Institute | Targeting NADPH Oxidase in angiogenesis | The purpose of this dealing is to study the importance of the enzyme NADPH oxidase in the growth of blood vessels and tumours that depend on the blood vessel growth. | Surrendered | 15/02/2010 | 15/02/2012 |
| DNIR-476 | Murdoch Children's Research Institute | Developing lentiviral vectors for gene therapy of Friedreich ataxia | The purpose of the dealing is to develop replication defective lentiviral vectors for gene therapy of Friedreich Ataxia. | Surrendered | 2/03/2010 | 6/05/2013 |
| DNIR-477 | Adelaide University | Human immunodeficiency vaccine studies | The aim of the proposed dealings is to test the efficacy of vaccines against HIV in mice by challenge with ecotropic HIV (EcoHIV), a genetically modified (GM) HIV that specifically infects rodents. | Expired | 12/04/2010 | 30/04/2026 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-478 | University of Canberra | Interferon-adjuvanted flavivirus vaccine | The proposed dealings are to introduce an interferon gene into the genome of Murray Valley encephalitis virus or chimeric Murray Valley encephalitis virus that has had two structural genes replaced with those of Dengue virus, with an aim to create interferon-adjuvanted flavivirus vaccines. | Expired | 23/03/2010 | 31/03/2025 |
| DNIR-479 | The University of Melbourne | Modulation of brain activity for understanding cardiovascular diseases | The purpose of this dealing is to use replication defective lentiviral vectors to deliver genes to brain regions of rodents to examine the role of specific neurons in the regulation of cardiovascular function. | Surrendered | 30/03/2010 | 16/10/2012 |
| DNIR-480 | The University of Queensland | In vivo modification of target cell populations to study signalling pathways | This study aims to use retroviral vectors to investigate signalling pathways involved in stem cell differentiation and the onset of metastasis in a whole animal context. | Expired | 5/05/2010 | 31/05/2015 |
| DNIR-481 | CSL Limited | Rescue of Influenza B viruses by reverse genetics for research purposes | | Withdrawn | | |
| DNIR-482 | The Kids Research Institute Australia | Comparative analysis of human and kangaroo Leishmania: defining human pathogenicity genes. | The purpose of this dealing is to use Australian Leishmania as a tool to identify genes involved in pathogenesis of human Leishmania species. | Expired | 28/05/2010 | 31/05/2019 |
| DNIR-483 | The University of Queensland | Manipulation of the immune system in mouse skin using immunoregulatory cytokines | This study aims to use genetically modified Fowlpox virus to investigate the ability of immunomodulatory molecules to enhance the action of an anti-cancer vaccine. | Surrendered | 1/06/2010 | 4/07/2014 |
| DNIR-484 | CSL Limited | Rescue of Influenza A viruses by reverse genetics for research purposes | | Withdrawn | | |
| DNIR-485 | QIMR Berghofer | Mouse studies using EcoHIV | The purpose of the dealings is to generate and use a genetically modified HIV that specifically infects rodents to analyse the role of specific host genes or drugs in regulating anti-viral immunity and virus replication. | Surrendered | 15/07/2010 | 27/05/2025 |
| DNIR-486 | Calimmune Australia Pty Ltd | Gene Therapy for HIV | This study aims to test an in vitro model for HIV gene therapy, by challenging transgenic cells expressing potential anti-HIV genes with GM HIV virions. | Expired | 20/07/2010 | 31/07/2015 |
| DNIR-487 | Harry Perkins Institute of Medical Research | The use of short hairpin microRNAi lentiviral based constructs and libraries for functional analysis | The purpose of this dealing is to use lentiviral mediated short hairpin RNAi sequences to identify genes and/or pathways involved in various diseases such as cancer and diabetes, as well as immunological and neurological disorders. | Licence issued | 25/08/2010 | 31/08/2030 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-488 | CSIRO | Identification of determinants of virulence and vector competence factors in Bluetongue virus | The purpose of the dealings is to use reverse genetics to produce genetically-modified Bluetongue virus to identify determinants of virulence and vector competence. | Expired | 30/08/2010 | 31/08/2015 |
| DNIR-489 | St Vincent's Institute of Medical Research | The Role of micro-RNAs in Cancer Models | This study aims to use replication-defective lentiviral vectors to study genes and micro-RNAs involved in tumour invasion and metastasis. | Surrendered | 1/09/2010 | 8/07/2012 |
| DNIR-490 | CSIRO | Identification of determinants of virulence and vector competence factors in ephemeroviruses | The purpose of the dealings is to produce genetically modified insect-vectored animal Rhabdoviruses to identify determinants of virulence and vector competence. | Expired | 22/10/2010 | 31/10/2015 |
| DNIR-491 | Australian Institute of Marine Science | Cloning and over-expression of a metalloprotease implicated in the virulence of a coral pathogen vibrio corallilyticus | This study aims to elucidate the mechanism of action of a virulence factor from the coral pathogen Vibrio coralliilyticus. The virulence factor, a metalloprotease, will be overexpressed in an attenuated vaccine strain of V. cholerae. | Expired | 31/10/2010 | 31/10/2015 |
| DNIR-492 | CSIRO | Construction of a Taura syndrome virus infectious clone | The purpose of the dealings is to use reverse genetics to produce genetically modified (GM) Taura syndrome virus to identify virulence determinants. | Expired | 28/10/2010 | 30/11/2016 |
| DNIR-493 | The University of Queensland | Molecular analysis of Streptococcus pyogenes | The aim of the dealing is to gain an understanding of the role of S. pyogenes gene products in streptococcal infection and disease. | Expired | 24/11/2010 | 30/11/2015 |
| DNIR-494 | Peter MacCallum Cancer Centre | Regulation of tumour suppression | This the purpose of this study is to use replication-defective lentiviral vectors to study regulation of the p53 tumour suppressor pathway. | Expired | 29/11/2010 | 30/11/2015 |
| DNIR-495 | CSIRO | Generation of recombinant Rabbit Caliciviruses | The purpose of this project is to study the biology of rabbit caliciviruses by generating GM caliciviruses and developing GM cell lines. | Expired | 22/12/2010 | 31/12/2020 |
| DNIR-496 | CSIRO | Characterisation of the molecular determinants of host range and pathogenicity for Henipaviruses | This the purpose of this study is to generate and characterise, in vivo and in vitro, genetically modified (GM) Hendra virus and Nipah virus. Viral genes and non-coding regions will be mutated, deleted or replaced in order to determine their role in pathogenesis, host range and transmission. | Licence issued | 5/01/2011 | 31/01/2031 |
| DNIR-497 | The University of Queensland | Expression and characterization of novel genes from Australian snakes | This study aims to use clone and express venom proteins from 20 Australian elapid snakes that may useful in the treatment of envenomation victims or as therapeutic agents. | Expired | 13/01/2011 | 31/01/2021 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-498 | Western Sydney Local Health District | Isolation and characterisation of genes involved in antifungal drug metabolism including drug resistance in pathogenic yeasts | The aim of the proposed dealings is to elucidate the mode of action of the antifungal drug miltefosine in pathogenic yeasts, ie Cryptococcus neoformans and Candida species. | Surrendered | 19/01/2011 | 12/06/2014 |
| DNIR-499 | The Walter and Eliza Hall Institute of Medical Research | Augmenting anti-viral immunity | | Withdrawn | | |
| DNIR-500 | Macfarlane Burnet Institute for Medical Research and Public Health | Xenotropic murine leukemia virus-related virus (XMRV) and prostate cancer | | Withdrawn | | |
| DNIR-501 | Central Adelaide Local Health Network | A phase 1 study of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with metastatic melanoma | A clinical trial assessing the feasibility, safety and efficiacy of GM autologous T cells for the treatment of metastatic melanoma. | Surrendered | 21/07/2011 | 10/01/2014 |
| DNIR-502 | Harry Perkins Institute of Medical Research | Lentiviral gene overexpression and knock-down using short hairpin micro RNAi | | Withdrawn | | |
| DNIR-503 | The University of Melbourne | Functional analysis of Schistosoma ssp egg-secreted proteins using vector-based RNAi | This study aims to use replication-defective lentiviral vectors to generate GM Schistosoma spp to analyse the function of egg-secreted proteins at different stages of the Schistosoma life cycle. | Surrendered | 10/08/2011 | 19/12/2013 |
| DNIR-504 | Virax Holdings Limited | Clinical study of the efficacy and safety of intra-tumoural injection of TG1042 in nodular basal cell carcinoma | This clinical trial aims to test the efficacy and safety of TG1042 for the treatment of nodular basal cell carcinoma | Expired | 3/08/2011 | 4/08/2013 |
| DNIR-505 | Adelaide University | Lentiviral vectors to assess HIV vaccine efficacy | The purpose of the proposed dealings is to use lentiviral vectors to express HIV genes in mice as a model of HIV infection. | Expired | 26/08/2011 | 29/08/2026 |
| DNIR-506 | CSIRO | Expression of a fatty acid modifying enzyme in Candida tropicalis | The purpose of this dealing is to determine whether it is possible to use GM Candida tropicalis to produce industrial quantities of Omega-hydroxyfatty acids | Expired | 9/09/2011 | 30/09/2014 |
| DNIR-507 | The University of Sydney | The use of virus vectors for research in plants | | Withdrawn | | |
| DNIR-508 | Flinders University | Investigation of Dengue virus replication and pathogenesis | | Withdrawn | | |
| DNIR-509 | Griffith University | The role of host and viral factors in chikungunya virus disease | The applicant aims to genetically modify structural proteins of Chikungunya virus to understand their role in viral infection. | Licence issued | 22/12/2011 | 31/12/2026 |
| DNIR-510 | Australian National University | Recombinant Mucosal Vaccines | | Withdrawn | | |
| DNIR-511 | Public and Environmental Health Reference Laboratories, Pathology Queensland | Investigation of replication and virulence determinants in Alphaviruses | In this study, the applicant plans to genetically modify proteins implicated in replication and virulence of pathogenic Ross River virus and assay for resulting changes in genotypic or phenotypic traits in vivo. | Licence issued | 6/12/2011 | 31/12/2031 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-512 | Deakin University | Molecular Virology of HIV-1 | The aim of the proposed dealings is to generate replication defective (RD) GM HIV-1 viral particles pseudotyped with envelope proteins of different viruses and use them for in vitro studies to investigate how these GM viruses gain entry into cells. | Surrendered | 23/12/2011 | 11/01/2018 |
| DNIR-513 | Intervet Australia Pty Ltd | Innovax ILT - Vaccine Seed Production | | Withdrawn | | |
| DNIR-514 | Queensland University of Technology | Identification of novel virulence determinants of pathogenic Legionella pneumophila 130b using an avirulent environmental Legionella isolate | The applicant proposes to use GM Legionella to identify and analyse virulence determinants from L. pneumophila. | Surrendered | 3/05/2012 | 23/12/2014 |
| DNIR-515 | Queensland University of Technology | Effect of genetically modified bananas enriched in carotenoids on postprandial carotenoid and vitamin A levels | The applicant proposes to conduct a human nutritional study to determine how efficiently pro-vitamin A is absorbed and converted to vitamin A (retinol) following consumption of genetically modified bananas with elevated levels of pro-vitamin A carotenoids. | Expired | 3/05/2012 | 31/12/2014 |
| DNIR-516 | The University of Queensland | Analysis of developmentally important genes involved in disease | This study aims to use genetically-modified retroviral and lentiviral vectors to identify genes that induce or accelerate tumour formation in the brain. | Expired | 15/06/2012 | 19/06/2017 |
| DNIR-517 | CSIRO | Genomic Analysis of the Canonical Case of Virulence Evolution: Myxomatosis in Australia | | Withdrawn | | |
| DNIR-518 | The University of Queensland | Isolation, expression and characterization of the toxins expressed by the Australian paralysis tick (Ixodes holocyclus). | This study will use GM bacteria and yeast to express putative toxin proteins from the Australian paralysis tick, for the purpose of developing a vaccine against tick bite for companion animals. | Surrendered | 26/09/2012 | 15/09/2026 |
| DNIR-519 | The University of Melbourne | Infection of monkeys with SHIV (HIV / SIV chimera) | In this study, macaque monkeys will be infected with a GM lentivirus to test the effectiveness of experimental vaccines against Human Immunodeficiency Virus. | Surrendered | 10/11/2012 | 13/05/2025 |
| DNIR-520 | The University of Melbourne | Testing of novel replication competent immunomodulatory viruses as vaccine candidates | The applicant proposes to test the efficacy of GM Vaccinia virus and GM Fowlpox virus as vaccine candidates. | Surrendered | 5/11/2012 | 13/05/2025 |
| DNIR-521 | University of Canberra | Generation of recombinant, attenuated hepatitis D viruses | | Not Issued | | |
| DNIR-522 | Clinical Network Services (CNS) Pty Ltd | Clinical investigation of NT-501, encapsulated human NTC-201 cell implants releasing Ciliary Neurotrophic Factor (CNTF) | | Withdrawn | | |
| DNIR-523 | Royal Prince Alfred Hospital | A clinical trial to treat Hemophilia B using AAV-based gene therapy | The applicant is planning to conduct a clinical gene therapy trial using a GM adeno-associated viral vector encoding human Factor IX to treat patients with severe Hemophilia B. | Surrendered | 10/04/2013 | 29/05/2017 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-524 | Macfarlane Burnet Institute for Medical Research and Public Health | Bat Retroviruses | The aim of the dealings is to create genetically modified replication defective viral particles to study the properties of endogenous bat beta- and gamma-retroviruses. | Licence issued | 22/10/2013 | 25/10/2028 |
| DNIR-525 | The University of Melbourne | The role of gut-resident T cells in protecting against enteric Listeria infection | In this study, GM Listeria monocytogenes will be used to study the role of gut-resident T cells in protecting against intestinal Listeria infection. | Licence issued | 26/04/2013 | 30/04/2028 |
| DNIR-526 | Melbourne Health | Replication of Hepatitis B virus, duck hepatitis B virus (DHBV) and woodchuck hepatitis B virus and the testing of antiviral agents. | | Withdrawn | | |
| DNIR-527 | The University of Melbourne | Influenza A virus PB1-F2 protein: A virulence factor and initiator of inflammation | In this study, the applicants will use GM Influenza A virus to study the effect of PB1-F2 on the host response to influenza infection. | Licence issued | 4/06/2013 | 7/06/2028 |
| DNIR-528 | Zoetis Australia Research & Manufacturing Pty Ltd | Evaluation of a cytolysin expressed in Corynebacterium glutamicum | The applicant proposes to evaluate a cytolysin expressed in Corynebacterium glutamicum | Surrendered | 10/05/2013 | 13/04/2016 |
| DNIR-529 | Adelaide University | Recombinant Viral Vaccines to Treat and Prevent Cancer, Allergy and Infectious Diseases | The aim of this dealing is to generate GM Vaccinia virus and GM lentiviral vectors and evaluate their efficacy as vaccine candidates against target antigens. | Licence issued | 28/05/2013 | 30/09/2028 |
| DNIR-530 | University of South Australia | Recombinant Viral Vaccines to Treat and Prevent Peanut Allergy | DNIR 529, 530 and 531 applications considered together and issued as one licence - DNIR 529. | Integrated into DNIR-529 | | |
| DNIR-531 | University of South Australia | Recombinant viral vaccines to treat and prevent skin cancer | DNIR 529, 530 and 531 applications considered together and issued as one licence - DNIR 529. | Integrated into DNIR-529 | | |
| DNIR-532 | University of New South Wales | HCV founder virus evolution: evolution and vaccine targets | The aim of the dealings is to use genetically modified HIV to study the evolution of Hepatitis C Virus (HCV) during infection. | Surrendered | 4/07/2013 | 26/07/2017 |
| DNIR-533 | University of New South Wales | HCV founder viruses as vaccine targets: vector LucR-E- | DNIR 532 and 533 applications considered together and issued as one licence - DNIR 532. | Integrated into DNIR-532 | | |
| DNIR-534 | QIMR Berghofer | A Phase 1 study of haploidentical haematopoitic stem cell transplantation with add-back of donor T cells transduced with inducible caspase 9 suicide gene in patients with poor risk haematological malignancies | | Withdrawn | | |
| DNIR-535 | Griffith University | Investigation of malaria parasite proteins | The aim of the dealings is to use genetically modified Plasmodium species to investigate the function of Plasmodium proteins. | Licence issued | 26/08/2013 | 31/08/2028 |
| DNIR-536 | Ascend Biopharmaceuticals Pty Ltd | Clinical study of the efficacy and safety of intra-tumoural injection of ASN-002 in basal cell carcinoma | The aim of the dealings is to investigate the efficacy and safety of intra-tumoural injection of genetically modified ASN-002 in basal cell carcinoma in a clinical study. | Licence issued | 29/10/2013 | 5/11/2028 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-537 | CSIRO | The molecular basis of the pathogenicity of Newcastle disease in chickens | The aim of the dealings is to generate and use GM ND viruses to study the role of individual ND viral genes, or combinations of genes and determine their role in the pathogenicity of the disease. | Expired | 2/12/2013 | 31/01/2019 |
| DNIR-538 | University of New South Wales | HIV biology | The aim of the dealings is to use GM lentiviruses based on Human immunodeficiency virus (HIV) and Simian immunodeficiency virus to study aspects of HIV biology. | Licence issued | 4/07/2014 | 12/07/2029 |
| DNIR-539 | Queensland University of Technology | Development and use of a banana streak virus-based virus vector to investigate banana-Fusarium interactions | The aim of the dealings is to use genetically modified banana streak virus-based vectors to introduce genetic material related to Fusarium disease development or resistance into banana plants in order to identify key genes in banana-Fusarium interactions. | Surrendered | 6/01/2014 | 11/06/2021 |
| DNIR-540 | Flinders University | Mouse model for studies of B cells migration into the eye | The aim of the dealings is use genetically modified lentiviral vectors to study B-cell mediated inflammation in the eye. | Surrendered | 17/12/2013 | 5/08/2016 |
| DNIR-541 | Advanced Analytical Australia Pty Ltd | R & D for Norovirus and Hepatitis A. | | Withdrawn | | |
| DNIR-542 | CSIRO | The molecular determinants of pathogenicity, tissue tropism and transmissibility of influenza A virus. | The aim of the dealings is to generate GM Influenza A viruses for the in vitro and in vivo study of viral genes and their role in disease. | Licence issued | 30/01/2014 | 28/02/2029 |
| DNIR-543 | University of New South Wales | HIV Biology of Latency and Assembly | The aim of the dealing is to use GM RD HIV-1 to study its latency and assembly | Licence issued | 21/02/2014 | 20/02/2029 |
| DNIR-544 | Western Sydney Local Health District | Plasmid ecology and microbial husbandry in the Enterobacteriaceae | | Withdrawn | | |
| DNIR-545 | Australian National University | Using Aspergillus nidulans as a heterologous host for mining the secondary metabolomes of fungal phytopathogens | | Withdrawn | | |
| DNIR-546 | Macquarie University | Investigation of the role of glia in the control of blood pressure | The aim of the dealings is generate GM lentiviral vectors encoding the light chain of tetanus toxin to investigate the role of glia in the control of blood pressure. | Expired | 28/05/2014 | 31/05/2019 |
| DNIR-547 | Zoetis Australia Research & Manufacturing Pty Ltd | Evaluation of toxin expression in Pichia pastoris and Chinese hamster ovary cells (Cricetulus griseus). | Evaluation of toxin expression in Pichia pastoris and Chinese hamster ovary cells (Cricetulus griseus). | Surrendered | 14/08/2014 | 13/04/2016 |
| DNIR-548 | Zoetis Australia Research & Manufacturing Pty Ltd | Evaluation of toxin expression in Chinese hamster ovary cells (Cricetulus griseus) | DNIR 547 and 548 applications considered together and issues as one licence - DNIR-547. | Integrated into DNIR-547 | | |
| DNIR-549 | Treidlia Biovet Pty Ltd | Manufacture of Foot Rot Vaccine for sheep and goats. | The aim of the dealings is to use genetically modified Pseudomonas aeruginosa in the manufacturing of a foot rot vaccine for sheep and goats. | Licence issued | 12/09/2014 | 12/09/2029 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-550 | Harry Perkins Institute of Medical Research | Generation of fluorescent lentiviral transduced tumour cell lines | The aim of the dealings is use genetically modified lentiviral vectors to produce fluorescent-labelled tumour cell lines, for use in a range of in vitro and in vivo experiments. | Expired | 2/10/2014 | 15/10/2019 |
| DNIR-551 | Monash University | Human Immunodeficiency Virus anti-viral development | The aim of the dealings is use genetically modified HIV, which specifically infects rodents, to investigate the properties of new anti-viral drugs. | Licence issued | 2/12/2014 | 30/11/2029 |
| DNIR-552 | Western Sydney University | Use of N11 murine microglia for drug discovery | The aim of the dealings is to use a GM mouse cell line (N11) that secretes a GM retrovirus to screen plant and fungal extracts for anti-inflammatory compounds. | Licence issued | 19/12/2014 | 19/12/2029 |
| DNIR-553 | Australian National University | Assessing HIV vaccine efficacy | The aim of the dealings is use genetically modified HIV, which specifically infects rodents, to investigate the efficacy of HIV vaccines. | Surrendered | 3/12/2014 | 4/04/2019 |
| DNIR-554 | QIMR Berghofer | Production and clinical trial of a genetically modified Plasmodium falciparum blood stage vaccine | The aim of the dealings is to assess genetically-modified Plasmodium falciparum for safety, immunogenicity and efficacy as a malaria vaccine in healthy human volunteers. | Expired | 17/02/2015 | 17/02/2025 |
| DNIR-555 | Griffith University | New studies on the virulence and physiology of Burkholderia pseudomallei | The aim of the dealings is to study virulence factors in GM B. pseudomallei for the development of a diagnostic assay. | Expired | 11/06/2015 | 11/05/2025 |
| DNIR-556 | Monash University | Factors controlling developmental transitions in the fungus Candida albicans | The aim of the dealings is use genetically modified Candida albicans to identify and characterise factors and mechanisms that enable this organism to produce pathogenic morphological structures. | Expired | 17/04/2015 | 17/04/2025 |
| DNIR-557 | Monash University | An investigation of a single intranasal administration of the interferon alpha compound “DEF201” in longtail macaques. | Project aim is to determine the bio distribution and potential toxic effects of GM replication defective adenovirus DEF201 in fascicularis macaques | Expired | 3/07/2015 | 3/07/2020 |
| DNIR-558 | The University of Melbourne | Generation of protein for structural studies of membrane-bound pore forming toxins | The aim of this study is to clone and express bacterial pore-forming toxin genes so as to purify the toxin proteins and carry out structural studies. | Licence issued | 31/07/2015 | 4/08/2030 |
| DNIR-559 | Amgen Australia Pty Ltd | Evaluation of the efficacy and safety in the treatment of solid tumours with talimogene laherparepvec | The aim of the dealings is to conduct clinical trials to study safety and efficacy of a GMO in the treatment of different types of solid tumours. | Surrendered | 4/11/2015 | 30/05/2024 |
| DNIR-560 | RMIT University | Generation of recombinant toxin molecules | A project using chimeras of naturally occurring proteins for potential therapeutic use. | Licence issued | 10/12/2015 | 10/12/2030 |
| DNIR-561 | Griffith University | Development of an Alphaviral vector to deliver bioactive factors to bone. Potential use to treat diseases resulting in severe reduction of bone density | The aim of the dealings is to develop a GM Ross River Virus and conduct in vitro and in vivo experiments to investigate its potential as a vector delivering bioactive factors to bone tissue and potentially treat bone or joint diseases. | Expired | 21/12/2015 | 22/12/2025 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-562 | Centenary Institute of Cancer Medicine and Cell Biology | Molecular changes and therapies for Hepatitis B virus infection | | Withdrawn | | |
| DNIR-563 | Curtin University | Expression of genes from plant pathogenic fungi into a model fungus, Parastagonospora nodorum. | The applicant proposes to use GM P. nodorum in in vitro and in vivo experiments to develop an understanding of fungal pathogenicity and fungicide resistance. | Licence issued | 24/06/2016 | 24/06/2031 |
| DNIR-564 | CMAX Clinical Research Pty Ltd | Phase I/IIa Study of DVC1-0101 in subjects with intermittent claudication secondary to peripheral artery disease | The Phase I/IIa clinical trial would assess the safety and tolerability of genetically modified (GM) Sendai virus as a therapeutic agent to stimulate the growth of new blood vessels in individuals who experience limb pain as a result of peripheral artery disease. | Surrendered | 29/04/2016 | 6/09/2021 |
| DNIR-565 | Baker Heart & Diabetes Institute | Using adeno-associated virus vectors to study striated musculature and related tissues in vitro and in vivo | To use GM AAV to study changes in striated musculature when exposed to single cytokines, to aid in development of treatment for muscle wasting caused by disease or injury. | Surrendered | 21/07/2016 | 19/07/2019 |
| DNIR-566 | Monash University | Biochemical Studies of Cholesterol Dependent Cytolysin Proteins | The aim of this study is to clone and express bacterial pore-forming toxin genes so as to purify the toxin proteins and analysed in vitro using imaging and biophysical techniques. | Licence issued | 5/08/2016 | 5/08/2031 |
| DNIR-567 | Acura Bio Pty Ltd | Expression of PRS060 protein by recombinant Corynebacterium glutamicum | Use GM C. glutamicum to overexpress a genetically modified Anticalin protein (PRS060) on a large scale for the purposes of manufacturing a human therapeutic product | Expired | 1/09/2016 | 1/09/2021 |
| DNIR-568 | Queensland University of Technology | Development and use of a Cucumber mosaic virus-based vector to investigate banana-Fusarium interactions | The aim of the dealings is to use a genetically modified Cucumber mosaic virus vector to identify key genes related to virulence or resistance in Fusarium wilt disease of banana. | Surrendered | 29/09/2016 | 11/06/2021 |
| DNIR-569 | Pfizer Australia Pty Ltd | Gene therapy, Open-Label, Dose-escalation study of SPK-9001 (adeno-associated viral vector with human factor IX gene) in subjects with hemophilia B | This trial aims to assess the safety and tolerability of gene therapy treatment using a genetically modified adeno-associated viral vector encoding human Factor IX in patients with severe Hemophilia B | Expired | 8/09/2016 | 9/09/2026 |
| DNIR-570 | CSIRO | Characterisation of the Molecular Determinants of Host Responses and Pathogenicity of Filoviruses | Viral genes of family Filoviridae viruses will be examined to determine their role in pathogenesis, host responses, host range, and cross-species transmission. | Licence issued | 1/03/2017 | 1/03/2027 |
| DNIR-571 | Women's and Children's Health Network Incorporated | Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA | This clinical trial aims to assess the safety and efficacy of gene therapy using a genetically modified adeno-associated viral vector encoding human sulfoglucosamine sulfohydrolase (SGSH) in paediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA) | Surrendered | 14/03/2017 | 20/11/2024 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-572 | The University of Queensland | Analyses of gut and systemic infection with recombinant listeria | GM L. monocytogenes will be used to study the ability of gut-resident T cells to protect against intestinal Listeria infection. | Surrendered | 13/04/2017 | 17/12/2025 |
| DNIR-573 | The University of Melbourne | Molecular Biology of retroviral Replication, Pathogenesis and Productive Infection | To study molecular mechanisms regulating viral gene expression and function, to better understand molecular aspects of viral replication and latency for development of therapeutics. | Licence issued | 23/05/2017 | 23/05/2027 |
| DNIR-574 | The University of Melbourne | Examination of HIV Latent Infection | | Withdrawn | | |
| DNIR-575 | The University of Sydney | Fine tuning transplantation tolerance with co-stimulatory molecules | To study immunological tolerance of transplanted organs in mice, using GM AAV as a vector to express proteins that may enhance or block tissue acceptance in the liver of transplant recipients. | Licence issued | 27/06/2017 | 27/06/2027 |
| DNIR-576 | James Cook University | New strategies for improved tuberculosis vaccines | GM Mycobacterium bovis BCG strains will be used to express known immunogens and virulence factors of Mycobacterium tuberculosis to develop improved tuberculosis vaccine strains and test vaccination regimens in an animal model of human tuberculosis. | Licence issued | 3/11/2017 | 3/11/2027 |
| DNIR-577 | PSI CRO Australia Pty Ltd | Gene-transfer, open-label, dose-escalation study of SPK-8011 [adeno-associated viral vector with B-domain deleted human factor VIII gene] in individuals with hemophilia A | Gene therapy, open-label, dose-escalation study of SPK-8011 (recombinant adeno-associated viral vector with B-domain deleted human factor VIII gene) in subjects with haemophilia A | Surrendered | 17/11/2017 | 31/10/2023 |
| DNIR-578 | University of South Australia | A recombinant viral vaccine vector platform to produce polyclonal antibodies in milk and egg. | To study the efficacy and safety of a GM viral vaccine vector to produce polyclonal antibodies in milk and eggs | Surrendered | 20/12/2017 | 7/01/2026 |
| DNIR-579 | Griffith University | Investigating the mode of action of novel drug leads against Giardia duodenalis | GM Giardia duodenalis will be used to study the mode of action of novel anti-Giardia drug candidates and the role of specific G. duodenalis proteins in mediating their effect. | Licence issued | 13/12/2017 | 13/12/2027 |
| DNIR-580 | Novotech (Australia) Pty Limited | MVA-NP+M1: a new Influenza vaccine for use in human clinical trials | To assess the safety, tolerability, and efficacy of GM Vaccinia virus (MVA strain) in the prevention of influenza A | Expired | 23/01/2018 | 23/01/2023 |
| DNIR-581 | Murdoch Children's Research Institute | Cardiac Regeneration | This study aims to investigate the function of various genes and signalling pathways involved in heart development and regeneration. This project will test whether selected genes implicated in heart development are sufficient to promote cardiac regeneration in adult mice in vivo. | Licence issued | 13/04/2018 | 13/04/2028 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-582 | Monash University | Genetic manipulation of cells by viral transduction using in vivo models | This study aims to study the growth, spread and treatment response of melanoma. The project will investigate the effect of silencing genes involved in cell growth or differentiation on the development of human melanoma tumours transplanted into mice. | Licence issued | 10/05/2018 | 10/05/2028 |
| DNIR-583 | Novotech (Australia) Pty Limited | Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for high risk Locally Advanced Cervical Cancer: AIM2CERV. | The study drug, ADXS11-001 is a genetically modified Listeria monocytogenes encoding human papillomavirus antigen. The clinical trial aims to treat subjects with high risk locally advanced cervical cancer following chemotherapy and radiotherapy. | Surrendered | 16/05/2018 | 25/11/2019 |
| DNIR-584 | CSIRO | Large-scale fermentation of SCV vaccines. | To test and optimise the fermentation conditions, and to manufacture large-scale (> 25 L) volumes of GM Vaccinia virus vaccines. | Surrendered | 1/06/2018 | 15/02/2024 |
| DNIR-585 | Novotech (Australia) Pty Limited | Clinical Trial of an oncolytic vaccine for the treatment of cancers caused by the human papilloma virus (HPV) | The proposed clinical trial will investigate the safety, tolerability and efficacy of a two-component 'oncolytic vaccine' for the treatment of human cancers caused by high-risk Human Papilloma Virus (HPV). | Surrendered | 23/10/2018 | 7/12/2022 |
| DNIR-586 | The Children's Hospital Westmead | A global study of a single one-time dose of AVXS-101 delivered to paediatric patients with genetically diagnosed and pre-symptomatic Spinal Muscular Atrophy with multiple copies of SMN2. | To use a recombinant AAV encoding the human survival motor neuron 1 (SMN1) gene to treat paediatric patients with Spinal Muscular Atrophy (SMA) before development of irreversible injury due to motor neuron loss | Expired | 3/08/2018 | 3/08/2023 |
| DNIR-587 | GlaxoSmithKline Australia Pty Ltd | Clinical Trials with Respiratory Syncytial Virus (RSV) Investigational Vaccine ChAd155-RSV | To investigate the safety, tolerability and efficacy of a recombinant ChAd155-RSV as a prophylactic vaccine for prevention of RSV lower respiratory tract infections in infants. | Expired | 25/09/2018 | 25/09/2023 |
| DNIR-588 | Janssen-Cilag Pty Ltd | Recombinant Respiratory Syncytial Viral Vaccine (Ad26.RSV.preF) for Clinical Studies | To assess the safety and tolerability a prophylactic RSV vaccine | Expired | 20/11/2018 | 19/11/2023 |
| DNIR-589 | The University of Melbourne | Using adeno-associated viral vectors to study striated musculature and related tissues in vitro and in vivo | To use GM AAV to study changes in striated musculature when exposed to single cytokines, to aid in development of treatment for muscle wasting caused by disease or injury | Licence issued | 3/12/2018 | 3/12/2028 |
| DNIR-590 | Queensland University of Technology | Development and use of Banana streak virus-based vectors to investigate banana-Fusarium interactions | | Withdrawn | | |
| DNIR-591 | QIMR Berghofer | Virus-mediated approaches to examine cardiovascular disease in vitro and in vivo | This study aims to determine the role of genes in the regulation of cardiac regeneration and disease by over expressing the genes in mice using adenovirus and adeno-associated virus vectors. | Licence issued | 16/01/2019 | 16/01/2029 |
| DNIR-592 | Novotech (Australia) Pty Limited | An Oncolytic Immunotherapy Product for use in Clinical Trials | To study the safety and efficacy of the GM HSV-1 in the treatment of different solid tumour types, in combination with an anti-cancer drug | Expired | 23/01/2019 | 23/01/2024 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-593 | Hudson Institute of Medical Research | Endometrial MSC as a cell-based therapy for pelvic organ prolapse (POP) in an ovine model | This application aim to use a replication-defective (RD) lentivirus, encoding the fluorescent protein mCherry, to evaluate the use of endometrial mesenchymal stem cells (eMSC) in a cell-based therapy for Pelvic Organ Prolapse (POP). | Licence issued | 25/03/2019 | 25/03/2029 |
| DNIR-594 | Merck Sharp & Dohme (Australia) Pty Ltd | A cytomegalovirus prophylactic vaccine (V160) for use in clinical trials | The GMO V160 is a conditionally replication defective cytomegalovirus (CMV) designed as a vaccine for prevention of CMV infection. The intended clinical programme is to evaluate its efficacy in prevention of CMV infection in adults and children. | Expired | 1/04/2019 | 1/04/2024 |
| DNIR-595 | Inghams Group Limited | US corn importation for Inghams to produce poultry feed | The applicant intends to import US corn, which is expected to contain GM grain, into Australia for processing to produce poultry feed. | Expired | 23/05/2019 | 23/05/2024 |
| DNIR-596 | Ridley Corporation Limited | US corn importation for Ridley to produce stockfeed | The applicant intends to import US corn that may contain GM seed, into Australia for processing into stockfeed. | Expired | 31/05/2019 | 31/05/2024 |
| DNIR-597 | Australian National University | Viral mediated approaches to examine cell growth and proliferation | | Withdrawn | | |
| DNIR-598 | PPD Australia Pty Ltd | A Phase 1, double blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of Dengusiil in healthy adults | The proposed clinical trial will evaluate the safety of the GMOs when administered to healthy adults. Secondary objectives are to measure the immune response and viraemia induced by the GMOs. | Expired | 13/08/2019 | 13/08/2024 |
| DNIR-599 | Medpace Australia Pty Ltd | A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma | To study the safety and efficacy of the GMO in the treatment of malignant pleural mesothelioma, in combination with an anti-cancer drug. | Expired | 1/08/2019 | 1/08/2024 |
| DNIR-600 | BioMarin Pharmaceutical Australia Pty Ltd | Studies to evaluate the efficacy and safety of BMN 270, an Adeno-Associated Virus vector-mediated gene transfer of human factor VIII in haemophilia A patients | To assess the efficacy and safety of gene therapy treatment using a GM AAV vector encoding activated human factor VIII in adult patients with severe Haemophilia A. | Licence issued | 28/08/2019 | 28/08/2029 |
| DNIR-601 | IQVIA RDS Pty Ltd | BacTRL-IL-12 Phase 1 Trial in Humans with Various Cancers | To evaluate the safety of bacTRL-IL-12, delivered as a single infusion in adults with advanced solid tumours. Secondary objectives are to evaluate the effect of the GMO on tumour size, duration and overall survival rates following infusion and the possible relationship between glycemic exposure with tumoral colonisation and efficacy. | Expired | 6/09/2019 | 6/09/2024 |
| DNIR-602 | TheraVir Pty Ltd | A clinical trial with a herpes simplex virus GMO (T3011) in patients with solid tumours. | To study the safety and tolerability of the GMO administered into tumours of cancer patients | Surrendered | 26/09/2019 | 21/06/2024 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-603 | Monash University | Limiting EAE through transplantation of HSCs | To use a genetically modified (GM) replication-defective lentivirus to express a therapeutic fusion protein, NgR(310)ecto-myc-Fc, in murine haematopoietic stem cells (HSCs). The modified HSCs (free of virus) will be subsequently used to study the therapeutic benefits of NgR(310)ecto-myc-Fc in a mouse model of progressive multiple sclerosis | Licence issued | 21/10/2019 | 21/10/2029 |
| DNIR-604 | Novotech (Australia) Pty Limited | An Immune Stimulating Oncolytic HSV-1 for use in Clinical Trials in Patients with Solid Tumours (VG161) | Clinical trial to study the safety and tolerability use of a genetically modified Herpes Simplex Virus 1 (HSV-1), namely VG161, to treat advanced malignant solid tumours. | Expired | 22/10/2019 | 22/10/2024 |
| DNIR-605 | Medpace Australia Pty Ltd | Clinical evaluation of GT005 in patients with age-related macular degeneration | Clinical evaluation of GT005 in patients with age-related macular degeneration | Surrendered | 8/01/2020 | 2/04/2024 |
| DNIR-606 | Peter MacCallum Cancer Centre | Clinical Study GO-004: An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors | The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with immune checkpoint blockade in patients with advanced solid tumours. | Expired | 15/01/2020 | 15/01/2025 |
| DNIR-607 | Merck Sharp & Dohme (Australia) Pty Ltd | An oncolytic viral therapy V938 in combination with Pembrolizumab (MK-3475) for use in clinical trials. | | Re-categorised | | |
| DNIR-608 | Clinical Network Services (CNS) Pty Ltd | Clinical trials with a prophylactic influenza A/H3N2 live, M2-deleted, intranasal vaccine (H3N2 M2SR) (with CCI) | | Re-categorised | | |
| DNIR-609 | Novotech (Australia) Pty Limited | Clinical Trials with Hepatitis Treatment Vaccine (VTP-300) | Clinical trial to study the safety, tolerability and immunogenecity of genetically modified Chimpanzee adenovirus (ChAdOx1-HBV)and vaccinia virus (MVA-HBV), namely VTP-300, to treat patients with chronic hepatitis B infection. | Expired | 24/02/2020 | 24/02/2025 |
| DNIR-610 | Novotech (Australia) Pty Limited | Clinical Trials with Zika Chikungunya Vaccine (SCV1002) | A Phase I, open label, single centre, single dose escalation study to investigate the safety, tolerability and immunogenicity of intra-muscular administration of SCV1002 in adult healthy volunteers. | Expired | 2/03/2020 | 2/03/2025 |
| DNIR-611 | Monash University | Understanding how Helicobacter pylori causes disease | The aim of this licence application is to examine the role of virulence factors from cancer-associated Helicobacter pylori in causing the disease. The genetically modified (GM) H. pylori strains with and without introduced mutations in the virulence factors will be used for in vitro (cell lines and primary cells) and in vivo (mice) studies. | Licence issued | 11/03/2020 | 11/03/2030 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-612 | University of New South Wales | Identification of protective anti-HCV antibodies in subjects that clear infection to inform vaccine design | To generate cell culture derived hepatitis C virus (HCV) variants with different patient-derived viral envelopes. A secondary aim is to characterise the infectivity and susceptibility to neutralisation by patient antibodies for each variant, and to study the fate of the virus in blood mononuclear cells and hepatocytes. | Licence issued | 8/05/2020 | 8/05/2030 |
| DNIR-613 | The University of Queensland | Antibiotic resistance gene transfer in bacteria from water sludge | To investigate horizontal transfer of antibiotic resistance genes in environmental samples | Licence issued | 28/05/2020 | 28/05/2030 |
| DNIR-614 | QIMR Berghofer | Manufacture and characterisation of a P. falciparum NF54 Inducible Gametocyte Producer (NF54/iGP3) Master Cell Bank for use in Phase I Clinical Trials utilising the Induced Blood Stage Malaria Infection Model | The aim of this licence application is to produce a good manufacturing practice (GMP) grade master cell bank of a genetically modified (GM) Plasmodium parasite, P. falciparum NF54/iGP3 Clone 3, which produces high numbers of gametocytes in vivo in the presence of the antibiotic, trimethoprim and to assess its safety and infectivity in pre-clinical studies. | Licence issued | 18/05/2020 | 18/05/2031 |
| DNIR-615 | Novartis Pharmaceuticals Australia Pty Limited | Supply of Luxturna (voretigene neparvovec) for the treatment of patients. | To supply Luxturna to patients suffering from bi-allelic RPE65 mutations | Licence issued | 26/05/2020 | |
| DNIR-616 | The University of Queensland | Understanding influenza virus pathogenesis | To identify the role of specific mutations in Influenza A virus that increase disease severity | Licence issued | 11/06/2020 | 11/06/2030 |
| DNIR-617 | Griffith University | GM HIV that are more infectious than wild type HIV | To assess infectiousness of GM HIV. | Licence issued | 9/06/2020 | 9/06/2030 |
| DNIR-618 | CSIRO | Genetic control strategies for plant pathogenic fungi | To determine if new genetic technologies, namely gene drives, can be used to control plant pathogenic fungi | Surrendered | 16/07/2020 | 28/06/2023 |
| DNIR-619 | Novotech (Australia) Pty Limited | CodaVax-H1N1, a live-attenuated vaccine for the use in clinical trials for breast cancer | Treatment of breast cancer with a codon-optimised live attenuated genetically modified influenza virus | Expired | 28/07/2020 | 28/07/2025 |
| DNIR-620 | Western Sydney Local Health District | Therapeutic treatment of patients with Mycobacterium abscessus disease | This licence is for the treatment of non-tuberculous Mycobacteria infection (NTM) with a cocktail of naturally occurring and a GM bacteriophage | Expired | 22/04/2020 | 22/04/2025 |
| DNIR-621 | Novartis Pharmaceuticals Australia Pty Limited | Supply of Zolgensma (Onasemnogene abeparvovec) for the treatment of patients with spinal muscular atrophy (SMA) | This licence authorises the commercial supply of Zolgensma to patients suffering from spinal muscular atrophy | Licence issued | 24/08/2020 | |
| DNIR-622 | Accelagen Pty Ltd | rBCG Vaccine to reduce incidence and severity of COVID-19 infection in high risk groups | rBCG Vaccine to reduce incidence and severity of COVID-19 infection in high risk groups such as Health care workers and people over 65 with co-morbidity | Expired | 9/06/2020 | 9/06/2022 |
| DNIR-623 | PPD Australia Pty Ltd | A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of a GMO in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) | This trial aims to assess the safety and efficacy of gene therapy treatment using a genetically-modified adeno-associated viral vector encoding human progranulin in patients with frontotemporal dementia. | Licence issued | 21/09/2020 | 21/09/2030 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-624 | Pfizer Australia Pty Ltd | A clinical trial to evaluate the efficacy and safety of PF-07055480 in adult male participants with moderately severe to severe haemophilia A | Phase III clinical trial with replication deficient GM AAV carrying human factor VIII to treat haemophilia patients | Expired | 8/10/2020 | 8/10/2025 |
| DNIR-625 | BioMarin Pharmaceutical Australia Pty Ltd | Clinical trial to determine the safety and efficacy of BMN 307, an Adeno-associated virus vector-mediated gene transfer of human phenylalanine hydroxylase in patients with phenylketonuria | To assess the efficacy, safety and tolerability of a single injection of BMN 307, a gene therapy treatment using GM AAV encoding human phenylalanine hydroxylase to reduce plasma Phe in phenylketonurics with baseline plasma Phe > 600 µmol/L. | Surrendered | 17/09/2020 | 30/05/2024 |
| DNIR-626 | Novotech (Australia) Pty Limited | Clinical Trials with a SARS-CoV-2 oral vaccine (bacTRL-Spike) | Clinical Trials with a SARS-CoV-2 oral vaccine (bacTRL-Spike) | Expired | 10/08/2020 | 10/08/2025 |
| DNIR-627 | South Australian Health and Medical Research Institute | Generating mouse models with altered inheritance and sex bias | The aim of this licence application is to develop a genetic method to control invasive pest mice by spreading mutations that cause infertility, embryonic death or bias the sex of offspring. | Licence issued | 25/09/2020 | 25/09/2030 |
| DNIR-628 | The University of Melbourne | Identification of molecular factors that influence reassortment and pandemic potential of highly pathogenic avian influenza H5 viruses | Identify gene segments, critical regions within gene segments, and functional interactions of gene products that influence reassortment in HPAI H5 viruses | Licence issued | 30/09/2020 | 30/09/2030 |
| DNIR-629 | Novotech (Australia) Pty Limited | Clinical trial with ICM-203 for the treatment of arthritis | This trial aims to assess the safety and efficacy of gene therapy treatment using a genetically-modified adeno-associated viral vector encoding transcription factor Nkx3.2 in patients with arthritis. | Expired | 15/01/2021 | 15/01/2026 |
| DNIR-630 | CSL Innovation Pty Ltd | Human Embryonic Kidney 293 cells containing recombinant ChAdOx1 vector expressing COVID-19 insert | The aim of this dealing is to manufacture and supply frozen bulk drug substance for subsequent formulation operations as part of an overall program for the supply of recombinant antigen for the prevention of COVID-19. | Surrendered | 2/11/2020 | 28/02/2023 |
| DNIR-631 | Novotech (Australia) Pty Limited | SARS-CoV-2 prophylactic vaccine for use in clinical trials | This Phase I trial aims to assess the safety and efficacy of a vaccine candidate against disease caused by SARS-CoV-2. | Surrendered | 28/01/2021 | 20/04/2022 |
| DNIR-632 | Seqirus Pty Ltd | Formulation and Fill/Finish of a recombinant ChAdOx1 vector that expresses the spike protein of SARS-CoV-2 | The aim of this dealing is to receive frozen bulk drug substance for subsequent formulation and fill finish operations as part of an overall program for the supply of recombinant antigen for the prevention of COVID-19. | Surrendered | 14/12/2020 | 11/05/2023 |
| DNIR-633 | Murdoch Children's Research Institute | Administration of AVXS-101 to patients with genetically diagnosed spinal muscular atrophy | To assess the safety and efficacy of a recombinant AAV serotype 9 vector encoding SMN1 in infants with Spinal Muscular Atrophy (SMA) | Expired | 29/03/2021 | 29/03/2026 |
| DNIR-634 | The University of Queensland | Dissecting COVID-19 pathogenesis by advanced molecular technologies | To study viral replication, pathogenesis, immune evasion, immunomodulation and drug susceptibility by assessing the effects of targeted mutations in various proteins. | Licence issued | 10/06/2021 | 10/06/2031 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-635 | Novotech (Australia) Pty Limited | Clinical Trials with 4D-310 for the treatment of Fabry Disease | This trial aims to assess the safety, tolerability, and pharmacodynamics of 4D-310 in patients with Fabry disease | Expired | 4/06/2021 | 4/06/2026 |
| DNIR-636 | Avance Clinical Pty Ltd | Clinical trial to determine the safety and efficacy of SC-Ad6-1, an adenovirus based COVID-19 vaccine | To assess the safety, tolerability, immunogenicity and efficacy of SC-Ad6-1 as a second generation, prophylactic vaccine to prevent COVID-19. | Expired | 15/04/2021 | 15/04/2026 |
| DNIR-637 | Janssen-Cilag Pty Ltd | A recombinant COVID-19 vaccine (Ad26.COV2.S) for use in clinical trials | To conduct clinical trials to assess the safety, reactogenicity and immunogenicity of the recombinant COVID-19 vaccine (Ad26.COV2.S) in pregnant women and children. | Surrendered | 5/05/2021 | 18/12/2025 |
| DNIR-638 | Avance Clinical Pty Ltd | Serotype 5 Based Recombinant Vector Encoding the Human CYP21A2 Gene to treat Congenital Adrenal Hyperplasia | To test the safety and efficacy of a recombinant AAV serotype 5 vector encoding the human CYP21A2 gene in participants with Congenital Adrenal Hyperplasia (CAH). | Expired | 30/06/2021 | 30/06/2026 |
| DNIR-639 | Monash University | Investigating the genetic basis of dengue and chikungunya virus resistance to Wolbachia | Identify genetic determinants to dengue and chikungunya viruses that might confer resistance to the antiviral effects of Wolbachia in infected mosquitoes | Licence issued | 25/08/2021 | 25/08/2031 |
| DNIR-640 | Treidlia Biovet Pty Ltd | Generation of recombinant toxin molecules from Clostridium tetani | To manufacture recombinant tetanus toxins for study of their potential to treat muscular disorders | Licence issued | 20/08/2021 | 20/08/2031 |
| DNIR-641 | Treidlia Biovet Pty Ltd | Generation of recombinant toxin molecules | To manufacture recombinant ApxIVA toxins in E. coli for use in a vaccine against swine pleuropneumoniae, caused by Actinobacillus pleuropneumoniae | Licence issued | 25/08/2021 | 25/08/2031 |
| DNIR-642 | Diagnostic Technology Pty Limited | Recombinant production of Neosaxitoxin and Microcystin in E. coli | | Withdrawn | | |
| DNIR-643 | Griffith University | Development of heterologous viral envelope pseudotyped virus platforms for research in emerging viral pathogens | The aim of this application is to develop a platform using heterologous viral envelope pseudotyping i.e., the surface of an un-related virus will be decorated with viral surface proteins of pandemic viral pathogens, to examine the function of the surface (envelope or spike) proteins of pandemic viral pathogens. | Licence issued | 28/09/2021 | 28/09/2031 |
| DNIR-644 | Pfizer Australia Pty Ltd | Establish safety and efficacy of PF- 06939926 in patients with Duchenne Muscular Dystrophy | To test the safety and efficacy of a recombinant AAV serotype 9 vector encoding a miniaturised version of human dystrophin protein in participants with Duchenne muscular dystrophy (DMD). | Licence issued | 8/09/2021 | 8/09/2028 |
| DNIR-645 | Peter MacCallum Cancer Centre | Viral immune activating agents as cancer therapeutics | | Withdrawn | | |
| DNIR-646 | The University of Melbourne | Two types of split gene drive for D.melanogaster lab experiments | The aim of this licence application is to develop and explore split gene drive designs to confer sex biased progeny and insecticide sensitivity in model organism Drosophila as a proof-of-concept. | Licence issued | 11/10/2021 | 11/10/2031 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-647 | Medpace Australia Pty Ltd | A Phase I/II, multicenter, open-label, single dose, dose ranging study to assess the safety and tolerability of ST-920, an AAV2/6 human alpha galactosidase A gene therapy in subjects with Fabry disease. | Clinical trial to assess safety and tolerability of ST-920, an AAV2/6 human alpha-galactosidase A gene therapy to treat Fabry disease | Surrendered | 21/10/2021 | 28/05/2025 |
| DNIR-648 | Medpace Australia Pty Ltd | Clinical trial to determine the safety and efficacy of FLT180a, an Adeno-associated virus vector-mediated gene transfer of the Padua variant of human Factor IX in patients with haemophilia B | To assess the safety, tolerability and confirm the dose of FLT180a, a gene therapy treatment for adult male patients with haemophilia B using GM AAV encoding the Padua variant for human Factor IX | Expired | 1/11/2021 | 1/11/2026 |
| DNIR-649 | The Walter and Eliza Hall Institute of Medical Research | Use of the inducible gametocyte producing P. falciparum line NF54/iGP3 for controlled human malaria infection model | Characterise the GM Plasmodium falciparum NF54/iGP Clone 3 in vitro in cell lines and in vivo in a mouse model using trimethoprim-induced gametocytes to assess safety and infectivity. | Licence issued | 10/01/2022 | 10/01/2027 |
| DNIR-650 | Merck Sharp & Dohme (Australia) Pty Ltd | Clinical trial of a live attenuated tetravalent Dengue vaccine (V181) in adults | The proposed clinical trial will evaluate the safety and tolerability of the GMOs when administered to healthy adults. Secondary objectives are to measure the immune response induced by the GMOs. | Licence issued | 1/03/2022 | 1/03/2027 |
| DNIR-651 | BioMarin Pharmaceutical Australia Pty Ltd | Clinical Trial with BMN 331 in patients with Hereditary Angioedema | To determine safety, tolerability and efficacy of GM AAV (BMN-331) in patients with Hereditary Angioedema who are deficient in C1 Esterase Inhibitor (C1-INH). | Surrendered | 30/03/2022 | 20/09/2024 |
| DNIR-652 | PPD Australia Pty Ltd | A Phase 3 clinical trial with DTX301 in patients with late-onset ornithine transcarbamylase deficiency | Clinical trial to test the safety and efficacy of DTX301 in participants with late-onset ornithine transcarbamylase deficiency | Surrendered | 11/04/2022 | 5/08/2025 |
| DNIR-653 | Novotech (Australia) Pty Limited | An Oncolytic Immunotherapy Product for use in Clinical Trials | The purpose of the clinical trials is to study the safety, tolerability and efficacy of the GMO in the treatment of mucosal solid tumours, as a single agent or in combination with anticancer drugs. | Surrendered | 2/05/2022 | 3/06/2022 |
| DNIR-654 | The University of Melbourne | Understanding Coronavirus infection and disease | To study virus host-range, virulence, replicative fitness, transmissibility and susceptibility to antiviral drugs and vaccines, with the aim of developing better vaccines, antiviral drugs, and other treatment regimens for COVID-19. | Licence issued | 17/10/2022 | 17/10/2027 |
| DNIR-655 | Bayside Health | Phage therapy for severe lung disease due to Mycobacterium abscessus | This licence is for the treatment of non-tuberculous Mycobacteria infection (NTM) with a cocktail of naturally occurring and a GM bacteriophage | Licence issued | 12/07/2022 | 12/07/2027 |
| DNIR-656 | BioCina Pty Ltd | Expression and Purification of fusion protein targeting tumor specific cells | Large-scale production of GM E. coli expressing a fusion protein for use in cancer treatment. | Licence issued | 12/01/2023 | 12/01/2028 |
| DNIR-657 | Seqirus Pty Ltd | Influenza prophylactic vaccine for use in a clinical trial | The proposed Phase 1 clinical trial will evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine. | Licence issued | 23/01/2023 | 23/01/2028 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-658 | Flinders University | Testing of immortalised cell lines for replication competent retroviruses | This licence authorises the testing of cell lines generated using early retroviral vector technology to demonstrate that they are free of replication competent retroviruses. | Licence issued | 23/02/2023 | 23/02/2028 |
| DNIR-659 | CSL Innovation Pty Ltd | Supply of etranacogene dezaparvovec for the treatment of people with haemophilia B | To supply etranacogene dezaparvovec to patients suffering from haemophilia B with an increased bleeding tendency due to deficiency of the blood coagulation protein FIX (congenital Factor IX) | Licence issued | 5/04/2023 | |
| DNIR-660 | The University of Queensland | Use of recombinant Adeno-associated viral vectors to enable evaluation of human vaccine responses in mice | To use genetically modified adeno-associated viral vectors expressing human cytokines to study immunological responses in mice | Licence issued | 19/04/2023 | 19/04/2028 |
| DNIR-661 | Novotech (Australia) Pty Limited | Clinical trial of genetically modified HSV-1-based vector for the treatment of solid tumours | To evaluate the safety, tolerability, and efficacy of the GMO in participants with solid tumours. | Licence issued | 21/04/2023 | 21/04/2028 |
| DNIR-662 | Australian Veterinary Serum Laboratories | Expression of Australian paralysis tick holocyclotoxins in Pichia pastoris for development of therapeutics | To produce purified holocyclotoxins for assessment of antibody therapies and vaccine development for companion animals. | Licence issued | 19/05/2023 | 19/05/2028 |
| DNIR-663 | Novotech (Australia) Pty Limited | A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children with SCN1A positive Dravet Syndrome. | This clinical trial aims to assess the safety and efficacy of gene therapy treatment using a genetically modified adeno-associated viral vector in children with SCN1A-positive Dravet Syndrome. The GMO is designed to increase expression of the SCN1A gene in certain types of brain cells, correcting the genetic defect which causes this disorder. | Licence issued | 6/06/2023 | 6/06/2028 |
| DNIR-664 | Novotech (Australia) Pty Limited | Clinical trial of genetically modified adeno-associated virus for the treatment of autosomal dominant optic atrophy (ADOA) | To evaluate the safety, tolerability and efficacy of gene therapy in adult patients with ADOA associated with OPA1 mutation | Licence issued | 16/06/2023 | 16/06/2028 |
| DNIR-665 | South Australian Health and Medical Research Institute | Generating mouse models with altered inheritance | The aim of this project is to develop a gene drive in a laboratory to control invasive pest mice. | Licence issued | 26/06/2023 | 26/06/2028 |
| DNIR-666 | Beyond Drug Development Pty Ltd | Clinical evaluation of VOY-101 in patients with advanced non-neovascular age-related macular degeneration | This clinical trial is to test the safety and preliminary efficacy of a single, unilateral, intravitreal injection of an AAV2 vector therapy in subjects with late-stage non-neovascular age-related macular degeneration (AMD). | Licence issued | 3/07/2023 | 3/07/2028 |
| DNIR-667 | The Children's Hospital Westmead | Clinical trials involving Adeno-associated virus (AAV) gene therapy | To perform a broad range of clinical trials targeting genetic disorders caused by mutations affecting a single gene within a hospital setting. The trials use AAV viral vectors for in vivo administration of gene therapy in eligible patients | Licence issued | 10/08/2023 | 10/08/2028 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-668 | Parexel International Pty Ltd | A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP9001 in Non- Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION) | Clinical trial for patient with Duchennes Muscular Dystrophy (DMD) | Licence issued | 22/08/2023 | 22/08/2028 |
| DNIR-669 | Janssen-Cilag Pty Ltd | Clinical trial of genetically modified adeno-associated virus for treatment of geographic atrophy secondary to age-related macular degeneration | To evaluate the efficacy and safety of the GMO in patients with geographic atrophy secondary to age-related macular degeneration. | Surrendered | 7/08/2023 | 18/12/2025 |
| DNIR-670 | QIMR Berghofer | Gene Drive Anopheles farauti | Laboratory-contained research to develop a gene drive mosquito to control the spread of malaria | Licence issued | 25/08/2023 | 25/08/2028 |
| DNIR-671 | Novotech (Australia) Pty Limited | Clinical trial with a genetically modified Salmonella Typhimurium in patients with advanced solid tumours. | To evaluate the safety and preliminary anti-tumour activity of the GMO in patients with metastatic or unresectable solid tumours. | Licence issued | 1/09/2023 | 1/09/2028 |
| DNIR-672 | IQVIA RDS Pty Ltd | Clinical trial with Anti-CD19 CAR-T cell therapy in patients with relapsed/refractory B cell non-Hodgkin lymphoma | To evaluate the safety and tolerability of CAR-T cell therapy in patients with B cell non-Hodgkin lymphoma to determine the maximum tolerated dose and recommended Phase 2 dose | Licence issued | 11/09/2023 | 11/09/2028 |
| DNIR-673 | CSIRO | Molecular determinants of Newcastle disease virus pathogenicity | This project aims to investigate the molecular basis for differences in pathogenicity associated with Newcastle disease virus strains of differing virulence. | Licence issued | 25/09/2023 | 25/09/2028 |
| DNIR-674 | Monash University | Use of mouse lines containing diphtheria toxin genes for cardiovascular studies | | Withdrawn | | |
| DNIR-675 | Monash University | Use of DTA transgenic mice | | Withdrawn | | |
| DNIR-676 | Monash University | DTA Expressing Strains for Investigating Immunity in Mucosal Sites | | Withdrawn | | |
| DNIR-677 | Monash University | Use of transgenic mice expressing Diphtheria Toxin A to study roles of various cellular processes | To use DTA expressing mice to study the roles of various cellular processes. | Licence issued | 31/10/2023 | 31/10/2028 |
| DNIR-678 | Novotech (Australia) Pty Limited | Clinical trial of a genetically modified alphavirus replicon-based vaccine for the prevention of influenza | Clinical trial of a genetically modified alphavirus replicon-based vaccine for the prevention of influenza | Licence issued | 18/10/2023 | 18/10/2028 |
| DNIR-679 | Graythan Regulatory Services Pty Ltd | Treatment of patients with advanced solid tumours with a genetically modified alphavirus | To determine the safety and tolerability of the GMO alone, and in combination with a checkpoint inhibitor, in patients with advanced cancers. | Licence issued | 30/11/2023 | 30/11/2028 |
| DNIR-680 | The University of Melbourne | Vaccinia vectored vaccines against SARS-CoV-2 and Influenza A virus | Assessment of MVA vectored vaccine against IAV and SARS-Cov-2 in mice. | Licence issued | 12/12/2023 | 12/12/2028 |
| DNIR-681 | Adelaide University | Testing of mammalian cell lines for replication competent virus associated with prior genetic modification | The purpose of the proposed dealings is to enable the testing of historically generated cell lines, previously transduced with early viral vector technology, with no historical documentation to demonstrate that they are free of replication competent viruses | Licence issued | 16/01/2024 | 16/01/2029 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-682 | Novotech (Australia) Pty Limited | Clinical evaluation of RZ-004 in patients with retinitis pigmentosa | To test the safety and preliminary efficacy of subretinal injection of the gene therapy RZ-004 in participants with retinitis pigmentosa caused by an autosomal dominant RHO mutation. | Licence issued | 10/01/2024 | 10/01/2029 |
| DNIR-683 | Novotech (Australia) Pty Limited | Clinical trial of genetically modified alphavirus replicon-based vaccine for the prevention of COVID-19 | To evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine against COVID-19 | Licence issued | 12/01/2024 | 12/01/2029 |
| DNIR-684 | Beyond Drug Development Pty Ltd | A clinical trial to evaluate the safety, tolerability and efficacy of an AAV9 gene therapy in female children with Rett Syndrome | The purpose of the proposed trial is to assess the safety, tolerability and efficacy of an AAV9 based gene therapy in female children aged 4-10 years with Rett Syndrome, associated with mutation in MECP2 gene. | Licence issued | 15/01/2024 | 15/01/2029 |
| DNIR-685 | Bioproperties Pty Ltd | Formulation and filling of a genetically modified infectious laryngotracheitis virus for the vaccination of chickens | The purpose of this application is to formulate and fill the genetically modified vaccine for infectious laryngotracheitis virus (ILTV) in chickens. | Licence issued | 13/02/2024 | 13/02/2029 |
| DNIR-686 | The University of Melbourne | in vitro and in vivo studies with feline alphaherpesvirus-1 derived immunocontraceptives | The applicant aims to construct and investigate the effectiveness of immunocontraceptives based on feline herpesvirus-1, using in vitro and in vivo models. | Licence issued | 30/04/2024 | 30/04/2029 |
| DNIR-687 | BioCina Pty Ltd | Expression and Purification of an Epsilon Toxin (ETX) Vaccine Candidate | The aim of this project is to express a genetically modified (GM) toxin in GM E. coli. The purified toxin will be evaluated as a vaccine candidate. | Licence issued | 7/03/2024 | 7/03/2029 |
| DNIR-688 | Premier Research (Australia) Pty Ltd | Clinical trial of a treatment for refractory/relapsing B-cell malignancies | A clinical trial to assess the safety and effect of INT2104, a lentiviral vector with a transgene for a chimeric antigen receptor specific for CD20, in a broad population of patients with relapsed or refractory B-cell malignancies | Licence issued | 17/04/2024 | 17/04/2029 |
| DNIR-689 | The University of Sydney | An intracellular VenomORF library expression platform | This study aims to develop a third-generation lentivirus based genomic platform which can be utilised to identify the bioactive proteins of therapeutic value from venom of different organisms | Licence issued | 12/04/2024 | 12/04/2029 |
| DNIR-690 | PPD Australia Pty Ltd | Clinical trial of a genetically modified adeno-associated virus in patients with peripheral manifestations of Gaucher Disease | Clinical trial of genetically modified adeno-associated virus for the treatment of patients with Gaucher disease | Licence issued | 19/03/2024 | 19/03/2029 |
| DNIR-691 | The University of Melbourne | Demonstration of split gene drives in zebrafish | To develop a proof of concept study to explore the split gene drive homing mechanism in zebrafish. The intent is to apply the results of this study to control invasive vertebrate species by conferring sex bias. | Licence issued | 11/06/2024 | 11/06/2029 |
| DNIR-692 | Syneos Health Australia Pty Ltd | A clinical trial to evaluate the safety and efficacy of SPK-8011 in adults with severe or moderately severe haemophilia A | The purpose of the proposed trial is to assess the safety, tolerability and efficacy of an AAV based gene therapy in adults suffering with severe or moderately severe haemophilia A. | Surrendered | 25/06/2024 | 21/05/2025 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-693 | CSL Innovation Pty Ltd | Clinical trial of etranacogene dezaparvovec in patients with haemophilia B | The purpose of this clinical trial is to evaluate the safety and efficacy of the GMO in adults with haemophilia B | Licence issued | 3/05/2024 | 3/05/2029 |
| DNIR-694 | BioCina Pty Ltd | Manufacturing unencapsulated Streptococcus pneumoniae as a whole cell vaccine | The aim of this project is to manufacture the GMO, formulate and fill the GM vaccine for subsequent inactivation. | Licence issued | 22/04/2024 | 22/04/2029 |
| DNIR-695 | BioMarin Pharmaceutical Australia Pty Ltd | Supply of Roctavian (valoctocogene roxaparvovec) to patients with severe haemophilia A | Commercial supply of Roctavian for the therapeutic treatment of patients with Severe Haemophilia A | Surrendered | 20/08/2024 | 20/11/2024 |
| DNIR-696 | Seqirus Pty Ltd | Clinical trial of self-amplifying mRNA vaccine for pandemic influenza | The proposed Phase 1 clinical trial will evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine | Licence issued | 31/07/2024 | 31/07/2029 |
| DNIR-697 | Public and Environmental Health Reference Laboratories, Pathology Queensland | Destruction of nonviable Hendra virus (HeV) and Australian Bat Lyssavirus (ABLV) recombinant plasmids | The aim of this dealing is to destroy stored stocks of plasmids encoding full length, partial or GM Hendra virus and Australian Bat Lyssa Virus genomes | Expired | 10/09/2024 | 10/09/2025 |
| DNIR-698 | Murdoch Children's Research Institute | A Clinical Trial of ECUR-506 for treatment of Males with Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency | The proposed clinical trial will evaluate safety and efficacy of an AAV-based gene therapy for the treatment of OTC deficiency. | Licence issued | 19/09/2024 | 19/09/2029 |
| DNIR-699 | Seqirus Pty Ltd | Clinical trial of a multi-valent self-amplifying mRNA vaccine for the prevention of Influenza | The proposed Phase 2 clinical trial will evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine | Licence issued | 31/07/2024 | 31/07/2029 |
| DNIR-700 | TFS Trial Form Support Australia Pty Ltd | Clinical trial of AAV gene therapy (AGTC-501) for X-linked retinitis pigmentosa | The purpose of this clinical trial is to evaluate the efficacy, safety, and tolerability of subretinal injection of the gene therapy AGTC-501 in male participants with X linked retinitis pigmentosa | Licence issued | 3/10/2024 | 3/10/2029 |
| DNIR-701 | Source Certain Operations Pty Ltd | Import of corn, soybean and wheat | Import of corn, soybean and wheat seed samples for provenance analysis. | Licence issued | 10/10/2024 | 10/10/2029 |
| DNIR-702 | Adelaide University | Engineering bacteria to make bacterial toxins for cancer treatment | Expression of recombinant bacterial toxins in GM E. coli to reduce the viability of bowel cancer cells. | Licence issued | 17/10/2024 | 17/10/2029 |
| DNIR-703 | Medpace Australia Pty Ltd | A clinical trial of UB-VV111 in combination with rapamycin for the treatment of relapsed/refractory CD19+ hematologic malignancies | To assess the safety, efficacy, and pharmacokinetics/pharmacodynamics of UB-VV111 in combination with and without rapamycin in adult subjects with relapsed/refractory CD19+ hematologic malignancies. | Licence issued | 19/11/2024 | 19/11/2029 |
| DNIR-704 | The Children's Hospital Westmead | A Clinical Trial of ECUR-506 for treatment of Males with Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency | The proposed clinical trial will evaluate safety and efficacy of an AAV-based gene therapy for the treatment of OTC deficiency. | Licence issued | 30/10/2024 | 30/10/2029 |
| DNIR-705 | Western Sydney Local Health District | Clinical trial of GM AAV for treatment of genetic XYLT2 deficiency | The purpose of this clinical trial is to test the safety and efficacy of GM AAV in adult patients with genetic XYLT2 deficiency, specifically to test efficacy for brittle bone disease | Licence issued | 12/11/2024 | 12/11/2029 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-706 | La Trobe University | Expression of Staphylococcus aureus toxins | The purpose of this project is to express Staphylococcus aureus toxins in E. coli for characterisation of their superantigen mechanisms. | Licence issued | 14/01/2025 | 14/01/2030 |
| DNIR-707 | The Royal Children's Hospital | Bermagene geperpavec (B-VEC) | To treat a small number of patients with dystrophic epidermolysis bullosa. | Licence issued | 19/12/2024 | 19/12/2029 |
| DNIR-708 | Seqirus Pty Ltd | Preparation of influenza vaccines using attenuated influenza A viruses | The purpose of the dealings is to produce and propagate vaccines against non-seasonal Influenza A, based on an attenuated Influenza A virus, in cell lines at small and large scales and to conduct quality control experiments. | Licence issued | 22/01/2025 | 22/01/2030 |
| DNIR-709 | BioCina Pty Ltd | Manufacture of genetically modified Salmonella enterica enterica Serovar Typhimurium bacterial strains to derive nanocells | To manufacture genetically modified Salmonella Typhimurium bacteria capable of producing nanocells. | Licence issued | 13/01/2025 | 13/01/2030 |
| DNIR-710 | The University of Melbourne | Exploring gene drives in Plasmodium to control malaria | This project aims to develop and investigate gene drives in Plasmodium berghei and Plasmodium falciparum to modulate parasite populations | Licence issued | 12/02/2025 | 12/02/2030 |
| DNIR-711 | The University of Melbourne | Understanding seasonal coronavirus infection and disease | The primary aim is to develop genetically modified (GM) HCoV-NL63 strains capable of infecting mice to better understand HCoV-NL63 infection. These studies may assist in the development of better vaccines and antiviral drugs that could be broadly effective against both SARS-CoV-2 and HCoV-NL63. | Licence issued | 10/02/2025 | 10/02/2030 |
| DNIR-712 | The Florey Institute of Neuroscience and Mental Health | Prodromal disease characterisation in murine models of familial prion disease | The project is to develop human genetic prion disease in mouse by introducing human genes related to prion disease. This animal model data will provide evidence for a future longitudinal study involving patients. | Licence issued | 24/02/2025 | 24/02/2030 |
| DNIR-713 | The University of Sydney | A constitutive VenomORF library expression platform | This study aims to develop a third-generation lentivirus genomic platform to characterise the bioactivity of proteins from the venom of different organisms. | Licence issued | 10/02/2025 | 10/02/2030 |
| DNIR-714 | IQVIA RDS Pty Ltd | In Vivo Gene Therapy to Generate Anti-BCMA CAR-T Cells in Patients with Relapsed and Refractory Multiple Myeloma | To assess the safety, tolerability, preliminary efficacy and pharmacokinetics/pharmacodynamics of the GMO in adult patients with relapsed and refractory multiple myeloma. | Licence issued | 6/03/2025 | 6/03/2030 |
| DNIR-715 | Valo Therapeutics (Australia) Pty Ltd. | A clinical trial to assess safety and clinical activity of the GMO PeptiCRAd-1 in patients with solid tumours | | Cease to consider | | |
| DNIR-716 | PPD Australia Pty Ltd | A clinical trial of an AAV-based gene therapy (EPI-321) for the treatment of facioscapulohumeral muscular dystrophy (FSHD) in adults | The purpose of this clinical trial is to assess the safety, tolerability and biological activity of EPI-321 (the GMO) in adult patients with facioscapulohumeral muscular dystrophy (FSHD) | Licence issued | 24/03/2025 | 24/03/2030 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-717 | PPD Australia Pty Ltd | Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Refractory Systemic Lupus Erythematosus | To evaluate the safety and tolerability of CAR-T cell therapy in patients with Refractory Systemic Lupus Erythematosus | Surrendered | 25/03/2025 | 7/08/2025 |
| DNIR-718 | Adelaide University | Investigating immune evasion mechanisms in cancer | Using genetically modified Murine Leukemia Virus (MLV) to transduce human and murine cells to express different genes in order to understand their effects on immune invasion. | Licence issued | 31/03/2025 | 31/03/2030 |
| DNIR-719 | Adelaide University | Use of genetically modified Staphylococcus aureus strain to express an extracellular virulence factor. | To use GM Staphylococcus aureus overexpressing a protease to generate positive controls for comparative analysis. | Licence issued | 24/03/2025 | 24/03/2030 |
| DNIR-720 | The University of Newcastle | Characterisation of toxin biosynthesis pathways from environmental microorganisms | This study aims to develop genetically modified microbial hosts to enable heterologous expression of aquatic microbial toxins. Biosynthesis gene clusters involved in the molecular pathway will be characterised for future development of bioactive compounds. | Licence issued | 12/05/2025 | 12/05/2030 |
| DNIR-721 | QIMR Berghofer | Obesity linked cancer | The aim of the proposed dealings is to modulate gene expression in mammary duct epithelial cells of mice using lentiviral vectors in order to induce ductal carcinogenesis in situ. | Licence issued | 16/04/2025 | 16/04/2030 |
| DNIR-722 | James Cook University | Production of transgenic Nippostrongylus brasiliensis hookworms that secrete therapeutic foreign molecules | Evaluate the prophylactic and/or therapeutic potential of transgenic hookworms expressing foreign molecules in mice. | Licence issued | 28/04/2025 | 28/04/2030 |
| DNIR-723 | Boehringer Ingelheim Pty Ltd | Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors | To evaluate the safety and efficacy of the GM VSV for the treatment of solid tumours. | Licence issued | 2/05/2025 | 2/05/2030 |
| DNIR-724 | Novotech (Australia) Pty Limited | Clinical trial of GM AAV for treatment of Amyotrophic Lateral Sclerosis | To test the safety and efficacy of GM AAV for the treatment of Amyotrophic Lateral Sclerosis | Licence issued | 30/01/2025 | 30/01/2030 |
| DNIR-725 | ICON Clinical Research Pty Limited | Clinical trial of genetically modified adeno-associated virus for the treatment of haemophilia B | The purpose of this clinical trial is to evaluate the safety and efficacy of genetically modified adeno-associated virus in adult and paediatric patients with haemophilia B | Licence issued | 30/04/2025 | 30/04/2030 |
| DNIR-726 | CTI Clinical Trial and Consulting Services Australia Pty Ltd | Clinical trial of GM adeno-associated virus for treatment of frontotemporal dementia | To assess the safety, tolerability and pharmacodynamic effects of a GM AAV in adult participants with frontotemporal dementia (FTD) | Licence issued | 13/05/2025 | 13/05/2030 |
| DNIR-727 | Premier Research (Australia) Pty Ltd | A Phase I Study to Evaluate the Safety and Tolerability of a Lentiviral Vector (INT2106) in participants with refractory Generalised Myasthenia Gravis | To assess the safety and effectivity of INT2106, a lentiviral vector with a transgene for CAR19, in patients with generalised myasthenia gravis (GMG) | Surrendered | 17/06/2025 | 2/11/2026 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-728 | Flinders University | Use of a Diphtheria Toxin Subunit A expressing transgenic mouse model to study molecular and cellular physiology of common human diseases | Use of a Diphtheria Toxin Subunit A expressing transgenic mouse model to study molecular and cellular physiology of common human diseases | Licence issued | 2/07/2025 | 2/07/2030 |
| DNIR-729 | The Walter and Eliza Hall Institute of Medical Research | Experimental malaria infection of healthy malaria-naive adults with the genetically modified Plasmodium falciparum | The study will infect healthy participants with GM Plasmodium falciparum via mosquito bite to create a master cell bank (MCB) for future human clinical trial. | Licence issued | 4/07/2025 | 4/07/2030 |
| DNIR-730 | IQVIA RDS Pty Ltd | Phase 3 clinical trial of a new formulation of live attenuated tetravalent dengue vaccine in adults | The Phase III clinical trial aims to evaluate the immunogenicity and safety of 2 doses of a new formulation of the tetravalent dengue vaccine compared to the currently approved commercial vaccine in adults in dengue non-endemic area. | Licence issued | 30/07/2025 | 30/07/2030 |
| DNIR-731 | Sanofi-Aventis Australia Pty Ltd | Clinical trial of an adeno-associated viral vector-mediated gene therapy for the treatment of non-congenital myotonic dystrophy type 1 | To evaluate the safety, tolerability, and efficacy of the GMO, an adeno-associated viral vector-mediated gene therapy, in participants with non-congenital myotonic dystrophy type 1 (DM1). | Licence issued | 14/08/2025 | 14/08/2030 |
| DNIR-732 | Worldwide Clinical Trials Pty Limited | Clinical Study of Vusolimogene Oderparepvec in Patients with Advanced Melanoma | To evaluate the clinical benefits and safety of Vusolimogene Oderparepvec in combination with nivolumab for the treatment of patients with advanced (unresectable, Stage IIIb-IV) melanoma whose disease has progressed while being treated with an antiPD-1 antibody and an anti-CTLA-4 antibody. | Licence issued | 8/09/2025 | 8/09/2030 |
| DNIR-733 | Worldwide Clinical Trials Pty Limited | Clinical trial of RP2 in Adult Patients with Metastatic Uveal Melanoma | To test the safety and efficacy of RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab in immune checkpoint inhibitor-naïve adult participants with inoperable metastatic uveal melanoma. | Licence issued | 8/09/2025 | 8/09/2030 |
| DNIR-734 | BioCina Pty Ltd | Expansion of E. coli coded with tetanus toxin and derivatives and manufacture of toxin proteins | Manufacture of GM E. coli master cell banks for supply to client | Licence issued | 24/09/2025 | 24/09/2030 |
| DNIR-735 | Bristol-Myers Squibb Australia Pty Ltd | Clinical trial of BMS-986515, healthy Donor Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases | The purpose of this clinical trial is to evaluate the safety and tolerability of BMS-986515 in trial participants with severe, refractory autoimmune diseases. | Licence issued | 6/11/2025 | 6/11/2030 |
| DNIR-736 | Viral Vector Manufacturing Facility Pty Ltd | Large scale manufacture of lentiviral and adeno-associated viral vectors | To manufacture a broad range of lentiviral and adeno-associated virus (AAV) vectors in quantities greater than 25 L per vessel. The GMOs will subsequently be formulated, filled and finished for in-house process development and client-based therapeutic use. | Licence issued | 12/11/2025 | 12/11/2030 |
| DNIR-737 | Syneos Health Australia Pty Ltd | Clinical trial of GM AAV for treatment of geographic atrophy secondary to age-related macular degeneration | To test the safety, tolerability and efficacy of VV-14295 in adults with geographic atrophy secondary to age-related macular degeneration. | Licence issued | 5/11/2025 | 5/11/2030 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-738 | Novotech (Australia) Pty Limited | Clinical trial of GM adeno-associated virus for the treatment of congenital myasthenia syndrome | To test the safety and efficacy of GM adeno-associated virus in patients with congenital myasthenic syndrome | Licence issued | 2/12/2025 | 2/12/2028 |
| DNIR-739 | Syneos Health Australia Pty Ltd | Clinical trial of 4D-150 in adults with Macular Neovascularisation Secondary to Age-Related Macular Degeneration | This clinical trial is a Phase 3 study designed to evaluate the efficacy, safety, and durability of GM AAV therapy in adults with neovascular age-related macular degeneration (nAMD). | Licence issued | 4/12/2025 | 4/12/2030 |
| DNIR-740 | Vow Group Pty Ltd | Manufacture of the cNISTmAb Monoclonal Antibody using the Genetically Modified NISTCHO Cell Line | To demonstrate the large-scale manufacturing capabilities of the GMO cell line platform. | Surrendered | 9/12/2025 | 19/08/2026 |
| DNIR-741 | Sanofi-Aventis Australia Pty Ltd | Clinical trial of an adeno-associated viral vector-based gene therapy for the treatment of geographic atrophy secondary to age-related macular degeneration | To evaluate the safety, tolerability and efficacy of SAR446597 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) | Licence issued | 9/02/2026 | 9/02/2031 |
| DNIR-742 | Adelaide University | Identification and characterisation of Apicomplexan drug and vaccine targets using genetically modified parasites | To characterise the function of currently uncharacterised parasite genes, investigate the effectiveness of developmental drugs on gene targets, and produce reporter lines for use in vaccine development. | Licence issued | 2/02/2026 | 2/02/2031 |
| DNIR-743 | Vow Group Pty Ltd | Production of therapeutic monoclonal antibodies (mAbs) in Chinese Hamster Ovary (CHO) suspension cell lines | Large-scale manufacturing of monoclonal antibodies using GM CHO cell lines | Licence issued | 22/04/2026 | 22/04/2029 |
| DNIR-744 | Adelaide University | Use of non-replicative HCV pseudoparticles to evaluate the efficacy of candidate HCV vaccines | To use genetically modified murine leukemia virus particles pseudotyped with hepatitis C virus envelope proteins in human cell infection assays to evaluate immune responses elicited by candidate hepatitis C vaccines | Licence issued | 21/04/2026 | 21/04/2031 |
| DNIR-745 | Adelaide University | AAV gene therapy for treatment of brain tumours | To use genetically modified adeno-associated viral (AAV) vectors expressing human cytokines to study immunological responses in mice. | Licence issued | 1/04/2026 | 1/04/2031 |
| DNIR-746 | University of Tasmania | Developing a biocontrol vaccine for pest species | To test immunocontraception vaccines in laboratory rats and mice. | Licence issued | 28/04/2026 | 28/04/2031 |
| DNIR-747 | Graythan Regulatory Services Pty Ltd | Clinical trial with a self-amplifying mRNA for the treatment of patients with advanced solid tumours | | Withdrawn | | |
| DNIR-748 | Medpace Australia Pty Ltd | A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1 | To test the safety and efficacy of FLT201 in adult patients with Gaucher Disease Type 1 | Licence issued | 8/05/2026 | 8/05/2031 |
| DNIR-749 | Medpace Australia Pty Ltd | A Phase 1, Open-Label Multicenter Study of UB-VV500 in Combination with Rapamycin in Relapsed or Refractory Multiple Myeloma | To evaluate the safety and efficacy of UB-VV500 (GMO) in combination with or without rapamycin in adult subjects with relapsed or refractory multiple myeloma. | Licence issued | 16/06/2026 | 16/06/2031 |
| DNIR-750 | Medpace Australia Pty Ltd | Clinical trial of GM adeno-associated virus (RJVA-001) in adults with inadequately controlled type 2 diabetes on multiple glucose-lowering agents | To evaluate the safety, tolerability, and preliminary efficacy of RJVA-001 in participants with inadequately controlled type 2 diabetes | Licence issued | 21/05/2026 | 21/05/2031 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-751 | Graythan Regulatory Services Pty Ltd | Clinical trial with a self-amplifying mRNA for the treatment of patients with advanced solid tumours | The aim of the clinical trial is to determine the safety and tolerability of a self-amplifying RNA encoding IL-12 alone, and in combination with a checkpoint inhibitor, in patients with advanced solid tumours. | Licence issued | 29/04/2026 | 29/04/2031 |
| DNIR-752 | Parexel International Pty Ltd | A Clinical Trial to Investigate the Efficacy of SGT-003 in Ambulant Males with Duchenne Muscular Dystrophy | Investigate the efficacy of a single intravenous dose of SGT-003 as gene therapy in ambulant males with Duchenne muscular dystrophy | Licence issued | 22/05/2026 | 22/05/2031 |
| DNIR-753 | Tetraneuron Australia Pty Ltd | Clinical trial of a genetically modified adeno-associated virus for the treatment of moderate dementia due to Alzheimer disease | To evaluate the safety, tolerability and efficacy of TET-101 for the treatment of/prevention of disease | Licence issued | 8/07/2026 | 8/07/2031 |
| DNIR-754 | Seqirus Pty Ltd | Preparation of influenza vaccines using genetically modified seasonal influenza viruses | The purpose of the dealing is to manufacture and test influenza virus vaccines using seasonal influenza GMO candidate vaccine viruses. | Licence issued | 20/07/2026 | 20/07/2031 |
| DNIR-755 | Public and Environmental Health Reference Laboratories, Pathology Queensland | Destruction of Hendra virus and Australian bat lyssavirus recombinant plasmids | To destroy stored stocks of plasmids encoding full length, partial or GM Hendra virus and Australian bat lyssavirus genomes | Licence issued | 6/07/2026 | 6/07/2028 |
| DNIR-756 | Novotech (Australia) Pty Limited | Clinical trial of GM Adeno-associated viral vector for treatment of Generalised Inherited Retinal Dystrophies | To Evaluate the safety, tolerability, and efficacy of a GM Adeno-associated viral vector in adults with Generalised Inherited Retinal Dystrophies (IRDs). | Licence issued | 13/07/2026 | 13/07/2031 |
| DNIR-757 | Syneos Health Australia Pty Ltd | Clinical Trial of GM AAV (VV-14299, VV14300) for treatment of type 1 diabetes mellitus | To test the safety, tolerability, and efficacy of VV-14299 and VV-14300 in adults with type 1 diabetes mellitus. VV-14299 and VV-14300 are gene therapies using a modified virus (adeno-associated virus) to deliver genes with the potential to help regulate blood sugar levels (insulin and glucokinase, respectively) into muscle. | Licence issued | 14/07/2026 | 14/07/2031 |
| DNIR-758 | AstraZeneca Pty Ltd | Clinical development of CT204V-CD19xCD20 for relapsed/refractory B-cell malignancy | To assess the safety, tolerability, cellular kinetics, pharmacodynamics and preliminary efficacy of CT204V-CD19×CD20 in adult subjects with relapsed/refractory B-cell malignancy | Licence issued | 4/08/2026 | 4/08/2031 |
| DNIR-759 | University of Tasmania | Using transgenic mice expressing Diphtheria Toxin A chain to investigate cellular processes and organ function | Use of DTA expressing mice to deplete target cell populations in order to assess their contribution to cellular processes and organ function. | Licence issued | 18/06/2026 | 18/06/2031 |
| DNIR-760 | CSIRO | Development of avian paramyxovirus (APMV) vectored vaccines | To generate recombinant APMV engineered to express selected AIV genes, with the aim of developing novel vaccine candidates that induce protective immunity in avian species against AIV and APMV | Licence issued | 13/08/2026 | 13/08/2031 |
| DNIR-762 | Western Sydney Local Health District | A novel anticoagulant therapy for the prevention of cardioembolic stroke | Establish the efficacy of recombinant AAV vector encoding a variant thrombomodulin gene in preventing thrombus formation in vivo | Licence issued | 24/09/2026 | 24/09/2031 |

| OGTR ID | Organisation | Project Title | Project Description | Status | Date Issued | Expiry/ Surrender Date |
|---|---|---|---|---|---|---|
| DNIR-763 | University of Canberra | Use of adeno-associated virus mediated delivery of hepatitis B virus in mice for research | This is laboratory research using an AAV genetically modified by the insertion of an HBV (GM AAV-HBV) genome or Cre recombinase (GM AAV-Cre) to enable the generation a mouse model for HBV infection | Licence issued | 8/10/2026 | 8/10/2031 |
| DNIR-764 | Syneos Health Australia Pty Ltd | Clinical Trial of GM AAV (VV-14303) for treatment of metabolic dysfunction-associated steatohepatitis (MASH) | To evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intramuscular injection of VV-14303 for the treatment of adults with biopsy-confirmed advanced hepatic fibrosis (F3) or cirrhosis stage 4 (F4, compensated) due to Metabolic dysfunction-associated steatohepatitis (MASH). | Licence issued | 29/09/2026 | 29/09/2031 |
| DNIR-765 | Southern Clinical Development Consulting Pty Ltd | A clinical trial of JY231 for the treatment of multiple sclerosis | To evaluate the safety and efficacy of JY231 (GMO) in adult subjects with multiple sclerosis. | Licence issued | 23/10/2026 | 23/10/2031 |
| DNIR-766 | Avance Clinical Pty Ltd | Clinical trial of GM adeno-associated virus for treatment of Danon disease | To test the safety and efficacy of gene therapy RP-A501 (AAV9.LAMP2B) in male patients ≥ 8 years old with Danon disease | Licence issued | 27/10/2026 | 27/10/2031 |